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SUMMARY 
 
Food allergy is a major health problem in the Western countries, affecting 3-8% of the population. What 
makes a dietary protein a food allergen has not yet been established, though several characteristics have 
been proposed to be shared by food allergens. One of the features believed to be a general characteristic 
of food allergens is resistance to digestion. This is based on studies showing that allergenic dietary proteins 
in general are more resistant to digestion than dietary proteins with no proven allergenicity, concluding 
that a correlation between stability to digestion and allergenic potential exist. Resistance to digestion is for 
this reason a test parameter included in the safety assessment of the allergenic potential of novel proteins 
in genetically modified foods. The association between resistance to digestion and allergenic potential has 
though been challenged in recent years. 
This PhD project aimed to investigate the sensitising potential of digestion products from the peanut 
allergen Ara h 1 and the cow’s milk allergen β-lactoglobulin (BLG) in a Brown Norway (BN) rat model. 
Further the project aimed to compare the IgE binding epitopes of intact and digested Ara h 1. 
This was done by digesting Ara h 1 and BLG in an in vitro model simulating the human gastric or gastro-
duodenal digestion process. Simulated gastric digestion was performed with immobilised pepsin for 120 
min at pH 2.5, while simulated duodenal digestion was performed with immobilised trypsin and 
chymotrypsin for 15 min at pH 6.5. Fractions of digestion products were made by separating the peptide 
fragments according to sizes in gel permeation chromatography (GPC). The intact allergens as well as 
digestion products hereof were thoroughly characterised by reverse phase high-performance liquid 
chromatography, MALDI-TOF mass spectrometry, amino acid analysis and GPC. To study the sensitising 
capacity groups of BN rats were immunised with the intact allergen or digestion products hereof by i.p. 
immunisation and specific antibody responses were examined by ELISAs, RBL-assay or avidity 
measurements. Comparison of intact and digested Ara h 1-specific IgE binding epitopes were performed by 
competitive immunoscreening using a random phage-displayed peptide library followed by mapping the 
identified IgE-binding epitope mimics on the surface of the Ara h 1 molecule. In addition to sera from the 
sensitised BN rats, sera from peanut allergic patients were used. 
Both the gastric as well as the gastro-duodenal digests of the peanut allergen Ara h 1 were found to be very 
efficient for sensitising the BN rats. While gastric digest consisted of peptide fragments of up to Mr 4,000 
the duodenal digest consisted of peptide fragments of up to Mr 2,000, yet both the peptide fragments in 
the gastric as well as in the gastro-duodenal digests were aggregated to complexes of larger sizes. After 
separation of the digested Ara h 1 into fractions the sensitising capacity was lost, though the IgE-binding 
capacity was retained. Epitope mapping of intact and digested Ara h 1 showed IgE binding epitopes of Ara h 
1 to be conformational in origin and at least to some extent surviving the digestion process. For the peanut 
allergic patients five motifs were found to account for more than 65% of all identified epitope mimics and 
were found for both the intact as well as the digested Ara h 1. Digested BLG with peptide sizes of up to Mr 
4,500 could on the other hand not induce any sensitisation response in the BN rats. They were instead 
suggested to possess tolerogenic capacity when co-administered together with intact BLG.  
The results presented in the current thesis demonstrate that even very small peptide fragments, originally 
thought to be too small to act as a food allergens may indeed possess all features of a ‘complete’ allergen. 
This implies that an association between allergenicity and resistance to digestion is not an absolute feature 
of food allergens. The presented work indicates that peptide fragments may either possess sensitising 
capacity per se or that the observed allergenic capacity could be a result of the small peptide fragments 
aggregating to complexes of larger sizes. The importance of formation of aggregates is suggested by the 
epitope mapping study, where survival of conformational epitopes is demonstrated. This together with the 
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findings, that fractionation of digestion products leads to a loss of the sensitising potential, reveals that the 
allergenicity had to be more than simply a result of the small peptide fragments aggregating, and more a 
result of them being in an aggregated state resembling the intact Ara h 1 molecule. While small peptide 
fragments derived from one food allergen may retain sensitising capacity this is not necessarily the truth for 
other food allergens. This was demonstrated with the cow’s milk allergen BLG, from which peptide 
fragments were shown not to be efficient for inducing any specific antibodies. Instead the results indicated 
that the peptide fragments derived from BLG had tolerogenic capacity, demonstrating that while some 
mixtures of peptides may guide the immune system in one direction, other mixtures of peptides may guide 
the immune system in another direction. Together these results demonstrate that several characteristics of 
digestion products from food allergens may collectively contribute the allergenic potential, where more 
than just peptide sizes and structures may contribute. 
In conclusion, the experimental data presented in this PhD thesis contribute to the understanding of 
induction of allergy by investigating the sensitising potential of peptides derived from a food allergen. It 
add knowledge to our understanding of the mechanisms underlying the sensitisation, but at the same time 
points to the difficulties, if not infeasibilities, in identifying features that can be used as an ubiquitous 
marker for allergenicity of a dietary protein. 
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RESUMÉ (DANSK) 
 
Fødevareallergi vurderes at være et voksende problem i de vestlige lande, hvor prævalensen ligger på 3-8% 
af befolkningen. Selv om vi spiser tusindvis af forskellige fødevareproteiner hver dag, er det kun et fåtal af 
disse der forårsager IgE-medieret allergi. Hvorfor nogle fødevareproteiner giver allergi og andre ikke gør, 
vides endnu ikke, men der er flere bud på hvilke karaktertræk der potentielt kunne bidrage til de allergene 
egenskaber. Stabilitet over for fordøjelse er en af dem. Denne antagelse er baseret på studier der viser at 
allergene fødevareproteiner generelt er mere resistente over for nedbrydning end fødevareproteiner der 
ikke vurderes at være allergene. Dette ledte til konklusionen at stabilitet over for fordøjelse korrelerer med 
det allergene potentiale. Stabilitet over for pepsinnedbrydning er derfor en et testparameter inkluderet i 
risikovurderingen af det allergene potentiale af ”nye” proteiner i genmodificerede fødevarer. I de senere år 
er der dog sat spørgsmålstegn ved graden af sammenhæng mellem et proteins stabilitet over for fordøjelse 
og det allergene potentiale. 
Formålet med nærværende ph.d.-afhandling var at undersøge den sensibiliserende evne af 
fordøjelsesprodukter fra jordnøddeallergenet Ara h 1 samt komælkeallergenet β-lactoglobulin (BLG) i en 
Brown Norway (BN) rottemodel. Endvidere var formålet at sammenligne IgE-bindingsepitoper for intakt og 
fordøjet Ara h 1. 
Dette blev udført ved at nedbryde Ara h 1 og BLG i en in vitro model der efterligner den humane 
gastrointestinale fordøjelsesproces. Den gastriske in vitro fordøjelse blev udført med immobiliseret pepsin 
ved pH 2,5 i 120 minutter, mens den intestinale in vitro fordøjelse blev udført med immobiliseret trypsin og 
chymotrypsin ved pH 6,5 i 15 minutter. Fraktioner af fordøjelsesprodukter blev fremstillet ved en 
separation of peptidfragmenter via gel filtreringskromatografi (GPC) i henhold til størrelser af peptider samt 
aggregater heraf. En grunding karakterisering af de intakte allergener samt diverse fordøjelsesprodukter 
herfra blev udført ved omvendt fase HPLC, MALDI-TOF massespektrometri, aminosyreanalyse samt GPC. 
For at undersøge den sensibiliserende evne af de intakte allergener, fordøjelsesprodukter og fraktioner 
herfra, blev grupper at rotter immuniseret ved i.p. injektion. Det specifikke antistofniveau i serum blev 
bestemt ved ELISA’er, RBL-assay og aviditetsanalyser. Sammenligning af IgE-bindingsepitoper på intakt og 
fordøjet Ara h 1 blev udført ved ”competetive immunoscreening” af et ”random phage-displayed peptide 
library” efterfulgt af en mapning af epitop-efterligningerne på overfladen af Ara h 1 molekylet. Foruden 
sera fra immuniserede rotter blev sera fra fem jordnøddeallergiske patienter anvendt. 
Nedbrudt Ara h 1 fra både den gastriske og den gastrointestinale fordøjelse havde sensibiliserende evne i 
BN rotterne. Mens peptidfragmenterne af Ara h 1 fra den gastriske proteolyse var op til 4 kDa havde 
peptidfragmenterne fra den gastrointestinale proteolyse en størrelse på op til 2 kDa. Peptidfragmenterne 
fra begge fordøjelsesprocesser viste sig dog at være aggregeret til komplekser af større størrelser. Den 
sensibiliserende evne af fordøjet Ara h 1 forsvandt når peptidfragmenterne blev opdelt i fraktioner. 
Epitopmapningsstudiet af intakt og fordøjet Ara h 1 resulterede i identificering af konformationelle Ara h 1-
specifikke IgE-bindingsepitoper, hvoraf flere overlevede den gastrointestinale fordøjelse. For de 
jordnøddeallergiske patienter blev der defineret fem motiver som tegnede sig for mere end 65% af alle 
identificerede epitop-efterligninger og blev fundet for både det intakte og det nedbrudte Ara h 1. Fordøjet 
BLG som indeholdt peptidfragmenter af størrelser op til 4,5 kDa kunne i modsætning til fordøjet Ara h 1 
ikke inducere et allergisk respons i BN rotterne. Derimod tydede sensibiliseringsstudiet med fordøjet BLG 
på at peptidfragmenterne heri besad tolerogene egenskaber, da de ved en co.-immunisering med det 
intakte BLG forårsagede et stærkt reduceret respons i forhold til BLG alene. 
Resultaterne præsenteret i denne afhandling demonstrerer at selv meget små peptidfragmenter, som 
oprindelig var anset for at være for små til at besidde allergene egenskaber, kunne agere som ”komplette” 
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allergener og indeholde både evnen til at binde IgE, udløse et degranuleringsrespons samt sensibilisere. 
Dette demonstrerer at en fuldstændig korrelation mellem stabilitet over for fordøjelse og det allergene 
potentiale ikke eksisterer. Studierne præsenteret i nærværende ph.d.-afhandling indikerer at enten 
besidder de små peptidfragmenter fra fordøjet Ara h 1 sensibiliserende kapacitet i sig selv eller også er den 
sensibiliserende evne et resultat af deres aggregering til komplekser af større størrelser. En sandsynlig 
signifikant betydning af aggregat-dannelser belyses i epitopmapningsstudiet, hvor overlevelse af 
konformationelle epitoper kun synes sandsynliggjort ved dannelse af sådanne aggregat-komplekser. Set i 
lyset af disse resultater samt den manglende sensibiliserende evne af de aggregerede peptider delt i 
fraktioner, synes en aggregering ikke i sig selv at være nok til at forklare den vedholdende sensibiliserende 
evne. I stedet peger studierne på at måden hvorpå peptiderne aggregere er af stor betydning og at en 
hypotese kunne være at peptidfragmenterne i fordøjet Ara h 1 er i en formation der symbolisere det 
intakte molekyle. Mens nogle allergener bibeholder deres sensibiliserende selv efter nedbrydning til små 
peptidefragmenter, er dette ikke tilfældet for alle allergener. Komælkeallergenet BLG mistede i 
modsætning til Ara h 1 dets sensibiliserende evne efter in vitro fordøjelse. Dette viser at mens én blanding 
af peptider kan dirigere immunsystemet i én retning vil en anden blanding af peptider sandsynligvis kunne 
dirigere immunsystemet i modsatte. Samlet viser nærværende studier at flere karaktertræk er 
medbestemmende for det allergene potentiale af et fødevareallergen og at dette ikke kun er baseret på 
nedbrydeligheden af proteinet, men også på strukturen af nedbrydningsprodukterne, sandsynligvis i 
samspil med andre karaktertræk. 
Resultaterne præsenteret i nærværende ph.d.-afhandling bidrager til forståelsen af, hvilke egenskaber der 
bidrager til et proteins allergene egenskaber og øger vores forståelse af de mekanismer der ligger til grund 
for at dirigere vores immunsystem mod sensibilisering. Det slås dog samtidig fast at det vil være en stor 
udfordring, måske umuligt, at identificere de egenskaber ved et protein der bestemmer dets allergene 
kapacitet. 
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ABBREVIATIONS 
 
ALA α-lactalbumin 
APC antigen presenting cell 
 
BAT basophil activation test 
BLG β-lactoglobulin 
BN  Brown Norway 
BSA bovine serum albumin 
 
CD cluster of differentiation 
CRD component-resolved diagnostics 
 
DBPCFC double-blind placebo-controlled food 
challenge 
DC dendritic cell 
 
eHF extensively hydrolysed formula 
EAST enzyme allergosorbant test 
EFSA European Food Safety Authority 
ELISA enzyme-linked immunosorbent assay 
 
FAE follicle associated epithelium 
FAO Food and Agricultural Organisation 
FEIA fluorescence enzyme immunoassay 
 
GALT gut-associated lymphoid tissue 
GI gastrointestinal  
 
HEL hen’s egg lysozyme C 
HR histamine release 
 
IEC intestinal epithelial cell 
Ig immunoglobulin 
IgE immunoglobulin E 
IL interleukin 
ILF isolated lymphoid follicle 
i.p. intraperitoneal 
i.v. intravenous 
 
M cell microfold cell 
MHC major histocompatibility complex 
MLN mesenteric lymph node 
MW molecular weight 
 
nd not described 
 
 
 
 
 
 
ns-LTP nonspecific-lipid transfer protein 
 
OAS oral allergy syndrome 
OT ovotransferrin 
OVA ovalbumin 
OVM ovomucoid 
 
PC phosphatidylcholine 
pHF partially hydrolysed formula 
PP Peyer’s patch 
PPV positive predictive value 
PR-10 pathogenesis-related protein-10 
 
RAST radioallergosorbent test 
RBL rat basophilic leukaemia 
 
SDS-PAGE sodium dodecyl sulfate-
polyacrylamide gel electrophorese 
SGF simulated gastric fluid 
SIF simulated intestinal fluid 
SPT skin prick test 
STI soybean trypsin inhibitor 
 
TCR T cell receptor 
TGF transforming growth factor 
Th3 cell T helper 3 cell 
Tr1 cell T regulatory 1 cell 
 
WHO World Health Organisation 
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GENERAL INTRODUCTION 
 
Food allergy is defined as an immune mediated adverse reaction observed upon ingestion of an otherwise 
harmless food [1-3]. Food allergy is a major health problem in the Western countries, where it affects 
around 5-8% of young children and 2-4% of adults [4;5], and appears to be an increasing problem [6-9]. 
Food allergy is most often due to an immunoglobulin E (IgE) mediated mechanism (type I food allergy) 
[5;10], where the pathogenesis is composed of two phases. The first phase involves a primary contact with 
the dietary protein where oral tolerance induction fails or is abrogated, leading to sensitisation, where 
naïve B cells are primed to become IgE secreting plasma cells. Subsequently, allergen-specific IgE antibodies 
bind to the high affinity receptor FcԑR1 on tissue mast cells and blood basophils. The second phase is a 
result of reexposure to the offending dietary protein or a cross-reacting protein, which binds and cross-links 
FcԑR1-bound IgE. This leads to a degranulation response of the mast cells or basophils, releasing preformed 
and newly synthesised mediators, responsible for the symptoms of the allergic disease [11-13].  
Among the large number of proteins, that humans eat, only minute proportions are allergens. This may 
suggest that certain dietary proteins possess specific intrinsic features of allergenicity. Yet there is no 
absolute answer to the question ‘what makes a dietary protein a food allergen?’ [14]. Even though the 
mechanism by which dietary proteins sensitise an individual remains basically unresolved, many food 
allergens are thought to sensitise through the gastrointestinal (GI) tract. Thus, resistance to proteolysis in 
the GI tract has received much attention in recent years and is generally thought to be a prerequisite for a 
protein to sensitise through the mucosal immune system of the GI tract [15-18]. The first systematically 
evaluation of proteolytic stability of allergenic as well as non-allergenic dietary proteins by means of an in 
vitro digestibility assay was conducted in 1996 by Astwood et al. [18]. This study in general showed 
allergenic dietary proteins to be resistant to peptic digestion in contrast to the non-allergenic dietary 
proteins which showed to be rapidly digested, leading to the conclusion that a correlation between 
resistance to digestion and allergenicity exist. This has contributed to the inclusion of pepsin resistance as a 
test parameter in the decision tree or weight-of-evidence approach used in the safety assessment of novel 
proteins in genetically modified foods [19-21]. 
Since the study by Astwood et al. [18] major efforts have been used for studying the digestibility of known 
food allergens and have thrown some doubt about an absolute association between stability to digestion 
and allergenic potential. Besides an assessment of the proteolytic susceptibility of food allergens, several 
studies have in addition evaluated the residual allergenicity of the emerging digestion product. By use of 
immunological assays, studies have assessed the IgE binding capacity and/or the eliciting capacity of the 
generated peptide fragments. However the sensitising capacity of degraded food allergens is not well 
investigated, probably as a result of the ethical impossibility for studying such in humans.  
 
Gastrointestinal tract – the fate of dietary proteins 
 
Every day humans eat numerous of different food proteins. Understanding the fate of such dietary proteins 
from the moment they reach the mouth until they are taken up and presented to immune cells in the gut-
associated lymphoid tissue (GALT) is essential in food allergy, since many food allergens are believed to 
sensitise via the GI tract and because of the role digestion may play in determining the allergenic potential 
of such dietary proteins [15;22].  
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The GI tract is the largest organ in the body conducting several functions in digestion and absorption of 
nutrients as well as maintaining the immune homeostasis in discriminating between adverse foreign matter 
and harmless food components, microorganisms and self-antigens [23]. However, occasionally humans are 
sensitised to harmless food proteins, developing food allergy. The immunological mechanisms involved in 
the sensitisation of individuals towards dietary proteins remain poorly understood but it is thought that 
allergens or digestive products hereof must cross the intestinal mucosa in order to interact with the 
immune system of the gut, the same prerequisite thought for an allergen to elicit an allergic reaction in 
individuals already sensitised [22;24]. 
 
Digestive system 
Ingested food undergoes complex series of digestive processes in order to extract the nutrients essential 
for maintenance of the health. Proteins are broken down by hydrolytic enzymes originating in the stomach, 
pancreas, and small intestine [25]. In the stomach proteins are exposed to proteolysis by different pepsins 
[25;26]. Pepsins have a wide specificity, preferentially cleaving peptide bonds between hydrophobic and 
aromatic amino acid residues like, phenylalanine, tyrosine, and tryptophan [27;28], with an activity 
optimum around pH 3.5 [29]. The gastric pH is thought to be between 1.2 and 3.0 [30-32] but may vary 
further during the ingestion of a meal, because of influence by the volume and meal content [22;32]. The 
period of time the food stays in the stomach also varies. The average transit time is estimated to around 1 
to 2 hours [33]. Subsequently, the gastric digests are released into the small intestine, where the pH is 
around 6 to 6.5 [34]. Here the gastric digests are subjected to proteases and peptidases, produced by the 
pancreas, such as trypsin and chymotrypsin, or produced by the brush border of the intestinal mucosa 
[25;30]. While trypsin cleaves peptide bonds at the carboxyl side of the basic amino acids arginine and 
lysine, chymotrypsin cleaves peptide bonds where the carbonyl group is aromatic, like in the amino acids 
phenylalanine, tyrosine and tryptophan [25;35], with an activity optimum at pH 8 and 7.8, respectively [36-
38]. In the stomach and small intestine digests are mixed with surfactant such as phosphatidylcholine (PC) 
and bile salts, which may influence the digestibility of proteins [39-43]. The susceptibility of dietary proteins 
to digestion varies greatly but the goal is to achieve a mixture of amino acids and small peptides that can 
rapidly and efficiently be absorbed over the intestinal mucosa and serve as nutrients for the body [25]. 
While the majority of proteins are digested to amino acids and small peptides, some larger immunologically 
active fragments may survive the digestion process, and be absorbed and presented to the immune system 
of the Peyer’s patches (PPs). The approximately transit time down the duodenum to the site of the first PPs 
is 15 min [41]. Also small quantities of intact protein may escape the digestion process, which has been 
shown for the cow’s milk allergens β-lactoglobulin (BLG) [44-46] and bovine serum albumin (BSA) [47] and 
the hen’s egg allergen ovalbumin (OVA) [45;46;48;49]. 
Several in vivo studies of human digestion have been performed [50;50-52]. However, such studies are 
technically and ethically difficult to conduct and at the same time expensive [22]. Therefore, several 
attempts have been made to develop in vitro models simulating the human digestion process [39;53-55]. In 
addition, in vitro digestion models have been made which did not attempt to mimics the human digestion 
process [18;56]. Little consistency appears to exist for the digestion conditions, as great differences in the 
model systems are evident on e.g. pH, enzyme to protein ratio, digestion time, or addition of surfactant. 
However it is important to notice that no single perfect in vitro digestion model can be made, because the 
extent of digestion significantly varies from person to person and are influenced by factors such as age, 
health and medication status [30;57]. 
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Absorption 
Most dietary proteins are digested to amino acids and small peptides which are absorbed through the 
intestinal mucosa by electrogenic and sodium-dependent transporters [58]. Larger immunologically active 
peptides and intact proteins may also be absorbed across the intestinal epithelial barrier to reach the 
specialised inductive sites of the mucosal immune system. Only a single layer of intestinal epithelial cells 
(IECs) separates the intestinal lumen from the GALT, yet, several routes are suggested for antigen transport 
(Figure 1) [59-61]. Proteinous antigens may cross the epithelial barrier by transcytosis through enterocytes 
where three distinct routes exist. Most proteins or peptides are sorted into lysosomal compartments for 
(further) degradation before release [62;63] but may also be transported through a separate non-
degradative pathway [63;64]. Additionally, in food sensitised individuals enhanced transepithelial allergen 
transport mediated by specific IgE bound to the low affinity receptor FcԑRII (CD23) has been suggested 
[65;66], protecting the allergens from lysosomal breakdown [67]. Antigens may also be taken up by 
specialised microfold (M) cells which are restricted to the follicle associated epithelium (FAE) covering the 
immune inductive sites of PPs and isolated lymphoid follicles (ILFs) [60;68;69]. M cells are characterised by 
reduced activity of intracellular lysosomes and an intra-pocket structure at basal site where antigen 
presenting cells (APCs) and lymphocytes are located, allowing M cells to easily take up antigens from lumen 
and transport them without digestion and processing [63;69]. Furthermore, dendritic cells (DCs) penetrate 
the epithelial layer to sample antigens in the intestinal lumen and migrate to local or distant lymphoid 
tissue [70]. There are also situations where small proteinous antigens may enter the inductive site of the 
mucosal immune system by paracellular diffusion through the intestinal epithelial barrier, where the IEC 
are joined by tight junctions. This pathway seems to be negligible under physiological conditions [63]. 
 
The route of antigen entry is not solved, due to the complexity of the GALT and the difficulty in studying a 
process with a high number of variables [23]. The location of antigen uptake may thus depend on different 
factors such as size of antigen, maturity of mucosa, medical status and microflora [63;71]. However, the 
site, pathway and mechanisms by which the dietary proteins or digestive products hereof enter the 
inductive site of the mucosal immune system may be of great importance for the immune response to that 
dietary antigen [24;58;61;63;72;73]. Although the normal immune response to dietary proteins is oral 
tolerance, proteins or digestive products are sometimes responsible for an adverse stimulation of the 
mucosal immune system, resulting in sensitisation [63]. 
 
Inductive system of the GALT 
In addition to the mode of antigen uptake in the GI tract, the way in which the antigen is presented to the 
effector immune cells in the GALT, also plays an important role in the development of oral tolerance versus 
sensitisation to dietary antigens.  
The GALT is divided into organised lymphoid tissue, which is the inductive site and consists of PP, ILF and 
mesenteric lymph node (MLN), and the non-organised lymphoid tissue, which is the effector site and 
consists of lymphocytes scattered throughout the epithelium and lamina propria (Figure 1) [60;61;72]. PPs 
are specialised lymphoid follicles, consisting of B cell follicles surrounded by T cell areas which are 
infiltrated by DCs [60]. PPs are thought to have an essential role in the induction of either antigen-specific 
immune responses or oral tolerance [74;75].  
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Figure 1. Overview of the mucosal immune system of the intestine. GALT can be divided into induction sites, which 
consist of Peyer’s patches (PP), isolated lymphoid follicles (ILF) and mesenteric lymph nodes (MLN) and effector sites, 
which consist of lymphocytes scattered throughout the epithelium and lamina propria. Dietary antigens may access 
the mucosal immune system by means of three different cell types: A. Antigens can cross the intestinal epithelial cells 
(IEC) through different transcellular routes, B. Antigens can be sampled by dendritic cells (DC) that extend processes 
through the epithelium and into the lumen, or C. Antigens can be taken up by microfold (M) cells overlying PPs and 
ILFs [60;61;72]. Modified from Spahn and Kucharzik [60]. 
 
 
After antigen transport across the epithelial barrier, proteinous antigens are readily taken up by the 
underlying APCs such as DCs located in the organised lymphoid tissue of e.g. PP. APCs process and present 
antigenic peptides in association with major histocompatibility complex (MHC) class II molecules for 
recognition by specific T cell receptors (TCRs) expressed on the surface of naïve T cells. Priming of T cells 
occurs either locally or after migration of APCs to distant sites of the immune system [72;76]. APCs have a 
fundamental role in determination of whether an immune response is directed towards food allergy or oral 
tolerance depending on the presence of appropriate signaling by co-stimulatory surface molecules and by 
cytokine secretion by the APC [23;61]. 
 
Food antigens taken up by IEC may be processed and presented on MHC class II molecules on their surface, 
indicating that IECs might function as APCs [77;78]. Several studies have shown that this presentation by 
IECs may contribute to the development of oral tolerance, since IECs do not express the co-stimulatory 
molecules required for full T cell activation [72;78;79] 
Oral tolerance is generally induced to food proteins and is defined as a state of unresponsiveness to a 
specific antigen, after prior exposure to that antigen by the oral route [23;58;61]. Multiple mechanisms 
may be involved in the induction of oral tolerance in the mucosal immune system of the GI tract, including 
(1) T cell anergy, mediated through TCR ligation in the absence of appropriate co-stimulatory signals 
provided by ligation of receptors on T cells (CD28) with receptors on APCs (CD80 and CD86) and by soluble 
cytokines secreted by APCs [80;81]. This results in abolishing of T cell capacity for production of their own 
growth factor interleukin (IL)-2 upon restimulation [82]; (2) T cell deletion, which occurs by means of 
apoptosis [83]; and (3) T regulatory cells, inhibiting immune responses through secreted or cell surface-
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bound suppressive cytokines [61]. T regulatory cells can be divided into different subgroups: suppressor 
CD8+ cells, T helper 3 (Th3) cells, T regulatory 1 (Tr1) cells, and CD4+CD25+ cells [76;84]. Mechanisms for 
suppression may be different for the different regulatory T cells, where CD8+ cells and Th3 cells suppress 
mainly through secreted transforming growth factor (TGF)-β [85;86], Tr1 cells suppress mainly through 
secreted IL-10 [87], and CD4+CD25+ suppress possible through surface-bound TGF-β [88]. Regulatory T cells 
may work locally or migrate to distant lymphoid organs, where they inhibit the generation of effector cells 
[84]. By producing immunomodulating cytokines, regulatory T cells are also important for keeping the 
Th1/Th2 profile balanced. 
Studies in experimental animal models have shown that oral tolerance can be induced after administration 
of either a single high dose of antigen or repeated lower doses [89;90]. Different mechanisms are involved 
in the two types of tolerance, termed high-dose tolerance and low-dose tolerance, respectively (Figure 2) 
[61]. Whereas high-dose tolerance is mediated by lymphocyte anergy [89] or deletion [83], low-dose 
tolerance is mediated by regulatory T cells [83;89]. However, low- and high-dose tolerance may not 
necessarily be reciprocal and likely have overlapping functions [58;76;84]. 
 
Abrogation of oral tolerance or failure to induce oral tolerance may result in development of adverse 
immunological reactions to dietary proteins [61;76;91]. The immune system will be primed, leading to cell-
mediated immunities or production of antibodies reacting with the ingested dietary antigen on subsequent 
exposures. 
When naïve Th cells are primed by APCs providing appropriate signals through surface expressed co-
stimulatory molecules and secreted cytokines, they differentiate into either Th1 or Th2 cells. Optimal Th 
cell activation requires, besides TCR ligation with MHC/peptide complex, co-stimulatory signaling through 
the interaction of CD28 on the Th cell and CD80/86 on the APC (Figure 2) [76;82;92]. The direction of Th cell 
differentiation to either Th1 or Th2 cells depends on the specificity of the signals provided by the APC 
where IL-4 seems to have the pivotal role in the differentiation to Th2 cells [93;94]. Th2 cells are defined on 
basis of their restricted cytokine profiles [95], which includes the production of the cytokines IL-4, IL-5 and 
IL-13 [96].  
 
When membrane-bound immunoglobulin (Ig) of naïve B cells come in contact with specific dietary antigens, 
activation of the surface molecule CD40 by ligation with the Th2 molecule CD40L and IL-4 and IL-13 
secreted by activated Th2 cells promote germ line ԑ transcript for Ig isotype class switching in B cells. Naïve 
B cells differentiate and proliferate into active plasma cells synthesising and secreting antigen-specific IgE 
[97;98]. Lymphocytes activated in the GALT leave through the draining lymphatics and reach the MLN, 
where they stay for a period for further differentiation, before migration into the bloodstream [72]. 
 
To this day the immunological mechanisms involved in food allergy versus tolerance induction remain 
poorly understood but is realised to depend on a complex network of communicating immune cells, which 
are the focus of intensive research. New knowledge in the mechanisms underlying food allergic 
sensitisation would be helpful for the development of new prophylactic and therapeutic strategies for food 
allergy [76]. 
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Figure 2. Mechanisms of oral tolerance 
versus immune response. When an 
antigen encounters the immune system 
of the gastro-intestinal (GI) tract, 
different mechanisms may be activated. 
Several factors may influence the 
outcome of the response to a dietary 
antigen. Some are related to the antigen, 
including the dose and nature of the 
antigen, while other factors are related 
to the host, including age, genetics and 
intestinal flora content. In normal 
circumstances oral tolerance to dietary 
proteins is induced. A. High-dose of 
antigen may lead to T cell receptor (TCR) 
ligation with peptide/major histo-
compatibility complex (MHC) in the 
absence of co-stimulatory molecules or 
in the presence of inhibitory molecules 
(CD95 and CD95 ligation), where anergy 
or deletion will be the result. B. Low-
doses of antigen cause activation of 
regulatory T cells, which may prevent 
immune responses either through 
secretion of or by cell-bound suppressive 
cytokines (interleukin (IL)-10 and 
transforming growth factor (TGF)-β). C. 
Initiation of an immune response 
requires the binding of TCR to 
peptide/MHC complexes in the presence 
of adequate co-stimulatory molecules 
(CD80 and CD86) as well as cytokines 
[61;91]. Modified from Chehade and 
Meyer [61]. 
 
 
 
Food allergy – an adverse response to dietary proteins 
 
Adverse reactions to foods can be defined as any anomalous reaction resulting from ingestion of a food or a 
food ingredient. Adverse reactions to foods can be divided into toxic and non-toxic reactions (Figure 3). 
While toxic reactions may occur in any individual ingesting an appropriate amount of the toxic compound, 
non-toxic reactions only occur in susceptible individuals [1] and is often referred to as ‘food 
hypersensitivity’ [2]. Non-toxic food reactions can be divided into immune mediated reactions also termed 
‘food allergy’ [1;2] and non-immune mediated reactions also referred to as ‘food intolerance’ [1] or ‘non-
allergic food hypersensitivity’ [2]. Non-immune mediated reactions are adverse physiologic reactions 
caused by some distinctive characteristics of the individual, such as metabolic disorders [3;10;76], and can 
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be divided into enzymatic, pharmacologic and undefined reactions [1]. Immune mediated reactions can be 
further divided into IgE mediated reactions also referred to as ‘Type I food allergy’ and non-IgE mediated 
reactions [1]. While IgE mediated food allergy are responsible for most food allergic reactions and is 
characterised by the presence of food-specific serum IgE antibodies [5;10;76], non-IgE mediated food 
reactions are associated with cell-mediated mechanisms or antigen-specific antibodies other than IgE 
(Figure 3) [2]. 
 
 
                                             Figure 3. Overview of adverse reactions to foods 
 
The factual prevalence of IgE mediated food allergy is unknown because appropriately performed 
worldwide epidemiologic studies have not been conducted [1]. There are global variations in food allergy 
prevalence but it is suggested to affect around 5-8% of young children and 2-4% of the adults in the 
Western countries [4;5], where it also gives the impression of being an increasing problem [6-9] or 
achieving increasing attention [8]. Various foods are responsible for allergic responses, however, only a few 
accounts for the majority of the reactions, including milk, peanut, egg, tree nuts, shellfish, fish, wheat and 
soy [4;5]. Additionally, the number of identified incriminating foods continue to increase, which could 
either be the result of the globalisation and thereby the introduction of new foods containing potential new 
allergenic proteins [99] or simply an increased attention for identification of dietary proteins causing the 
allergic responses. The increased attention that food allergy has achieved in recent decades as well as the 
introduction of genetically modified food products into the market have led to the recommendation that 
novel food products should be subjected to a careful and complete safety assessment including the 
evaluation of potentially allergenicity, before commercialisation [16]. The Food and Agricultural 
Organisation (FAO)/World Health Organisation (WHO) established in 2001 a decision-tree approach for 
predicting the potential allergenicity of novel proteins in genetically modified foods [19]. Later the Codex 
Alimentarius [21] and the European Food Safety Authority (EFSA) [20] recommended the use of a weight-
of-evidence approach. 
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Several factors influence the development of IgE mediated allergy, including genetics, environmental 
factors and antigen related features [61;100;101]. An important determinant is genetic predisposition, 
however, no specific genetic markers have been identified, suggesting that multiple genes have implication 
for development of food allergy, each probably playing only a tiny role [2]. Another possibility is that 
epigenetics play a significant role [102;103]. The fact that the increase in prevalence of allergic diseases in 
Western societies, which cannot solely be accounted for by the genetics, concur with a reduction of 
infections in early childhood, has led to a theory of a causative relationship [104;105]. Such theory is 
collectively known as the hygiene hypothesis and were formulated first time in 1989 [106]. However, the 
implication that increased environmental sanitation is associated with higher incidence of allergy, remain to 
be fully documented [100]. Other factors contributing to the development of allergy are suggested to be 
the age at which solid food is introduced, breast versus formula feeding, intestinal microflora composition, 
degree of gastrointestinal infection, intestinal permeability, mechanisms and site of intestinal antigen 
absorption, and adjuvant effects from e.g. tobacco smoke [61;100;101]. 
 
 
 
 
Figure 4. Overview of mechanisms leading to allergic reactions. The pathogenesis of IgE mediated food allergy has 
two phases; a sensitisation and an elicitation phase. Sensitisation usually occurs by the primary contact with a given 
allergen, where naïve B cells are primed to become IgE secreting plasma cells. Differentiation and proliferation to 
plasma cells require besides allergen recognition of membrane-bound IgE also signals provided by Th2 cells in form of 
ligation of CD40 by CD40L and cytokine secretion. Elicitation occurs upon reexposure to the same or a cross-reacting 
allergen, which cross-links FcԑRI-bound IgE on mast cells and basophils. This activation leads to release of preformed 
and newly synthesised mediators inducing the allergic symptoms characteristic of food allergy. 
 
The pathogenesis of IgE mediated food allergy is composed of two phases; (1) A primary contact with the 
dietary protein where oral tolerance induction fail or is abrogated, leading to sensitisation, where naïve B 
cells are primed to become IgE secreting plasma cells. Food-specific IgE antibodies then bind to FcԑRI, the 
high affinity receptor, expressed on tissue mast cells and blood basophils, and (2) upon subsequent contact 
with the incriminating protein, binding and cross linking of FcԑRI-bound IgE occur. This leads to 
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degranulation of mast cells or basophils, releasing preformed and newly synthesised mediators, such as 
histamine, β-hexoaminidase, cytokines and proteases (Figure 4) [11-13;76].  
Release of mediators is responsible for a variety of symptoms, ranging from mild local reactions to severe 
systemic anaphylactic reactions, which could potentially be life-threatening [4;10]. These allergic reactions 
occur within minutes to hours after ingestion of the incriminating food [107;108]. Besides the physiological 
consequences, food allergy may also have significant effect on the psychological wellbeing of the food 
allergic patient. 
Several diagnostic techniques are available for the diagnosis of IgE mediated food allergy. Double-blind 
placebo-controlled food challenge (DBPCFC) is the gold standard but is often replaced by or performed in 
combination with open or single-blind food challenges, skin prick test (SPT), in vitro assays for 
determination of specific IgE antibodies, case history and/or elimination and re-introduction of diet [1;4]. 
Diagnosis may be complicated by the fact that symptoms representative of IgE mediated food allergy may 
appear in patients without detectable levels of specific IgE [109;110] as well as detection of specific IgE 
does not necessarily correlate with clinical symptoms [108;111;112]. Novel diagnostic methods, focusing on 
protein and epitope specificity are under investigation [4]. 
No cure for food allergy exists. Currently, there are no therapeutic approaches of documented value 
[113;114] and avoidance of the offending foods is the only reliable management of food allergy [4;5]. 
However, a number of novel therapeutic strategies targeting food allergy are under investigation, including 
both food allergen specific and non-specific strategies [1;114]. The approaches undergoing the most 
extensive research are oral and sublingual immunotherapy, where doses of the dietary protein are given in 
progressively increasing quantities toward a steady dose, for induction of desensitisation. Studies to date 
indicate that immune therapy may indeed induce desensitisation but it remains unclear whether tolerance 
is achieved. Other food allergen-specific strategies include, epicutaneous immune therapy, peptide 
immune therapy, plasmid DNA immune therapy. Allergen non-specific strategies include probiotics and 
prebiotics, anti-IgE antibodies, Chinese herbal medicine, anti-cytokines and toll-like receptor agonists 
[113;114]. 
 
Food allergens 
An allergen is defined as the antigenic molecule giving rise to an allergic response [1] and is virtually always 
proteinaceous in nature [15]. A food allergen possess three distinct molecular properties; (1) the property 
to bind IgE antibodies, (2) the property to elicit an allergic reaction, and (3) the property to sensitise an 
individual [115]. Aalberse [115] states that for an allergen to be complete it must possess all three distinct 
properties. Not all allergens are complete allergens. Well-known examples of such incomplete allergens are 
the dietary proteins homologous to the birch pollen allergen Bet v 1, such as Mal d 1 from apple, Pru av 1 
from cherry, Cor a 1 from hazelnut and Api g 1 from celery, which are known to elicit allergic reactions but 
do not usually sensitise [115-117]. 
Allergens can be defined as being either major or minor. A major allergen is defined as one, recognised by 
IgE from more than 50% of individuals sensitive to the particular food from where the allergen origin [118]. 
Aalberse [115] however claims that this definition is unsatisfactory, since e.g. a major allergen is not 
necessarily synonymous with a major risk. 
  
More than 700 different allergens are defined, and of these it appears from the Informall Database on Food 
Allergies (http://foodallergens.ifr.ac.uk/allergenlist.html) and IUIS Allergen Nomenclature 
(http://www.allergen.org) that more than 200 are derived from foods. The food allergens originate from 
approximately 90 different species, with around 70% being of plant origin and around 30% being from 
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animals. Although humans in general eat a very varied diet, only few foods account for nearly half of the 
identified allergens, which are milk, peanut, egg, tree nuts, shellfish, fish, wheat and soy. Hypothetically, all 
food containing proteins could induce an allergic reaction, although foods appear to vary greatly in their 
likelihood of inducing allergy. 
Among the large number of proteins, eaten by humans, only minute proportions are allergens, suggesting 
that allergens hold special features of allergenicity. No definitive answer to the question ‘what makes a 
dietary protein a food allergen?’ exists, though it is clear that some dietary proteins are intrinsically more 
allergenic than others [14]. In general food allergens have been suggested to be water-soluble 
glycoproteins with a molecular weight (MW) of 10 to 70 kDa, that are abundant in the food and are stable 
to treatment with heat, acid and proteases [14;17;119]. However, many food allergens do not share such 
characteristics [17;119-121] while proteins considered not to cause allergy can be identified with those 
characteristics [119;121]. It appears likely that many factors may contribute to the overall allergenicity of 
any given protein, none of which is unique, but that some characteristics are more common among proven 
allergens than among other proteins considered to be non-allergenic, as stated by Huby et al. [14]. The only 
definitive requirement for a food protein to be an allergen is to possess IgE binding epitopes.  
Since no single characteristic of a dietary protein is sufficient for predicting its allergenic potential, it is 
recommend that the risk assessment process of novel proteins in genetically modified foods should 
implement a stepwise case-by-case approach that takes into account several types of information [16], 
including; (1) evaluation of the source of the gene, (2) the sequence homology of the newly introduced 
protein to known allergens, (3) the expression level of the novel protein in the modified food, (4) serum 
screening for the reactivity with IgE from the serum of individuals with allergy to the source of genetic 
material or (5) from the serum of individuals with allergy to materials that are related to the source 
material for the gene, (6) test for resistance to pepsin degradation [19-21] and (7) cell based assays [20]. In 
addition, animal models have been suggested for prediction of the sensitising capacity of the novel proteins 
[19].  
 
IgE – the main player in food allergy 
 
Immunoglobulins (Igs), also designated antibodies, are produced by plasma cells and maintain the key 
function of the humoral immune system. Antibodies are grouped into five isotypes, according to the heavy 
chain they possess, where each isotype is developed to perform distinctive roles. Antibodies hold a 
hypervariable region, in which the paratope is localised, the site of the antibody responsible for interaction 
with an antigenic molecule, allowing for generation of millions of different antibodies. Each antibody clone 
possess a unique binding capability. Consequently this huge variety of antibodies allows the immune 
system to recognise an equally immense diversity of antigenic molecules, with the main function of clearing 
the antigens from the human body. 
IgE antibodies were discovered in 1966 [122] and found to play the essential role in type I allergy [122;123]. 
IgE performs the immune response by binding to the high affinity FcԑRI expressed on mast cells and 
basophils. Cross-linking of the receptor-bound IgE antibodies causes degranulation and release of 
mediators responsible for the symptoms of the allergic reaction [11;13]. IgE is the least abundant antibody 
isotype in serum, with a concentration of 150 ng/mL [11] in comparison to e.g. 10 mg/mL for IgG [11;124]. 
Free IgE has a short half-live of only a few days [11;12;125]. The half-live may be increased to about two 
weeks when bound to the FcԑRI on mast cells [13;125]. Both the concentration of IgE as well as the half-live 
may be increased in atopic individuals, persons predisposed for developing type I allergy [125]. The 
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possibility exists for an IgE mediated response to last for years without any allergen stimulation, probably 
as a result of long-lived IgE producing plasma cells [98].  
Food allergy diagnosis often involves detection of specific IgE antibodies in combination with a recording of 
the patient’s clinical history and physical examination. The presence of specific IgE antibodies can be 
assessed by a series of different in vivo and in vitro testing methods [108;126]. Food challenges and SPT are 
commonly used in vivo methods performed for assessment of food-specific IgE [108;126;127]. IgE 
antibodies of particular food specificity can be measured in sera or plasma from individuals sensitised to 
that food using various in vitro testing methods, such as radioallergosorbent test (RAST), enzyme-linked 
immunosorbent assay (ELISA), fluorescence enzyme immunoassay (FEIA), enzyme allergosorbent test 
(EAST), immunoblotting or the commercially available ImmunoCAP [126]. Allergen-specific IgE can be 
detected by component-resolved diagnostics (CRD), which allows for detection of IgE, to specific allergens 
and may be a future commercially available useful tool [127]. Other in vitro tests used in the diagnosis of 
food allergy are cells based assays, such as basophil activation test (BAT), basophil histamine release (HR) 
test or humanised rat basophilic leukaemia (RBL) cell assay. Besides detection of specific IgE antibodies, 
these tests provide an evaluation of the biological functionality of the specific IgE [126]. 
Symptoms representative of type I food allergy may appear in patients without elevated levels of specific 
IgE. In addition presence of elevated levels of specific IgE may be observed in subjects without a clinical 
active allergy and only points to the occurrence of sensitisation. Presently, only food challenge tests with 
the offending food, provide reliable prediction of a clinical active type I food allergy in patients, while no in 
vitro tests at the moment seems to sufficiently predict the clinical reactivity although the outcome of the in 
vitro test may be representative of the associated risk [108].  
There is still a lack of knowledge about causal relation between antibody characteristics and the food 
allergic phenotype as well as epitope characteristics and the food allergic phenotype.  
 
Epitopes 
The word epitope was first defined by Jerne [128] in 1960 as an antigenic determinant or region of a 
molecule recognised by an antibody. At the present time epitopes describe the binding site of a molecule at 
the amino acid level for both B and T cells. Epitopes can be categorised as either linear or conformational 
based on the vicinity of the involved amino acids in the primary structure constituting the epitope [129-
132]. The first is the simplest epitope as the amino acids comprising the epitope are resulting from a 
contiguous stretch of the primary sequence. Most T cell epitopes appear to be in this category [133-135]. 
On the other hand, most B cell epitopes are thought to be conformational, involving amino acids from two 
or more stretches that are distant from one another in the primary sequence but brought together by 
structural folding of the polypeptide backbone [24;115;136-138].  
Definition of epitopes appears unclear. As Van Regenmortel [131;138] and Arnon and Van Regenmortel 
[132] outline, there is no clear boundary at the amino acid level for those residues that comprise an 
epitope. An epitope is identified by its ability to bind antibodies but there is no evidence that each amino 
acid in the binding area necessarily interacts with the antibody [131;132]. So even though epitopes are 
suggested to consist of at least 8 amino acid residues, energy calculations have indicated that as few as 5-6 
amino acids are the actual contributors to the binding between epitope and antibody molecule 
[133;138;139]. It has been estimated that by immunisation of an individual by a protein-antigen, more than 
100 different antibody clones can be formed. They may differ in their epitope specificity, though be 
directed against the same epitope areas, so that the entire molecule could be covered by many overlapping 
epitopes [140;141]. In addition, since only a limited degree of similarity between two structures is sufficient 
to allow the same antibody to bind, ‘true’ cross-reactivity may occur where a given antibody reacts with 
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another epitope than the one for which the antibody was originally developed. The ability of an antibody to 
react with more than one epitope resembles the inherent multi-specificity of an antibody [131]. Upon 
reexposure to the same antigen affinity maturation occurs, where progressively higher affinity B cell clones 
are generated, as a result of somatic hypermutation and antigen-specific selection of high affinity B cells 
[142-145]. 
Different methods for identification of specific B cell epitopes exist. For experimental reasons, the number 
of identified linear epitopes by far exceeds the number of identified conformational epitopes. Most of the 
mapping techniques are based on analysis of IgE binding to peptides derived from the primary sequence of 
the allergen [136;146], thereby only allowing for identification of linear epitopes. Identification of 
conformational epitopes requires more elaborated methods, such as X-ray crystallography, site-directed 
mutagenesis or phage display technology [136;138;146]. However, the only complete method for defining 
an epitope involves measurement of the crystal structure of an allergen in complex with an antibody [133]. 
 
Great diversity in the patterns of IgE epitope recognition have been seen in allergic patients, which may be 
elucidated by the individual development of antibody specificities, the polyclonal origin and the individual 
progression of affinity maturations. 
IgE epitope mapping of food allergens may provide valuable information regarding patient’s clinical history 
and contribute to food allergy diagnosis and treatment and as a tool for detecting candidate biomarker for 
persistency, severity or tolerance induction [147;148]. Also IgE epitope identification may be of relevance 
for design of allergy peptide vaccines [149], for design of recombinants for immunotherapy [146;150] and 
for the general understanding of what makes a protein a food allergen, an important issue for predicting 
the allergenic potential of novel proteins in genetically modified foods. 
 
Antibody characteristics in relation to the allergic phenotype 
At present no identified antibody characteristics and no identified structural features of IgE binding 
epitopes seem to be associated with the phenotype of the food allergic disease.  
As specific IgE is the main player in food allergic reactions, research has been made to find correlations to 
the allergic phenotype. Whereas the presence of specific IgE in serum does not associate with an active 
clinical food allergic disease, studies have shown that an increasingly higher concentration of specific IgE 
correlates with an increasingly greater likelihood of clinical reactions upon ingestion of the given food to 
which the IgE is specific [151-153]. A measure of the specific IgE level that could predict clinical reactivity 
would be desirable as an alternative to DBPCFC. The predictive value of specific IgE has been examined in 
numerous studies [151;153-155]. These studies indicate that calculation of a predictive decision points for 
instance for a 95% positive predictive value (PPV) of specific IgE should be established for each food 
separately. In general PPVs for specific IgE have been suggested to be a useful parameter for diagnosing 
symptomatic allergy [154;155]. However, the PPV of the specific IgE may come out very differently for the 
same foods in separate studies, where for example the 95% PPV for hen’s egg-specific IgE ranged from 1.35 
to 59.2 kUA/L [151;153-155]. High levels of specific IgE have been reported to relate to a persistent food 
allergic phenotype compared to a lower level of specific IgE in patients shown to outgrow their food allergy 
[155-159]. For example, Savilathi et al. [156;157] showed that patients with persistent cow’s milk allergy 
had higher cow’s milk specific IgE at the time of diagnosis than patients who later became tolerant. On the 
other hand conflicting results exist for the correlation between levels of specific IgE and severity. Lewis et 
al. [160] and Hourihane et al. [161] reported a significant correlation between levels of specific IgE and 
severity of the food allergic disease, while Sampson et al. [151] reported that such correlation do not exist.  
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The influence of the total IgE level has also been investigated, and it generally seems that an elevation of 
total IgE is positively correlated with elevated specific IgE. Elevated levels of total IgE does not necessarily 
associate with an clinical active allergic phenotype [152], but it generally appears that a high level of total 
IgE correlate with an increased risk of having a persistent food allergic phenotype [155;162]. Montesinos et 
al. [155] for example showed that the initial mean level of total IgE of individual with persistent hen’s egg 
allergy was more than twice as high as the mean total IgE level of individuals with transient hen’s egg 
allergy [155]. However, other studies showed that such correlation is far from general [163]. Also the ratio 
of specific IgE/total IgE has been examined, and was shown to correlate with the outcome of oral 
challenges, so that higher ratios correlated with an increased likelihood of symptomatic food allergy 
[164;165]. Yet, the overall conclusion appears to be that determination of total IgE as well as specific 
IgE/total IgE is less predictive than the determination of specific IgE alone, probably as a result of the age-
dependent total IgE level and the wide overlap in level between atopic and non-atopic individuals 
[164;166;167].  
 
Antibody avidity is the overall strength of binding between multivalent antibodies and the antigen for 
which they are specific. The role of IgE avidity in food allergy remains generally unresolved. El-Khouly et al. 
[165] showed in a study investigating the antibody avidity characteristics of peanut allergic individuals that 
the peanut allergen Ara h 2-specific IgE avidity correlated with the severity of the allergic disease. Likewise 
Wang et al. [168] reported that high affinity of IgE determined by binding to small peptides was associated 
with severity of milk allergy. No clear relationship between IgE avidity and level of specific IgE appears to 
exist [169;170]. 
Individuals allergic to a specific food may react with great heterogeneity to the different allergens present 
in that particular food. For example specific IgE from patients with peanut allergy have been shown to bind 
with considerable heterogeneity to the numerous peanut allergens [171;172]. A reacting pattern of great 
heterogeneity has been reported to correlate with the severity of the allergic disease. More diverse binding 
to the different peanut allergens was associated with an increased likelihood of developing severe allergic 
reaction upon ingestion of peanut, and that diversity was more important than the recognition of specific 
proteins [160;173]. 
A study by Christensen et al. [174] confirmed that several characteristics of the IgE repertoire may 
contribute to the functionality of the IgE mediated allergic response. In an in vitro test, based on BAT, they 
showed that the concentration of total IgE, the specific IgE/total IgE ratio, the affinity and clonality (epitope 
heterogeneity) all affected the degranulation response of the basophils. Individual properties of the IgE 
repertoire affected different aspects of the degranulation response of basophils (Figure 5), and showed 
that (1) higher total IgE concentration increased both the sensitivity and maximal degranulation level of the 
basophils, (2) higher ratios of specific IgE/total IgE increased both the sensitivity and the maximal 
degranulation level of the basophils, (3) increased equality in concentration of different clones of specific 
IgE increased the maximal degranulation level of the basophils, (4) higher affinity of individually specific IgE 
increased the sensitivity of the basophils, and (5) higher clonality increased the sensitivity of the basophils 
[174]. Such results indicate that no single parameter of the IgE repertoire solely determine the degree of 
the allergic response. 
 
The pathological role of specific IgG in food allergy, if any, has not been fully established. Conflicting results 
exist in studies comparing the specific IgG concentrations in atopic and non-atopic individuals, though most 
find a higher level of specific IgG in atopic individuals compared to non-atopic individuals [109;152;175-
178]. For example, Dual et al. [152] showed that the level of shrimp-specific IgG correlated directly with 
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shrimp-specific IgE reactivity, indicating that atopic individuals have a higher level of specific IgG than non-
atopic individuals. In contrast, de Jong et al. [175] found no difference in the level of specific IgG, between 
peanut allergic patients and control subjects. de Jong et al. [175] though found a greater diversity of the IgG 
recognition pattern of the peanut allergic patients compared to the individuals serving as control subjects. 
Similarly, a greater number of IgG epitopes was recognised by hen’s egg allergic patients compared to 
control subjects [179].  It is recognised that specific IgG is not a very useful parameter in the diagnosis of 
food allergy [175;178]. 
 
 
Figure 5. Properties of the IgE 
repertoire affecting the degra-
nulation response. Different 
characteristics of the IgE 
repertoire influences the de-
granulation response of baso-
phils in vitro, by either affecting 
the sensitivity (the amount of 
allergen needed for eliciting a 
half-maximal response) or the 
level of degranulation response 
(percentage mediator release 
of the possible maximum). A. 
Properties of the IgE repertoire 
affecting the sensitivity. B. 
Properties of the IgE repertoire 
affecting the maximal degra-
nulation response. Based on 
Christensen et al. [174]. 
 
 
 
 
 
 
A close relationship have been reported to exist between the specificity of IgE and IgG antibodies 
[157;177;180-183], where for example Jävinen et al. [180] reported that in individuals with persistent cow’s 
milk allergy, the IgG binding epitopes generally colocalised with the IgE binding epitopes and Savilahti et al. 
[157] showed that IgG4 epitopes overlapped with IgE epitopes in cow’s milk allergic patients. Colocalisation 
of IgE and IgG binding epitopes may have great implications for the development of tolerance, since it has 
been demonstrated that development and maintenance of tolerance could be associated with increased 
levels of specific IgG4 [156;157;176;184;185], which has been suggested to induce tolerance by blocking 
the binding of specific IgE to the given food allergen [184;186;187]. Also, high levels of specific IgA have 
been suggested to correlated with development and maintenance of tolerance [156;185;188;189], though 
substantial conflicting reports have been presented [109;157]. Recent studies have suggested an 
implication of free Ig light chain in clinical active type I allergic disease [190-192]. 
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Haddad et al. [193] and Selo et al. [194;195] showed that cleavage of BLG could result in four different 
outcomes: (1) complete suppression of IgE binding, (2) reduced IgE binding, (3) no effect on IgE binding, or 
(4) enhanced IgE binding. This indicates that a great heterogeneity in individual epitope specificity exist, 
which has also been shown for other milk allergens [159], as well as for peanut allergens [171;177;183]. 
Recent studies have suggested a particular important role for linear IgE binding epitopes in food allergy. It is 
suggested that IgE directed towards linear epitopes may react with foods in processed forms (heated and 
digested), while IgE binding to conformational epitopes may be impaired by such processing because of 
changes in allergen tertiary structure [4;148]. In addition, linear epitopes have been suggested to be 
potentially biomarkers for the characterisation of various phenotypes of food allergy [148]. For example, in 
studies of patients with cow’s milk and hen’s egg allergy, it was found that those with IgE directed towards 
linear epitopes in general were more likely to have persistent allergy, while those with IgE directed against 
conformational epitopes were more likely to develop clinical tolerance [158;159;179;180]. For example, 
studies with cow’s milk allergens [168;180;182;196] and hen’s egg allergens [158;179] have suggested an 
association between linear IgE epitope diversity and persistency. Likewise studies with milk allergens [168], 
peanut allergens [171;183] and wheat allergens [197] have indicated an association between linear IgE 
epitope diversity and severity. Shreffler et al. [171] found that patients with IgE antibodies recognising 
many epitopes, identified by IgE binding to overlapping peptides representing the primary sequences of the 
peanut allergens Ara h 1, Ara h 2 and Ara h 3, tended to develop more severe reactions upon ingestion of 
peanut compared to those who recognised few epitopes. Wang et al. [168] found the same pattern for the 
milk allergens αs1-, αs2- and κ-caseins as well as for BLG. In contrast, Heinzmann et al. [198] reported that 
the recognition pattern of linear IgE binding epitopes did not vary with the severity of cow’s milk allergy. 
The latter study was only based on the presence of specific IgE antibodies together with the clinical history 
of cow’s milk allergy, which in general make interpretation of the correlation between severity and epitope 
recognition difficult. 
Some of the identified linear IgE binding epitopes have been identified as candidate biomarkers for 
persistency and severity [158;159;172;182;196;199;200]. For example, Beyer et al. [172] reported that 
peanut allergic patients with persistent allergy recognised specific IgE epitopes, identified by recognition of 
immunodominant decapeptides, which was not recognised by patient who outgrew their allergy or were 
peanut sensitised but tolerated peanut ingestion. Järvinen et al. [196] identified five specific IgE binding 
epitopes on milk allergens as informative and reported that IgE recognition of one to three specific 
epitopes was indicative of persistent cow’s milk allergy, a study which was also based on IgE binding to 
selected decapeptides.  
In a study examining the effect of digestion on the allergenicity of kiwifruit proteins, patients with severe 
allergic reactions recognised epitopes which were resistant to digestion and epitopes emerging as a result 
of the digestion process, not accessible prior to digestion. Patients with mild reactions recognised digestion 
labile epitopes. It was suggested that recognition of epitopes developed from the digestion process could 
be an indicator of a severe allergic phenotype [201]. Likewise Takagi et al. [202] found that patients who 
could recognise pepsinolysis products from the hen’s egg allergen ovomucoid (OVM) were more likely not 
to outgrow their allergy than patients who did not recognise these digestion fragments, which is in 
agreement with results from a study by Urisu et al. [203]. Such results together indicate that combining 
digestion studies with epitope recognition patterns could be a useful tool for the prediction and diagnosis 
of the allergic phenotype. 
The above mentioned papers generally used methods only allowing identification of linear epitopes. Other 
studies which in addition to linear epitopes also focused on identification of conformational epitopes have 
indicated conformational epitopes to be of importance in food allergy [204-207]. This suggest that use of 
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overlapping short peptides resembling the primary sequence of an allergen for epitope identification, may 
not be ideal for all dietary proteins. 
Although there are some limitations with methods identifying IgE binding epitopes, IgE epitope pattern 
recognition identification is suggested as being a promising future tool in predicting, diagnosing and 
treating food allergic individuals [4;148], and may add new knowledge to the understanding of the 
mechanisms underlying tolerance versus sensitisation [4;148]. 
 
 
Resistance to digestion - a food allergen characteristic? 
 
One of the features proposed to be a characteristic shared by food allergens, which is also one of those that 
have received most attention in recent years, is resistance to digestion. Stability to proteolysis is generally 
believed to be an important feature of ‘complete’ food allergens because a protein able to sensitise the 
mucosal immune system of the GI tract must survive the digestion process as an intact protein or as large 
fragments [15-18]. This hypothesis seems highly reasonable, since the longer a significant portion of the 
protein resists digestion, the more likely it is to encounter the cells of the inductive mucosal immune 
system and further the more likely it is to retain adequate structure and size to be recognised by these 
cells. This increases the likelihood of sensitisation and upon reexposure to the allergen increases the 
likelihood for cross-linking of IgE molecules bound to the surface of effector cells, thereby eliciting allergic 
responses [15;17]. Studies where impairment of the digestion process led to increased allergenicity of the 
proteins under investigation further support the hypothesis [57;208;209]. For examples, studies with 
antacid drugs, medications that hinder peptic digestion by raising pH, converted normally degradable 
dietary proteins into potentially allergens, promoting sensitisation to caviar proteins in mice [210] and 
hazelnut proteins in mice and humans [211]. 
 
There is no evidence for a specific molecular weight (MW) above which peptides may behave as ‘complete’ 
allergens and below which they may not. Still many different suggestions for a lower MW limit, 
representing the minimum size of a peptide with inherent allergenicity, have been presented. Overall, the 
general opinion appears to be that the lower limit for allergenicity of peptides is a MW of approximately 3.5 
kDa [14;19;212;213]. Such suggestion may, in addition to experimental evidence, be based on the 
assumption that there must be at least two IgE binding sites on a peptide [14], each constituting a 
minimum of 15 amino acids covered by the antibody paratope [133]. This equals a minimum of 30 amino 
acid residues necessary for cross-linking of two IgE molecules and elicitation of an allergic response, and 
corresponds to an average MW of 3.5 kDa. 
 
In 1996 Astwood et al. [18] compared resistance to pepsin digestion in simulated gastric fluid (SGF) for 
allergenic and non-allergenic proteins. This study was a systematically evaluation of the stability of known 
food allergens and proteins with no proven allergenicity using a simple in vitro model of gastric digestion. 
The study showed that while major food allergens in general resisted the digestion process, non-allergenic 
proteins were in contrast rapidly digested. These results were in agreement with the hypothesis that it is a 
requisite for food allergens to survive the GI digestion process for retainment of sufficient structure and 
size for uptake and sensitisation when reaching the inductive immune system of the intestinal mucosa. 
Thereby Astwood et al. [18] concluded that stability to digestion is a significant and valid parameter for 
distinguishing food allergens from non-allergenic dietary proteins and suggested that the ability of food 
allergens to reach the intestinal mucosa in intact form is a necessity for allergenicity.  
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The study by Astwood et al. [18] contributed to the inclusion of pepsin resistance as a test parameter in the 
safety assessment of novel proteins in genetically modified foods. In both the report of FAO/WHO from 
2001 [19] and the report of Codex Alimentarius Commission from 2003 [21], concerning evaluation of 
allergenic potential of genetically modified foods, it is recommended that resistance of the novel protein to 
degradation in the presence of pepsin should be incorporated in the test regime. FAO/WHO [19] 
recommends that the purified protein in non-heated and non-processed from, as well as the main edible 
form, should be subjected to pepsin degradation. The pepsin-protein mixture should be prepared using 0.5 
mg of protein in 0.2 mL of 0.32% pepsin (w:v), corresponding to a pepsin to protein ratio of 12.8, in 30 
mM/L NaCl, pH 2.0, and maintained shaking at 37 °C for 60 min. Aliquots from the digestion mixture should 
be taken at different time points, at 0, 15 and 30 sec and at 1, 2, 4, 8, 15 and 60 min. Analysis for protein 
stability and presence of intact protein or intact peptide fragments greater than 3.5 kDa should be 
evaluated using 10-20% gradient Tricine sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gels or equivalent gel systems under both reducing and non-reducing conditions, followed by 
staining procedures (Figure 6) [19]. It is well recognised that the described digestion protocol do not mimic 
the physiological conditions of the human gastric digestion [21], wherefore the EFSA report from 2010 [20], 
concerning assessment of allergenicity of genetically modified organisms, recommends that resistance to 
digestion of novel proteins should be evaluated using other in vitro digestibility methods, methods 
designed to mimic physiological conditions and thereby simulating the conditions of the human digestion 
process.  
 
Since the study by Astwood et al. [18], further studies comparing the digestibility of allergens with non-
allergenic dietary proteins have been performed [56;120;214-217]. These studies did in general not support 
an obvious correlation between resistance to digestion and allergenicity. In contrast to the study by 
Astwood et al. [18], where most of the tested allergens were storage proteins, while all tested protein with 
no proven allergenicity were enzymes, Fu et al. [120] compared allergens with non-allergenic proteins of 
similar functions. Fu et al. [120] showed that some proteins, such as storage proteins were inherently more 
stable to digestion than other proteins, such as enzymes, and concluded that food allergens were not 
always more resistant to digestion measured in vitro than non-allergenic proteins and that it could be 
difficult to rank the allergenic potential of proteins based on their susceptibility to pepsin digestion. Kenna 
and Evans [214] likewise concluded that allergens and proteins with no allergenicity display similar stability 
to pepsin digestion in SGF and that resistance to digestion is not a characteristic equal to food protein 
allergenic potential.  
While the studies by Astwood et al., [18], Fu et al., [120], Kenna and Evans [214] and Thomas et al. [56] 
used the visual time disappearances of intact protein and/or large fragments in SDS-PAGE gels as the 
parameter  to assess digestion (which may be a highly subjective parameter for evaluation [217]), Herman 
et al. [216] calculated the half-life of the test protein, assuming a negative exponential (first-order kinetics) 
decline and Ofori-Anti et al. [217] estimated the time point achieving 90% digestion. Ofori-Anti et al. [217] 
report that all three methods have limitations. While the method by Astwood et al. [18], Fu et al. [120], 
Kenna and Evans [214] and Thomas et al. [56] rely on the reliable detection of bands with residual intact 
protein or fragments hereof, the methods by Herman et al. [216] and Ofori-Anti et al. [217] may be difficult 
to interpret for very labile proteins as well as very stable proteins. 
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Figure 6. Example of the visualisation of the digestion 
process of the peanut allergen Ara h 1. Ara h 1 was 
digested in an in vitro model simulating the human 
gastro-duodenal digestion. The digestion process was 
divided into 2 phases, resembling the gastric (A and B) 
and duodenal (C) digestion, respectively. Gastric 
digestion was performed with immobilised pepsin with 
an activity of 162 unit per mg of Ara h 1 (corresponding 
to a pepsin:Ara h 1 ratio of approximately 0.05 (w:w) for 
soluble pepsin), at pH 2.5 for 120 min at 37 °C, followed 
by duodenal digestion, performed with immobilised 
trypsin and chymotrypsin with an activity of 34.5 and 
0.44 unit per mg of Ara h 1, respectively, (corresponding to a trypsin:chymotrypsin:Ara h 1 ratio of approximately 
0.0025:0.01:1 (w:w:w) for soluble enzymes) at pH 6.5 for 16 min at 37 °C. Aliquots of 10 µL from the gastric digestion 
process were taken at the time points of 0, 1, 2, 4, 8, 16, 30, 60, 90 and 120 min and from the duodenal digestion 
process at the time points of 0, 2, 4, 8 and 16 min. SDS-PAGE was performed with 4-12% Bis-Tris Gel with MES running 
buffer under non- as well as reducing conditions. Gels were stained with SimpleBlue™ (SimpleBlue™ Safestain (Ready-
to-use, fast, sensitive and safe Coomassie® G-250) Invitrogen, Carlsbad, CA, USA). As standard markers Mark 12™ was 
used (Unstained standard, Invitrogen, Carlsbad, CA, USA). [Own unpublished data]. 
 
 
Degradation of known food allergens 
Besides comparative studies of the susceptibility to pepsinolysis of known allergens with proteins of no 
proven allergenicity, many studies have been performed, selectively studying the resistance of known food 
allergens to pepsin degradation. Table 1 summarises the pepsin stability data of purified food allergens 
originating from plants and Table 2 summarises the pepsin stability data of purified food allergens 
originating from animals. While studies of the susceptibility to pepsinolysis is simply used as a model 
system for evaluation of the general biochemical stability of proteins, or is designed only to mimic the 
digestion process that takes place in the stomach, several studies have been performed mimicking the 
physiologic digestion process that takes place in the duodenum as well, as recommended by the EFSA panel 
[20]. Digestion products from such studies reflect to a greater extent the peptide profile to which the 
inductive mucosal immune system is exposed, and thereby the situation of oral sensitisation [20]. Table 3 
summarises the stability data of purified food allergens exposed to simulated gastro-duodenal digestion.  
Nonreduced Reduced 
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Digestion conditions, known to influence the outcome of the digestibility assay, such as enzyme to allergen 
ratios, pH and digestion time, are included in the Tables. Studies of food allergen stability have been 
performed based on either enzyme mass to allergen mass ratios or enzyme mass to allergen molarity. Only 
enzyme mass to allergen mass ratios are included in the Table 1-3, based on the statement of Ofori-Anti et 
al. [217] that the use of a constant mass provides the most reliable comparison parameters. Enzyme 
activity unit per mg of allergen have also been included in the Tables, since different enzyme products can 
be purchased, as well as there may be batch to batch variation of individual products, with varying activity 
units per mg of solid enzyme. In addition, studies have been performed using enzymes immobilised to 
agarose. 
 
No clear definition seems to exist, defining an allergen as labile or stable to digestion. Yet, Goodman and 
Hefle [218] describe a protein no longer detectable after 2 min of digestion as unstable, a protein no longer 
detectable between 2 and 15 min of digestion as partially stable, while a protein still detectable after 60 
min of digestion is described as stable. In Tables 1-3, an allergen is defined as stable, under the given 
digestion conditions, when identifiable residual intact protein was left after termination of the digestion 
process. Stability time varied greatly among the allergens as well as did the stability time for individual 
allergens under different digestion conditions.  
Also no general consensus seems to exist about the importance of the stability of peptide fragments 
emerging from the proteolysis processes. While all studies on food allergen digestibility evaluated the 
stability of intact allergen, far less considered the stability of peptide fragments generated during the 
digestion process, and even less identified the size of the largest fragments (Tables 1-3). However, if the 
general assumption is that any peptide fragments larger than 3.5 kDa may be of importance for the 
potential allergenicity of a food allergen [14;19;212;213], although it can not necessarily be ranked 
alongside the intact protein, greater effort for identifying such fragments may be reasonable. Thomas et al. 
[56], Herman et al. [216], Takagi et al. [215] as well as Ofori-Anti et al. [217] all acknowledged the 
importance of considering stable peptide fragments derived from food allergens that are rapidly digested, 
such as the major peanut allergens Ara h 1 and Ara h 2 as well as the major hen’s egg allergen OVM, which 
form stable fragments upon digestion that retain significant IgE binding capacities [203;219-221]. In 
addition, the EFSA panel [20] expresses that the appearance of stable peptide fragment or aggregates 
hereof formed during the digestibility assay should be considered as a risk factor for allergenicity, and 
recommends that peptide fragments and aggregates should be further investigated. Thus in addition to the 
stability of the intact proteins, the stability of the peptide fragments formed during the digestion process, 
also needs to be evaluated [20]. 
 
Table 1. Stability of allergens derived from plant foods to digestion with pepsina. 
Source Allergenb Sizec 
(kDa) 
Pepsin:
aller-
gen 
MW 
ratio 
Enzyme 
activity 
unit/mg 
allergen 
pH Diges
-tion 
time 
(min) 
Stabi-
lity 
Stabi-
lity 
timed 
(min) 
Largest 
frag-
ments 
(kDa) 
Ref. 
Peanut Ara h 1, Cupin 
(Vicilin-type, 7S 
globulin) 
64 nde 162 2.5 120 no 4 4 * 
0.05 162 2.5 120 no 1 ~5.6 [222] 
12.8 nd 1.2 120 no 5 nd [120] 
3.04 10,000 1.2 60 no 0.5 nd [223] 
0.30 1,000 1.2 60 no 0.5 nd [223] 
0.03 100 1.2 60 no 0.5 nd [223] 
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Table 1. Stability of allergens derived from plant foods to digestion with pepsina. Continued…. 
Source Allergenb Sizec 
(kDa) 
Pepsin:
aller-
gen 
MW 
ratio 
Enzyme 
activity 
unit/mg 
allergen 
pH Diges
-tion 
time 
(min) 
Stabi-
lity 
Stabi-
lity 
timed 
(min) 
Largest 
frag-
ments 
(kDa) 
Ref. 
Peanut Ara h 2, 
Conglutin (2S 
albumin) 
17 3 10,000 1.2 60 no 0-2 ~10 [56] 
3 10,000 2 60 no 0-30 ~10 [56] 
19 nd 1.2 60 yes - - [18] 
12.8 nd 1.2 120 no 0.5 nd [120] 
3.04 10,000 1.2 60 no 16 ~10 [223] 
0.30 1,000 1.2 60 yes - - [223] 
0.03 100 1.2 60 yes - - [223] 
0.4 nd 2.1 40 no - - [220] 
Ara h 3, Cupin 
(Legumin-type, 
11S globulin, 
Glycinin) 
60 3.04 10,000 1.2 60 no 0.25 nd [223] 
0.30 1,000 1.2 60 no 0.25 nd [223] 
0.03 100 1.2 60 no 0.25 nd [223] 
0.002 nd 2 120 no <10 <14 [224] 
Ara h 6 
Conglutin (2S 
albumin) 
15 3.04 10,000 1.2 60 no 4 ~10 [223] 
0.30 1,000 1.2 60 no 16 ~10 [223] 
0.03 100 1.2 60 yes - - [223] 
nde 6.49 3 120 yes - - [225] 
Lectin? ? 19 Nd 1.2 60 no 8 non 
visual 
[18] 
12.8 nd 1.2 120 no 5 nd [120] 
Soy Gly m 1 (ns-LTP) 7 19 nd 1.2 60 no 0 non 
visual 
[18] 
12.8 nd 1.2 120 no 2 nd [120] 
Gly m 5, 
Conglycinin 
(Vicilin-type, 7S 
globulin) α-
subunit 
67 19 nd 1.2 60 no 2 non 
visual 
[18] 
12.8 nd 1.2 120 no 0 nd [120] 
Gly m 5, 
Conglycinin, 
(Vicilin-type, 7S 
globulin) β-
subunit 
48 19 nd 1.2 60 yes - - [18] 
12.8 nd 1.2 120 yes - - [120] 
Gly m 6, 
Glycinin 
(Legumin-type, 
11 S globulin) 
60 0.002 nd 2 120 no - <25 [224] 
STI, Trypsin-
inhibitor? 
19 3 10,000 1.2 60 yes - - [56] 
3 10,000 2 60 yes - - [56] 
19 nd 1.2 60 yes - - [18] 
12.8 nd 1.2 120 yes - - [120] 
  19 3.04 10,518 2 60 yes - - [215] 
   0.94 nd 1.2 60 yes - - [226] 
 Lectin? ? 19 nd 1.2 60 no 15 non 
visual 
[18] 
   12.8 nd 1.2 120 no 5 nd [120] 
Black gram ? 28 0.94 nd 1.2 60 no 15 ~16 [227] 
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Table 1. Stability of allergens derived from plant foods to digestion with pepsina. Continued… 
Source Allergenb Sizec 
(kDa) 
Pepsin:
aller-
gen 
MW 
ratio 
Enzyme 
activity 
unit/mg 
allergen 
pH Diges
-tion 
time 
(min) 
Stabi-
lity 
Stabi-
lity 
timed 
(min) 
Largest 
frag-
ments 
(kDa) 
Ref. 
Brazil nut Ber e 1, (2S 
albumin) 
9+4 16.7 nd 1.2 60 no 15 nd [228] 
0.05 182 2.5 120 yes - - [54] 
0.05f 182 2.5 120 yes - - [54] 
1.3 9,600 2 60 yes - - [229] 
16.7 nd 1.2 60 no 15 nd [230] 
Hazelnut Cor a 1, PR-10 
(Bet v 1 
homologueg) 
17.5 0.4 nd 1 30 no 0 ~1.6 [117] 
Sesame 
seed 
Ses i 1, (2S 
albumin) 
9+4 0.05 182 2.5 120 yes - - [231] 
0.05f 182 2.5 120 yes - - [231] 
0.05h 182 2.5 120 yes - - [231] 
Sunflower 
seed 
SFA-8, (2S 
albumin) 
? 16.7 nd 1.2 60 no 30 nd [228] 
16.7 nd 1.2 60 no 5 nd [230] 
Rapeseed Bra n 1, 
(2S albumin) 
9+4 16 nd 1.2 60 yes - - [232] 
Rice ? ~16 0.025 nd 1.2 120 yes - - [233] 
Yellow 
mustard 
Sin a 1, (2S 
albumin)  
9+4 19 nd 1.2 60 yes - - [18] 
Oriental 
mustard 
Bra j 1, (2S 
albumin) 
9+4 19 nd 1.2 60 yes - - [18] 
Potato Sola t 1 
(Phatatin) 
43 12.8 nd 1.2 120 no 0 nd [120] 
Celery Api g 1, PR-10 
(Bet v 1 
homologueg) 
15 0.43 nd 1 30 no 0 ~1.2 [117] 
Api g 2, (ns-LTP) 10 0.05 nd 2 120 yes - - [234] 
Peach Pru p 3, (ns-LTP) 10 20 nd 1.2 30 yes - - [235] 
6.4 nd 1.2 30 yes - - [236] 
0.017 nd 2 180 yes - - [237] 
Grape Vit v 1, (ns-LTP) 9 0.05 182 2.5 120 yes - - [43] 
0.05f 182 2.5 120 yes - - [43] 
Cherry Pru av 1, PR-10 
(Bet v 1 
homologueg) 
9 nde ≥60,000 2.5 120 no 30 nd [116] 
Pru av 3, (ns-
LTP) 
10 nde ≥60,000 2.5 120 yes - - [116] 
Pru av 4, 
(Profiling) 
15 nde ≥60,000 2.5 120 no 1 nd [116] 
Apple Mal d 1, PR-10 
(Bet v 1 
homologousg) 
17.7 1.74 nd 2 30 no 0 nd [238] 
0.4 nd 1 30 no 0 ~1.8 [117] 
Melon Cuc m 2, 
(Profiling) 
14 6.4 nd 1.2 30 no <30 non 
visual 
[236] 
Papaya Papain 
superfamily 
? 12.8 nd 1.2 120 no 0 nd [120] 
Pineapple Bromelain, 
papain 
superfamily 
? 12.8 nd 1.2 120 no 0 nd [120] 
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Table 1. Stability of allergens derived from plant foods to digestion with pepsina. Continued… 
Source Allergenb Sizec 
(kDa) 
Pepsin:
aller-
gen 
MW 
ratio 
Enzyme 
activity 
unit/mg 
allergen 
pH Diges
-tion 
time 
(min) 
Stabi-
lity 
Stabi-
lity 
timed 
(min) 
Largest 
frag-
ments 
(kDa) 
Ref. 
Kiwi Act c 1, actinidin 27.4 0.05 212 2.5 60 yes - - [239] 
Act c 2, 
taumatin-like 
protein 
24 0.05 212 2.5 120 yes - - [239] 
6.5 nd 1.2 60 no   [50] 
16 nd 1.2 60 no 1 nd [240] 
Actinidin, 
papain 
superfamily 
? 12.8 nd 1.2 120 no 0 nd [120] 
Avocado Pers a 1, 
chitinaseg 
32 20 nd 1.2 30 no 0 ~5-6 [235] 
aSummary of allergen stability to pepsin, simulating the digestion process that takes place in the stomach. Included in 
the Table is only digestibility results from pure plant food derived allergens, digested at 37 °C, for which it was possible 
to identify a pepsin to allergen ratio, either expressed by an MW ratio or an enzyme activity per mg allergen ratio, 
bAllergen name and structural family to which it belong are based on the Allergen nomenclature (IUIS Allergen 
Nomenclature Sub-Committee). www.allergen.org. cSizes of allergens are based on the Allergen nomenclature (IUIS 
Allergen Nomenclature Sub-Committee). www.allergen.org, dStability time is based on either the one described by the 
given author or from the visual appearance in a presented SDS-PAGE  eImmobilised enzymes, fSurfactant, gNon-
sensitising allergen, hPreheating, *Own unpublished data, Abbreviations: MW, molecular weight; nd, not described; ns-
LTP, nonspecific-lipid transfer protein; PR-10, pathogenesis-related protein-10; SDS-PAGE, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. 
Table 2. Stability of allergens derived from animal foods to digestion with pepsina. 
Source Allergenb Sizec 
(kDa) 
Pepsin:
aller-
gen 
MW 
ratio 
Enzyme 
activity 
unit/mg 
allergen 
pH Diges
tion 
time 
(min) 
Stabi-
lity 
Stabi-
lity 
timed 
(min) 
Largest 
frag-
ments 
(kDa) 
Ref. 
Cow’s milk Bos d 4 (ALA) 14.2 12.8 nd 1.2 120 no 0 nd [120] 
0.02 nd 2 90 no nd ~7.5 [241] 
0.02 nd 3 90 no nd ~7.5 [241] 
0.02 nd 4 90 yes - - [241] 
0.05 182 2.5 120 no 5 < 6.5 [41] 
0.05e 182 2.5 120 no 30 < 6.5 [41] 
Bos d 5 (BLG) 18.3 3 10,000 1.2 60 yes - - [56] 
3 10,000 2 60 yes - - [56] 
0.05e 182 2.5 60 yes - - [39] 
   0.007e 25 3 60 yes - - [39] 
   19 nd 1.2 60 yes - - [18] 
   12.8 nd 1.2 120 yes - - [120] 
   3.04 10,518 2 60 yes - - [215] 
   0.02 nd 2 90 yes - - [241] 
   0.02 nd 3 90 yes - - [241] 
   0.02 nd 4 90 yes - - [241] 
   0.05 182 2.5 60 yes - - [242] 
   0.05 182 2.5 60 yes - - [42] 
   12.8 42,240 1.2 120 no 0 nd [243] 
   0.05 165 2.5 60 yes - - [243] 
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Table 2. Stability of allergens derived from animal foods to digestion with pepsina. Continued… 
Source Allergenb Sizec 
(kDa) 
Pepsin:
aller-
gen 
MW 
ratio 
Enzyme 
activity 
unit/mg 
allergen 
pH Diges
-tion 
time 
(min) 
Stabi-
lity 
Stabi-
lity 
timed
(min) 
Largest 
frag-
ments 
(kDa) 
Ref. 
 Bos d 5, (BLG)  0.05e 165 2.5 60 yes - - [243] 
3.05 10,000 1.2 60 yes - - [217] 
0.94 nd 1.2 60 yes - - [226] 
nd 10,000 1.5 60 yes - - [201] 
16 55,356 1.2 60 yes - - [244] 
Bos d 6, (BSA) 37 3 10,000 1.2 60 no 0-2 ~6 [56] 
3 10,000 2 60 no 0-2 ~6 [56] 
19 nd 1.2 60 no 0.5 non 
visual 
[18] 
3.05 10,000 1.2 60 no 0.5 ~3.9 [217] 
12.8 nd 1.2 120 no 0 nd [120] 
0.02 nd 2 90 no nd ~11 [241] 
0.02 nd 3 90 no nd ~11 [241] 
0.02 nd 4 90 no nd ~31 [241] 
3.04 10,518 2 60 no 0.5 ~3.9 [215] 
13 nd 1.2 60 no 5 nd [50] 
0.025 nd 1.2 120 no <10 non 
visual 
[233] 
16.7 nd 1.2 60 no 5 nd [230] 
16 nd 1.2 60 no 0 nd [232] 
16.7 nd 1.2 60 no 0 nd [228] 
Bos d 7, (IgG) 160 0.02 nd 2 90 no nd ~30 [241] 
0.02 nd 3 90 yes - - [241] 
0.02 nd 4 90 yes - - [241] 
Bos d 8, (β-
casein) 
24 0.007e 25 3 60 no 10 7.4 [39] 
 19 nd 1.2 60 no 2 non 
visual 
[18] 
 12.8 42,240 1.2 120 no 0.1 nd [243] 
 0.05 165 2.5 60 no 10 ≥3.5 [243] 
 0.05e 165 2.5 60 no 10 ≥3.5 [243] 
 0.05 182 2.5 60 no 20 nd [242] 
Bos d 8, (α-
casein) 
? 12.8 nd 1.2 120 no 0 nd [120] 
Lactoperoxidase ? 12.8 nd 1.2 120 no 0 nd [120] 
 Lactoferrin  ? 3.05 10,000 1.2 60 no 0.5 ~5.4 [217] 
Hen’s egg Gal d 1, (OVM) 28 19 nd 1.2 60 no 8 non 
visual 
[18] 
   12.8 nd 1.2 120 no 0 nd [120] 
   3.04 10,518 2 60 no 0.5 <3 [215] 
   nd 10,000 2 60 no 0.5 4.5-6 [202] 
   nd 10,000 2 60 no 2 4.5-6 [202] 
   nd 10,000 2 60 no 30 4.5-6 [202] 
   0.05 nd 2 120 no 10 18 [245] 
   0.05 nd 2.5 60 no 10 18 [246] 
   0.05f nd 2.5 60 no 10 18 [246] 
 Gal d 2, (OVA) 44 3 10,000 1.2 60 yes - - [56] 
   3 10,000 2 60 yes - - [56] 
   0.05 182 2.5 60 yes - - [39] 
   0.007 25 3 60 yes - - [39] 
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Table 2. Stability of allergens derived from animal foods to digestion with pepsina. Continued… 
Source Allergenb Sizec 
(kDa) 
Pepsin:
aller-
gen 
MW 
ratio 
Enzyme 
activity 
unit/mg 
allergen 
pH Diges
tion 
time 
(min) 
Stabi-
lity 
Stabi-
lity 
timed 
(min) 
Largest 
frag-
ments 
(kDa) 
Ref. 
Hen’s egg Gal d 2 (OVA)  19 nd 1.2 60 yes - - [18] 
12.8 nd 1.2 120 no 5 nd [120] 
3.04 10,518 2 60 yes - - [215] 
3.04 10,518 2 60 nod 0.5 non 
visual 
[215] 
8  1.2 60 yes - - [247] 
2  1.2 60 yes - - [247] 
3.05 10,000 1.2 60 yes - - [217] 
16 55,356 1.2 60 no 15 nd [244] 
0.2 114 2.5 120 yes - - [248] 
0.05 nd 2.5 60 yes - - [246] 
0.05f nd 2.5 60 no 10 ~4 [246] 
0.05 172 2 60 yes - - [249] 
0.05e 172 2 60 yes - - [249] 
Gal d 3, (OT) 78 19 nd 1.2 60 no 0 non 
visual 
[18] 
12.8 nd 1.2 120 no 0 nd [120] 
Gal d 4, (HEL) 14 12.8 nd 1.2 120 no 60 nd [120] 
3.05 10,000 1.2 60 yes - - [217] 
16 55,356 1.2 60 no 8 nd [244] 
Phosvitin, 
kinase? 
? 19 nd 1.2 60 yes - - [18] 
Fish, whiff Lep w 1, 
Parvalbumin 
12 0.05f 212 2.5 120 yes/ 
nog 
0 nd [250] 
Shrimp Pen a 1, 
Tropomyosin 
36 12.8 nd 1.2 120 no 0 nd [120] 
 Lit v 1, 
Tropomyosin 
36 0.02 333 1.2 60 yes - - [251] 
Prawn Pen m 1, 
Tropomyosin 
38 0.02 333 1.2 60 yes - - [251] 
Crab Tropomyosin 34 0.02 333 1.2 60 yes - - [252] 
0.02 333 1.2 60 yes - - [253] 
aSummary of allergen stability to pepsin, simulating the digestion process that takes place in the stomach. Included in 
the Table is only digestibility results from pure animal foods derived allergens, digested at 37 °C, for which it was 
possible to identify a pepsin to allergen ratio, either expressed by an MW ratio or an enzyme activity per mg allergen 
ratio, bAllergen name and structural family to which it belong are based on the Allergen nomenclature (IUIS Allergen 
Nomenclature Sub-Committee). www.allergen.org. cSizes of allergens are based on the Allergen nomenclature (IUIS 
Allergen Nomenclature Sub-Committee). www.allergen.org, dStability time is based on either the one described by the 
given author or from the visual appearance in a presented SDS-PAGE, eSurfactant, fPreheating, gThe protein was stable 
as a dimer but not as a monomer, Abbreviations: ALA, α-lactalbumin; BLG, β-lactoglobulin; BSA, bovine serum 
albumin; HEL, hen egg lysozyme C; MW, molecular weight; nd, not described; OT, ovotransferrin; OVA, ovalbumin; 
OVM, ovomucoid; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 
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Table 3. Stability of allergens derived from plant and animal foods to digestion with pepsin followed by trypsin and 
chymotrypsina. 
Source Allergenb Sizec 
(kDa) 
Pepsin/Tryp-
sin/Chymo-
trypsin:aller-
gen MW 
ratio 
Enzyme 
activity 
units/mg 
allergen 
pH Diges
-tion 
time 
(min) 
Sta-
bi-
lity 
Stabi-
lity 
timed 
(min) 
Largest 
frag-
ments 
(kDa) 
Ref. 
Peanut Ara h 1, 
Cupin 
(Vicilin-type 
7S globulin) 
63.5 nde 162/ 
34.5/0.44 
2.5/6.5 120+
16 
no 4 2 * 
0.05/ 
0.0025/0.01 
162/ 
34.5/0.44 
2.5/6.5 120+
16 
no 1 - [222] 
Brazil 
nut 
Ber e 1, (2S 
albumin) 
9+4 0.05/ 
0.0025/0.01 
182/ 
34.5/0.44 
2.5/6.5 120+
120 
no 120+
nd 
1.1 [54] 
0.05/ 
0.0025/0.01f 
182/ 
34.5/0.44 
2.5/6.5 120+
120 
no 120+
nd 
1.1 [54] 
Sesame 
seed 
Ses i 1, (2S 
albumin) 
9+4 0.05/ 
0.0025/0.01 
182/ 
34.5/0.44 
2.5/6.5 120+
120 
no 120+
nd 
nd [231] 
0.05/ 
0.0025/0.01f 
182/ 
34.5/0.44 
2.5/6.5 120+
120 
no 120+
nd 
nd [231] 
0.05/ 
0.0025/0.01h 
182/ 
34.5/0.44 
2.5/6.5 120+
120 
no 120+
nd 
nd [231] 
Grape Vit v 1, (ns-
LTP) 
9 0.05/ 
0.0025/0.01 
182/ 
34.5/0.44 
2.5/6.5 120+
120 
yes - - [43] 
0.05/ 
0.0025/0.01f 
182/ 
34.5/0.44 
2.5/6.5 120+
120 
yes - - [43] 
Peach Pru p 3, (ns-
LTP) 
10 0.017/ 
0.017/0.017 
nd 2/7.8 180+
240 
yes - - [237] 
Celery Api g 2, (ns-
LTP) 
10 0.05/ 
0.0025/0.01 
nd 2/7.8 120+
120 
yes - - [234] 
Kiwi Act d 1 27.4 0.05/ 
0.0025/0.01 
212/ 
34.5/0.44 
2.5/6.5 60+ 
30 
yes - - [230] 
Act d 2 24 0.05/ 
0.0025/0.01 
212/ 
34.5/0.44 
2.5/6.5 120+
120 
yes - - [230] 
Apple Mal d 1g 17.7 1.74/ 
0.844/0 
nd 2/7.7 30+ 
30 
no 0 nd [238] 
Cow’s 
milk 
Bos d 4 
(ALA) 
14.2 0.05/ 
0.0025/0.01 
182/ 
34.5/0.44 
2.5/6.5 120+
120 
no 5 <<6.5 [41] 
 0.05/ 
0.0025/0.01f 
182/ 
34.5/0.44 
2.5/6.5 120+
120 
no 30 <<6.5 [41] 
Bos d 5, 
(BLG) 
18.3 0.05/ 
0.0025/0.01f 
182/ 
34.5/0.4 
2.5/6.5 60+ 
30 
yes - - [39] 
 0.05/ 
0.0025/0.01f 
182/ 
34.5/0.4 
3/6.5 60+ 
30 
yes - - [39] 
 0.05/ 
0.0025/0.01 
165/ 
34.5/0.5 
2.5/6.5 60+ 
30 
yes - - [243] 
 0.05/ 
0.0025/0.01f 
165/ 
34.5/0.4 
2.5/6.5 60+ 
30 
yes - - [243] 
 0.05/ 
0.0025/0.01 
182/ 
34.5/0.4 
2.5/6.5 60+ 
30 
yes - - [42] 
 0.05/ 
0.0025/0.01f 
182/ 
35.5/0.4 
2.5/6.5 60+ 
30 
yes - - [42] 
 0.05/ 
0.0025/0.01 
182/ 
34.5/0.4 
2.5/6.5 60+ 
30 
no 60+ 
15 
nd [242] 
Bos d 8 (β-
casein) 
24 0.05/ 
0.0025/0.01f 
182/ 
34.5/0.4 
2.5/6.5 60+ 
30 
no 10 ~1.73 [39] 
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Table 3. Stability of allergens derived from plant and animal foods to digestion with pepsin followed by trypsin and 
chymotrypsina. Continued… 
Source Allergenb Sizec 
(kDa) 
Pepsin/Tryp-
sin/Chymo-
trypsin:aller-
gen MW 
ratio 
Enzyme 
activity 
units/mg 
allergen 
pH Diges
-tion 
time 
(min) 
Sta-
bi-
lity 
Stabi-
lity 
timed 
(min) 
Largest 
frag-
ments 
(kDa) 
Ref. 
Cow’s 
milk 
Bos d 8 (β-
casein) 
 0.05/ 
0.0025/0.01f 
182/ 
34.5/0.4 
3/6.5 60+ 
30 
no 10 ~3 [39] 
   0.05/ 
0.0025/0.01 
165/ 
34.5/0.5 
2.5/6.5 60+ 
30 
no 10 non 
visual 
[243] 
   0.05/ 
0.0025/0.01f 
165/3 
4.5/0.4 
2.5/6.5 60+ 
30 
no 10 non 
visual 
[243] 
   0.05/ 
0.0025/0.01 
182/ 
34.5/0.4 
2.5/6.5 60+ 
30 
no 20 nd [242] 
Hen’s 
egg 
Gal d 1 
(OVM) 
28 0.005/ 
0.002/0.002 
nd 2/~7.5 30+ 
180 
no nd >20 [245] 
 Gal d 2 
(OVA) 
44 0.05/ 
0.0025/0.01f 
182/ 
34.5/0.4 
2.5/6.5 60+ 
30 
yes - - [39] 
   0.05/ 
0.0025/0.01f 
182/ 
34.5/0.4 
3/6.5 60+ 
30 
yes - - [39] 
   0.05/nd/nd 172/40/0.5 2/7 60+ 
60 
yes - - [249] 
aSummary of allergen stability to pepsin, simulating the digestion process that takes place in the stomach, followed by 
trypsin and chymotrypsin, simulating the digestion process that takes place in the duodenum. Included in the Table is 
only digestibility results from pure plant and animal foods derived allergens, digested at 37 °C, for which it was 
possible to identify a enzyme to allergen ratios, either expressed by an MW ratio or an enzyme activity per mg 
allergen ratio, bAllergen name and structural family to which it belong are based on the Allergen nomenclature (IUIS 
Allergen Nomenclature Sub-Committee). www.allergen.org. cSizes of allergens are based on the Allergen 
nomenclature (IUIS Allergen Nomenclature Sub-Committee). www.allergen.org, dStability time is based on either the 
one described by the given author or from the visual appearance in a presented SDS-PAGE, eImmobilised enzymes, 
fSurfactant, gNon-sensitising allergen, hPreheating, *Own unpublished data, Abbreviations: ALA, α-lactalbumin; BLG, β-
lactoglobulin; MW, molecular weight; nd, not described; ns-LTP, nonspecific-lipid transfer protein; OVA, ovalbumin; 
OVM, ovomucoid; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; STI, soybean trypsin 
inhibitor. 
 
More than half of the digestibility evaluated allergens, proved no stability to digestion (Table 1-3). For 
example for the plant derived food allergens 19 proved no stability to pepsinolysis, 5 showed both to be 
stable and labile, depending on the digestibility conditions, while 11 proved to be stabile to the pepsin 
digestion (Table 1). This indicates that no strict correlation exist between resistance to digestion and 
allergenicity. This viewpoint is in agreement with Fu et al. [120;254], stating in 2002 that such correlation 
was not absolute.  
 
Although the exact mechanisms by which food allergens sensitise are currently unknown, food allergens 
are thought to sensitise through the oral route, and consequently sensitise through the intestinal mucosal 
immune system [255]. Such food allergens are designated ‘complete’ allergens [115]. In addition to 
‘complete’ food allergens, some food protein, known to elicit allergic reactions, are thought not to induce 
allergic sensitisation [255;256]. Patients suffering from e.g. pollen or latex allergies may experience 
immediate reactions upon ingestion of foods, mainly fruits and vegetable [257]. Such association is due to 
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cross-reacting IgE antibodies, recognising structures of the dietary protein homologous to IgE binding sites 
of pollen or latex allergens [257]. In Europe, more than 70% of patients suffering from pollen allergy may 
experience symptoms after food intake. Here the food allergens from e.g. the pathogenesis-related 
protein-10 (PR-10) family, Mal d 1 from apple, Cor a 1 from hazelnut, Pru av 1 from cherry and Api g 1 from 
celery are allergens that cross-react with IgE antibodies specific for the major birch pollen allergen Bet v 1 
and e.g. the food allergens from the profiling family such as Pru av 4 from cherry is an allergen cross-
reacting with the birch pollen allergen Bet v 2 [257]. All five allergens are proteins labile to pepsinolysis 
(Table 1) [116;117] as well are other dietary proteins considered to be non-sensitising allergens 
[201;226;258]. These non-sensitising allergens are usually associated with oral allergy syndrome (OAS), 
which is mild allergic reactions restricted to the oral cavity [256;257]. An assessment of the stability to 
digestion may therefore not be relevant for such ‘incomplete’ food allergens and indicate that an in vitro 
digestibility assay for assessment of potential allergenicity could be misleading for allergens of non-
sensitising characteristic, eliciting allergic reactions based on cross-reaction with IgE antibodies raised 
against other non-food allergens.  
Taking into account only food allergens believed to sensitise through the intestinal mucosa, data from 
digestibility assays indicate that there are still more ‘complete’ food allergens that are susceptible to 
digestion than those completely stable. For example the major peanut allergen Ara h 1 and the major cow’s 
milk allergen β-casein have been shown to be highly labile proteins, braking down to small peptide 
fragments within minutes [222;223;243;259]. Hence for dietary proteins sensitising through the intestinal 
mucosal no significant correlation between resistance to digestion and allergenicity seems to exist. 
Susceptibility of food allergens to proteolysis has mostly been tested by analysing the effects of 
pepsinolysis. Comparing Table 1 and 2 with Table 3 reveals that some allergens, such as the major allergen 
Ber e 1 from Brazil nut may be resistant to pepsinolysis but on the other hand, be broken down in a process 
simulating the gastro-duodenal digestion [54], where the protein in addition to pepsinolysis also is 
proteolysed by trypsin and chymotrypsin. In addition, Takagi et al. [215] showed that some food allergens, 
such as the major cow’s milk allergen BLG was resistant to pepsinolysis in SGF and labile to digestion by 
pancreatin in simulated intestinal fluid (SIF). In contrast, other known allergens, such as the cow’s milk 
allergen BSA were labile to digestion in SGF, while resistant to digestion in SIF. Such results, in agreement 
with the perception of the EFSA panel [20], indicate the usefulness of not only implementing a degradation 
phase resembling the gastric digestion process but also a phase resembling the duodenal digestion process. 
This will achieve a more thorough knowledge of the general stability of the dietary protein, and get a more 
realistic picture of the digestion profile that the intestinal immune system may be exposed to. This is also in 
accordance with the message by Moreno [255] pointing out the importance of using physiologically 
relevant in vitro digestion, simulating the gastric as well as the intestinal digestion process. 
 
Factors influencing the outcome of the digestibility assay 
Extensive variability in assay condition and hence the resulting outcomes exist among the different 
digestibility studies (Table 1-3). For example the stability of Ara h 2 (Table 1) to pepsinolysis under different 
conditions resulted in either Ara h 2 being an easily digestible protein [56;120] or being a highly resistant 
protein [18;223]. Similar results were shown for the peanut allergen Ara h 6 [223;225] and the Brazil nut 
allergen Ber e 1 [54;228-230]. Also the milk allergen BLG, which is normally regarded as a protein highly 
resistant to pepsin digestion [18;39;42;56;120;215] was in a single study found to be susceptible to 
pepsinolysis [243] and in another study found to be susceptible to simulated gastro-duodenal digestion 
[242]. Comparison of such studies reveals the very importance of the assay condition used, and points to 
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the necessity for using the same assay condition for comparability between studies and the prerequisite to 
decide the assay condition most suitable for the assessment of allergenic potential of novel proteins.  
In addition, two separate studies using the same assay conditions, showed contradicting results, where 
Mandalari et al. [243] found BLG to be degraded by pepsin digestion, and Fu et al. [120] found BLG to be 
stable to the pepsinolysis. This indicates inter-laboratory differences, and points to the necessity of using 
standardised assay conditions.  
Factors such as digestion time, enzyme to allergen ratio, pH, purity of allergen, allergen processing, 
presence of surfactant and presence of food matrix may all have a great impact on the outcome of the 
digestion assay. The methods used for determination of residual intact protein as well as amount and sizes 
of emerging peptide fragments may on the other hand have a significant influence on the interpretation of 
the susceptibility of the given protein to digestion.  
 
Huge variations in protease to allergen ratios exist (Table 1-3). Many studies were performed under the 
assay condition with an enzyme activity of approximately 10,000 unit per mg of protein, presented by 
Thomas et al. [56]. These studies are far from physiological, based on a standard SGF used for preclinical 
assessment of pharmaceuticals and only gives a biochemical measure of a protein’s overall physiochemical 
stability [20;243]. Other studies were performed with an enzyme activity of approximately 180 units per mg 
of protein, presented by Moreno et al. [54]. These studies seek to elucidate the role of physiologically 
relevant digestion on the peptide profile of digestion products, and hence what the intestinal mucosal 
immune system is exposed to [20;41]. 
In a study by Takagi et al. [202] digestion of OVM at different pepsin to allergen ratios showed that the 
stability of the intact protein as well as some of the generated peptide fragments increased markedly by 
lowering the pepsin concentration 10 and 100-fold. In addition, Mandalari et al. [243] showed that BLG was 
resistant to pepsinolysis under physiologically relevant pepsin to allergen ratio, while it was degraded by 
increasing the pepsin concentration 256-fold. The enzyme to allergens ratio also significantly affected the 
stability of the peanut allergens Ara h 2 and Ara h 6. Both were shown to be stable at an enzyme activity of 
100 unit per mg of peanut protein. They were completely labile by raising the enzyme activity 100-fold 
[223]. These studies show that the digestibility of allergens is significantly influenced by the enzyme to 
protein ratio, so that an allergen appearing to be stable at one ratio became susceptible at higher ratios. In 
addition to the intact protein also the amount and sizes of stable fragment may significantly be affected by 
the enzyme to protein ratio, which is in agreement with the message by Fu et al. [120].  
 
The pH under which the digestion assay is performed also varies (Table 1-3). In studies of the susceptibility 
of food allergens to digestion in the presence of solely pepsin, the pH varied between 1 and 4. No single pH 
will ever mimic the condition in the stomach. While the pH of the fasted stomach is around 2 [30-32], the 
pH rises after the ingestion of food to a pH of up to 5 [20].  
Lucas et al. [201] digested kiwi allergens at different pH values and showed that the stability of the 
allergens was significantly affected by the pH where an increase from pH 1.5 to 2.5 significantly reduced 
proteolytic break down of the allergens and a further increase in pH to 3 abolished the break down. In 
addition, studies of the digestibility of codfish proteins showed that proteins were degraded within 1 
minute at pH ranging from 1.25 to 2.5, while only a marginal shift in pH from 2.5 to 2.75 completely 
abrogated the digestion of the cod allergens [57]. Also studies of hen’s egg allergen digestion showed that 
digestibility of both OVM, OVA, Ovotransferrin (OT) and hen’s egg lysozyme C (HEL) were pH dependent, 
though to different degrees [209]. These studies show that the digestibility of allergens may greatly be 
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affected by variation in pH, probably because of the pH-dependent activity of the enzymes as well as the 
pH dependent denaturation of proteins.  
 
Also addition of surfactant, such as PC and bile salts (which is secreted by the gastric mucosa or being a 
constituent of the bile, respectively) may greatly affect the susceptibility of proteins to digestion (Tables 1-
3). For example, addition of PC altered the kinetics of the BLG degradation, protecting the allergen from 
digestion by slowing the digestion process as well as altered the pattern of the generated peptide 
fragments [39;42;242;243]. A protective impact of PC was also seen on the degradation of the cow’s milk 
allergen α-lactalbumin (ALA) [41] as well as the grape allergen Vit v 1 [43]. In contrast PC did not influence 
the digestibility of the cow’s milk allergen β-casein [243], the Brazil nut allergen Ber e 1 [54] and the sesame 
allergen Ses i 1 [231]. The presence of bile salts may also affect the digestion of proteins, where Gass et al. 
[40] showed that the proteolysis with pancreatic enzymes trypsin and chymotrypsin of the cow’s milk 
allergens BLG and BSA was greatly accelerated by addition of bile salts, while the digestion rate of the hen’s 
egg allergen OVA and the minor soy allergen soybean trypsin inhibitor (STI) were unaffected. These studies 
show that addition of surfactant may influence the susceptibility to digestion, by either raising or 
decreasing the digestibility.  
 
Food processing may also affect the susceptibility of allergens to digestion. For example heat treatment of 
proteins prior to digestion may affect the digestibility. In a study by Takagi et al. [215] it was shown that 
preheating of OVA before digestion by pepsin in SGF significantly accelerated the digestibility. While the 
OVA was stable without preheating, it was rapidly digested within 0.5 min following preheating. Also, 
heating of BLG significantly increased its susceptibility to digestion in a time and temperature dependent 
manner [259]. In contrast heating of OVM, Ber e 1 or Ses i 1 prior to digestion did not alter the digestion 
pattern [54;202;231]. Since many foods containing allergenic proteins are commonly eaten in a processed 
state, these studies imply the importance of assessing of digestibility of such proteins after processing.  
 
The food matrix may also influence digestibility. This has been shown by Macierzanka et al. [242], who 
demonstrated that when digesting β-casein in an emulsified form the digestion rate was increased but on 
the other hand some peptide fragments were more resistant to digestion compared with the digestion of β-
casein in no emulsion. In the same study it was shown that the susceptibility of BLG was increased if 
presented in an emulsified form. The conclusion was that emulsification led to adsorption-induced changes 
in either the conformation or the flexibility of the allergens, rendering them more easily digested in 
simulated gastro-duodenal digestion [242]. Polovic et al. [50] studied the matrix effect of the plant 
polysaccharides pectin, and showed that the polysaccharides decreased the digestibility of the kiwi allergen 
Act c 2.  Also for BLG, addition of polysaccharides significantly reduced the digestibility in simulated gastro-
duodenal digestion [55;260;261]. Polysaccharides were also shown to modify the digestibility of peanut 
allergens, however, the pattern of digestion was dependent of the type of polysaccharides [262]. As also 
suggested by Ofori-Anti et al. [217] these studies show that investigation of digestibility using purified 
proteins, not taking into account the possible effect of the food matrices, could potentially be misleading, 
providing result which may differ from those received with digestion of whole food extracts.  
 
Evaluation of residual intact protein and peptide fragments formed during the digestion process has most 
commonly been accomplished by the use of SDS-PAGE and/or western blotting but other methods have 
also been used [20]. The methods used for detection of residual intact allergen and emerging peptide 
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fragments may greatly influence the resulting outcome and thereby the interpretation of the digestibility 
assay.  
Several studies have shown the significant implication that the choice of detection method may have on 
the outcome of the assessment of resistance to digestion. For example Lucas et al. [201] reported that 
immunoreactive peptide fragments of kiwi allergens could be detected by immunoblot but not with 
coomassie staining. Diaz-Perales et al. [235] further showed that neither protein staining nor IgE 
immunoblotting with sera from allergic patients resulted in the detection of any peptide fragment bands in 
SDS-PAGE from the digestion process of the avocado allergen Prs a 1, which was shown to be a food 
allergen highly susceptible to digestion. However, peptides resulting from the digestion of the Prs a 1 were 
shown to have similar inhibitory potency as the intact Prs a 1 in both immunoblot- and ELISA-inhibitory 
experiments. They could also induce positive SPT responses in 5 out of 8 allergic patients. The sizes of 
peptide fragments responsible for these reactions were 5.1, 2.5 and 1.4 kDa. Thomas et al. [56] even 
reported that the type of electrophoresis gel and fixation techniques could influence the detectability of 
peptide fragments [56]. Such results indicate the importance of evaluating residual intact protein and 
peptide fragments hereof in assays with appropriate sensitivities, and that the use of more than one 
method could be worthwhile. Goodman and Hefle [218] pointed to the importance of choosing suitable 
detection methods, since proteins may have different staining ability because of different amino acid 
composition. For these reasons Ofori-Anti et al. [217] suggested the inclusion of a 10% diluted control 
sample of undigested protein in the assay gel to control for differences in staining between proteins and 
between experiments. Since evaluation of SDS-PAGE fractionation of peptide fragments resulting from the 
digestion process may in some situations only allows for detection of fully stable allergens and/or 
permanent peptide fragments of adequate large size [235], Vieths et al. [53] implicated the need of using 
immunological assays to investigate the potential allergenicity of food proteins instead of monitoring the 
degradation of bands by analytical electrophoresis. In a study by Mandalari et al. [42], residual intact BLG 
after simulated gastro-duodenal digestion was evaluated in SDS-PAGE as well as with RP-HPLC. While 
visualisation of bands in SDS-PAGE indicated that no intact BLG was left after the digestion process, RP-
HPLC showed that around 10% residual BLG was left intact. Similar results were obtained for the kiwi 
allergen Act d 2 [239]. These studies imply that evaluation of residual intact protein with other protein-
chemical methods in addition to SDS-PAGE may be very useful. 
 
Since several factors may influence the outcome of the digestibility assay, and only small variations in the 
assay conditions may significantly influence the outcome, standardisation of the assay conditions would 
definitely make sense as emphasised several times [56;120;217]. As the evaluation of allergenic risk 
potential is considered for human intake, it would in addition make sense to use in vitro models, mimicking 
the average human digestion process, and thereby including in addition to simulated gastric digestion a 
simulated duodenal digestion process. 
 
The variability in in vitro digestion results as a result of different experimental conditions suggests that 
variations in digestion affect the peptide profile presentation to the intestinal mucosal immune system and 
hence the potential allergenicity of dietary proteins. This was indicated in the study by Dupont et al. [39] 
who showed that changes in the pH as well as addition of PC could greatly influences the residual 
allergenicity of the gastric as well as gastro-duodenal digests. Heating prior to digestion decreased the 
eliciting capacity of BLG [259], and the presence of polysaccharides influenced the allergenicity of digestion 
products of peanut allergens, with the IgE reactivity being decreased in a degree dependent on the type of 
polysaccharides present [262]. 
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No perfect digestion method exists or will ever exist, but it seems reasonable to carefully consider under 
which condition proteins should be digested, depending on propose of the study. 
 
Assessment of the allergenic potential of digestion products 
As discussed in the previous sections the relationship between resistance to digestion and allergenicity is 
not straightforward. Therefore digestibility assays should be combined with immunological assays. This 
would allow for an elucidation of the role of peptide fragments emerging from the digestion process, by an 
assessment of their allergenic capacity. The following questions could be addressed by conducting 
immunological assays in connection to the evaluation of susceptibility to digestion; do the peptide 
fragments generated during the digestion process retain IgE binding and eliciting capacity equivalent to the 
parent allergen? Will the IgE binding and eliciting capacity be reduced or even abolished, or could the 
peptide fragments be even more allergenic than the parent allergen? In addition implementation of animal 
studies could answer questions like; do the peptide fragments generated during the digestion process 
retain sensitising capacity? Will they simply be ignored by the immune system or will the peptide fragments 
be able to induce tolerance mechanisms? Based on knowledge from vaccine research with mixtures of 
small peptides, all three situations may occur, having shown peptides to be ignored, induce tolerance or 
induce active immunity [263;264].  
 
In food allergy, the sizes of absorbed peptides and thereby the sizes of peptides encountered by the cells of 
the immune system could theoretically be of significant importance at several levels. For example, 
Moldaver and Larché [265] outlined that intact allergens but not small peptides corresponding to 
sequences of the primary structure of the allergen, may activate APCs by a cross-linking of allergen-specific 
antibodies bound to Fc receptors on the surface of the APCs (Figure 7A). Activated APCs may subsequently 
present processed peptides representing potential T cell epitopes to allergen-specific T cells for T cell 
activation in the presence of appropriate co-stimulatory signals [61;266]. Contrary, small peptide fragments 
may not be big enough to cross-link the specific antibodies on the APCs, subsequently leading to quiescent 
APCs, where peptide presentation to T cells results in the induction of immune tolerance [265]. Likewise, 
cross-linking of surface expressed antibodies have been demonstrated to be of major importance for the 
activation of naïve B cells [267] as well as memory B cells [268] (Figure 7B). Studies have shown that cross-
linking of surface expressed antibodies on B cells by multivalent molecules initiate signalling cascades that 
targets the molecule for processing and subsequently presentation to specific T cells (see section 1.1.3) and 
eventually lead to activation of naïve B cells in the presence of appropriate co-stimulatory signals 
[269;270]. In contrast, univalent molecules have been shown to be significantly less efficient in such 
activation processes [271]. In another study it was shown that only a dimeric and not a monomeric allergen 
could activate memory B cells for specific IgE secretion in a secondary immune response [268]. Further, it is 
well recognised that cross-linking of FcԑRI bound IgE antibodies is a requisite for the degranulation 
response of mast cells and basophils (Figure 7C) [11;12;125].  
Nevertheless, there is no evidence for a specific MW or amino acid sequence length above which such 
cross-linking may be possible if two epitopes exist within close vicinity. The general opinion though appears 
to be that cross-linking acquire a molecular size of a minimum of 3.5 kDa [14;19;212;213], corresponding to 
around 30 amino acids. 
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To evaluate the effect of digestion on the allergenicity of food allergens, three distinct molecular properties 
need to be addressed; (1) the ability to bind IgE antibodies, (2) the ability to elicit an allergic reaction, as 
well as (3) the ability to sensitise, as these are the features of ‘complete’ allergens [115]. 
Several studies have evaluated the IgE binding capacity of digests generated during the in vitro proteolysis, 
showing that different outcomes may be achieved. A study on the effect of peptic digestion on the IgE 
binding ability of the peanut allergen Ara h 3 and the soy allergen glycinin showed that these proteins did 
not retain any IgE binding capacity after 120 min of digestion [224]. Likewise a study by Untermayr et al. 
[210] showed that 5 sec of peptic digestion were sufficient to abrogate the IgE binding capacity of caviar 
proteins. Other studies found that the IgE binding capacity was retained after digestion, though in a 
reduced manner. For example, Takagi et al. [202] found that one fifth of OVM allergic patients had serum 
IgE that could bind to the pepsin digested OVM which contained peptide fragments with sizes between 4.5 
and 6.0 kDa. Such result was confirmed by studies of Urisu et al. [203] and Yamada et al. [219] who also 
found pepsin digested OVM to bind IgE, though at a reduced level compared to intact OVM. Likewise, the 
IgE binding capacity of cod allergens were retained after pepsin digestion though in a strongly reduced 
degree compared to the parent protein [57]. Again, other studies have shown that the IgE binding capacity 
Figure 7. Cellular levels where the sizes of 
peptides theoretically could be of great 
importance for the development of an allergic 
response. Cross-linking events may have 
significant impact on the activation of; A. 
Antigen presenting cells (APC), B. B cells and C. 
mast cells and basophils. A. Cross-linking of 
allergen-specific antibodies bound to Fc 
receptors on the surface of APC may lead to 
activation of the APC, subsequently resulting in 
activation of T cells, whereas failure of cross-
linking may lead to a quiescent APC, 
subsequently resulting in induction of 
regulatory T cells. B. Cross-linking of surface 
expressed antibodies on a naïve B cell may lead 
to activation of T cells and subsequently 
activation of the naïve B cell, whereas failure of 
cross-linking may lead to a significant 
weakening of such activation steps. Cross-
linking of surface expressed antibodies on a 
memory B cell may lead to activation and 
differentiation into an IgE secreting plasma cell, 
whereas failure of cross-linking will not result in 
such activation and differentiation events. C. 
Cross-linking of FcԑRI-bound IgE antibodies on a 
mast cell or a basophil may lead to 
degranulation response and subsequently an 
allergic reaction, whereas failure of cross-linking 
will not lead to any mediator release response. 
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of digestion products equal the IgE binding capacity of the intact allergen. For example, gastro-duodenal 
digestion products of the grape allergen Vit v 1 were found to have IgE binding capacity similar to that of 
the intact Vit v 1 [43] and peptic digestion products of the cow’s milk allergen BLG had similar IgE binding 
reactivity as the intact BLG [194]. At last few studies have shown the digestion products of food allergens to 
be even more IgE reactive than their parent allergen. This has been shown for the milk allergen BLG [193] 
as well as for kiwi allergens [201], and was suggested to be a result of the emerging of new epitopes, not 
accessible prior to digestion.  
Only a minority of the studies, which have evaluated the IgE binding capacity of digestion products, have 
made the effort to correlate the binding capacity to the sizes of the peptide fragments generated during 
the digestion products. However, epitope mapping studies have contributed to the knowledge of IgE 
binding capacity of small peptides, collectively demonstrating that even very small peptides representing 
short amino acid sequences of the primary structure of food allergens may indeed contain the ability to 
bind IgE [172;196;197;272]. 
Studies have demonstrated that caution should be taken when evaluating the IgE binding capacity of 
peptide fragments and that the immunologically assay should be chosen with care, because of the great 
impact it may have one the resulting outcome. For example, Diaz-Perales et al. [235] showed that 
immunoblotting with sera from avocado allergic patients did not reveal any IgE binding of digestion 
products from the avocado allergen Prs a 1, a dietary protein highly susceptible to peptic digestion. 
However, the digestion products were shown to have an inhibitory potency equally to that of the intact 
allergen in both immunblot- and ELISA-inhibitory assays. Similar results were found in another study, 
revealing that while digestion products of hazelnut allergens showed no IgE binding capacity when tested 
by immunoblotting, the digestion products had a very strong binding capacity in EAST assays [53].  
 
Not only IgE binding but also the association between stability to digestion and allergic eliciting capacity has 
been studied. When studying elicitation the biological relevance of the IgE-peptide interaction is studied.  
Similarly to the above described IgE binding results, studies of elicitation capacity of digestion products 
have likewise shown different allergens to give different results, showing digestion products to either lose 
the eliciting capacity [57], retain the eliciting capacity though in a reduced manner compared to the parent 
protein [235;259] or retain the eliciting capacity with a magnitude equal to that of the parent protein 
[43;222]. For example, Eiwegger et al. [222] showed that the gastric as well as gastro-duodenal digestion 
products of the peanut allergen Ara h 1, containing peptide fragments of sizes less than 6 kDa had a HR 
pattern from basophils identical to that of the intact Ara h 1. Few studies correlated elicitation results to 
the sizes of the peptide fragments. 
A study by Untermayr et al. [57], showed that digestion products of cod allergens retained IgE binding 
capacity but not eliciting capacity, demonstrates that an IgE binding capacity do not necessary correlate 
with a capacity to trigger allergic reactions and that additional requirement are set for peptides to inhere 
eliciting capacity compared to IgE binding capacity. 
 
For ethical reasons sensitisation studies cannot be performed in humans. Animal models have been 
regarded as a good alternative [273;274]. Although an evaluation of sensitising capacity has only been 
performed with a limited numbers of dietary proteins, several murine models have been regarded as good 
candidates for animal models of food allergy. This is among other things based on their ability to 
discriminate between allergenic and non-allergenic proteins as well as discriminating between allergens of 
varying allergenicity [275;276]. The ability to mount a specific IgE response against dietary allergens must 
be the first requirement for a good animal model of food allergy. This ability has been reported to be seen 
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in the C3H/HeJ mouse strain [276], the Balb/c mouse strain [247;277;278] as well as in the Brown Norway 
rat strain [279;280]. These murine sensitisation studies were all performed by oral route with or without 
use of adjuvant or by intraperitoneally (i.p.) immunisation without use of adjuvant. These studies were 
reported to succeed in discriminating between allergenic and non-allergenic dietary proteins and might 
support the implementation of validated animal models in the assessment of allergenic potential of novel 
proteins, as expressed in the WHO/FAO rapport from 2001 [19], The Codex Alimentarius from 2003 [21] 
and the rapport of EFSA from 2010 [20].  
Several sensitisation studies have been performed with extracts from allergenic foods or with purified 
intact food allergens whilst only a few sensitisation studies have been performed with break down products 
originating from allergenic proteins. Yet, Aldemir et al. [275] and Bowman and Selgrade [281] reported that 
a good correlation exists between digestive lability of foods and failure to induce an IgE response via the 
oral route. These conclusions seem to be based on interpretation of results showing that IgE production in 
mice could be stimulated by oral exposure to peanut and Brazil nut, and to some extent to hen’s egg white, 
which are confirmed allergenic foods. Oral exposure to turkey extract, a food not considered to be 
allergenic did on the other hand not induce specific IgE. The authors interpreted these results in connection 
with in vitro pepsin digestibility assay showing that peanut, Brazil nut and hen’s egg white all contained 
digestion stable proteins or peptide fragments, while turkey was completely digested after 15 min [276].  
 
The small numbers of studies which have addressed residual sensitising capacity of degradation products 
from food allergens, by measure of specific IgE have all been performed on milk proteins. This is probably a 
result of the great interest in the design of safe hypoallergenic infant milk formulas as well as the 
requirement for an evaluation of residual sensitising capacity of such hypoallergenic formulas [282;283]. 
Historically, assessment of the residual sensitising capacity have been performed by oral sensitisation 
studies in guinea pigs [273;284;285], however the reaginic antibody response assessed in these animals is 
of the IgG1a subtype, making this animal model less than perfect for studying IgE mediated allergic disease.  
A sensitisation study with Sprague-Dawley rats immunised i.p. with cow’s milk infant formulas based on 
either intact proteins, partially hydrolysed proteins (pHF) or extensively hydrolysed proteins (eHF) with the 
use of Al(OH)3 as adjuvant, showed that the pHF as well as eHF were able to induce specific IgE, though to a 
degree which were 100 and 10,000 times lower, respectively, than the level induced by the formula based 
on intact proteins [286]. In another study, Balb/c mice were immunised i.p. with different pHFs and eHFs 
with Al(OH)3 as adjuvant [287]. These studies showed that all pHFs were able to induce specific IgE 
antibodies, shown by a positive skin test after intradermal injection with intact BLG or the formula itself, 
while only one out of two eHFs were able to induce specific IgE antibodies. These hydrolysates could all 
induce specific IgG1 antibodies, though in various amounts, signifying the different degree of immunogenic 
potency [287]. Recently, sensitisation studies have been conducted in a mouse model of orally induced 
cow’s milk allergy [288], where C3H/HeOuJ mice were orally sensitised with whey proteins or partially 
hydrolysed products hereof with cholera toxin as an adjuvant [289;290]. These studies showed that while 
intact whey protein could induce a specific IgE response, no detectable specific IgE antibodies were 
measured in sera from mice dosed with partially hydrolysed whey products. However, in one study an 
acute skin response was evident after whey skin challenge in the ear, suggesting some residual sensitising 
capacity of the partially hydrolysed whey not evident by ELISA analysis of the specific IgE [290]. In own 
studies it was not possible to demonstrate sensitising capacity of a protein source for eHF containing 
peptides up to 2.5 kDa when administered to Brown Norway rats by i.p. immunisation with or without 
Al(OH)3 as adjuvant (own unpublished results). Animal studies have also been performed with degradation 
products from the milk allergen BSA [291-293]. A single i.p. immunisation of BDF1 mice with digestion 
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products of BSA using Al(OH)3 as adjuvant failed to sensitise the mice, in contrast to intact BSA. The studied 
degradation products were pepsin digested for more than 12 min. However, by two i.p. immunisation of 
the mice, only BSA digestion products digested for more than 40 min failed to induce IgE [292]. The MW of 
digestion products emerging from the digestion after 40 min was in the range of 8 to 16 kDa.  
 
While it is regarded as mandatory for safety reasons to evaluate the residual sensitising capacity of infant 
formulas market as hypoallergenic [282;283], it may also be important to evaluate the potential positive 
immune modulatory capacity. This can be achieved by examining the products ability to induce oral 
tolerance to the parent dietary proteins. Oral tolerance is well recognised as the common immune 
response to orally administered dietary proteins [61;274] and has been demonstrated in several studies 
using animal models of oral administration of a food, food ingredient or a purified protein. A subsequent 
i.p., subcutaneous or intravenous (i.v.) immunisation step (with the same or another relevant food or 
protein) demonstrated suppression of specific IgE response if oral tolerance was induced compared to 
animals only receiving post-immunisation [273;292;294-298].  
In studies examining tolerance induction by hydrolysed milk products, it was found that pHFs were able to 
induce oral tolerance, whereas eHFs were not [294-297]. For example, van Esch et al. [295] showed in CH3-
HeOuJ mice that whey based pHF given by gavage could induce tolerance to whey in contrast to whey 
based eHF, and Fritsché et al. [294] showed in Sprague-Dawley rats that oral administration of whey based 
pHF was able to induce specific oral tolerance to BLG, whereas an eHF whey based formula was not. 
Similarly, Peng et al. [297] showed that while a pHF whey product could induce oral tolerance in naive CH3-
HeN mice to BLG, BSA and ALA, eHFs could not. Neither intact pHF nor eHF could on the other hand induce 
tolerance in mice already sensitised to BLG, BSA and ALA. Strikingly, the same group found the same pHF 
whey product to be effective for induction of oral tolerance to casein. eHF based on either whey or caseins 
could induce tolerance in naïve mice, whereas none of the products could induce tolerance in already 
sensitised  CH3-HeN mice [296]. Although no ubiquitous agreement for the definition of pHF and eHF exist 
[299], von Berg [300] reports that hydrolysed cow’s milk formulas are divided into pHF and eHF depending 
on the degree of modification, where eHF generally contain more than 95% peptides with MW of less than 
3 kDa and is primarily intended for secondary prevention, whereas the MW of peptides present in pHF has 
a higher percentage of peptides with a MW between 3 and 10 kDa and a much lower percentage of 
peptides less than 3 kDa and suggested for use in primary allergy prevention. 
In a study by Dosa et al. [292] pretreatment of BDF1 mice i.v. by digestion products of BSA prior to i.p. 
immunisation with intact BSA, showed that BSA digested 12-40 min suppressed the specific IgE response 
towards intact BSA, whereas pretreatment with digestion products digested for either a shorter or longer 
period had no significant effect on the suppressing mechanisms. 
In addition to milk products, Fritsché [273] showed in Sprague-Dawley rats that moderately hydrolysed soy 
proteins could induce oral tolerance to intact soy proteins, whereas strongly hydrolysed soy proteins were 
not able to achieve this. 
Together these studies show the importance of peptide composition of products used for oral tolerance 
induction and that the tolerogenic capacity may be inherent in peptide size combinations. That the nature 
of the peptides may have significant importance for the tolerogenic capacity was shown in a study by 
Pecquet et al. [298]. This study examined the ability of trypsin digested BLG and peptides hereof to induce 
oral tolerance to BLG by oral gavage of Balb/c mice and identified the tolerogenic peptides. They concluded 
that the size, sequence as well as structure of the peptides appeared to be crucial for the tolerogenic 
capacity of the peptides. 
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So far, only little is known about the correlation between peptide size and structure and sensitising capacity 
as well as the correlation between peptide size and structure and tolerogenic properties. Nevertheless 
understanding the connection, if any, between the size and structure of peptides and the sensitising versus 
tolerogenic capacity remains fundamental for a better understanding of the influence of digestibility of the 
allergenic capacity and for a better understanding of the mechanisms responsible for guidance of the 
immune response toward different directions.  
 
 
Thesis objective 
 
The aim of the work presented in this thesis was to study the sensitising capacity of peptides from food 
allergens using a Brown Norway rat model of food allergy. The Brown Norway rat is a high Ig, particularly 
IgE, responder strain that to a certain degree resembles atopic humans in their predisposition to develop 
IgE mediated allergy [279]. The Brown Norway rat model is generally accepted to be a useful model for the 
examination of food allergy [274], since it among other things generates IgG and IgE antibodies of similar 
protein specificity [279;301] as well as of similar epitope specificity [302] to those produced in humans 
[302]. The major peanut allergen Ara h 1 and the major cow’s milk allergen BLG were used as model 
allergens. Pepsin or trypsin and chymotrypsin were used as enzymes for simulated gastric or gastro-
duodenal digestion. The effect of digestion on the allergenicity was studied by examination of: 
• The sensitising potential of well-characterised gastro-duodenal digestion products of Ara h 1 in the 
Brown Norway rat model and comparing the sensitising potential to different doses of intact Ara h 
1. Specific antibody responses were measured by ELISAs and the biological functionality of the IgE 
antibodies was assessed by RBL-assay (Paper 1) 
• The sensitising capacity of well characterised gastric digestion products of Ara h 1 as well as 
fractions hereof in Brown Norway rats. Specific antibody responses were measured by ELISAs 
(Paper 2).  
• The IgE binding epitopes of gastro-duodenal digests of Ara h 1 and intact Ara h 1. This was achieved 
with sera from the sensitisation study described in Paper 1, as well as with sera from peanut 
allergic patients using a random phage-displayed peptide library followed by mapping of the 
selected IgE binding epitope mimics on the Ara h 1 surface (Paper 3) 
• The sensitising capacity of well characterised gastro-duodenal digestion products of BLG as well as 
fractions hereof and comparing it to the sensitising capacity of intact BLG. Specific antibody 
responses were measured by ELISAs (Paper 4). 
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Summary
Background Food allergies are a public health issue of growing concern, with peanuts in
particular being associated with severe reactions. The peanut allergen, Ara h 1, belongs to the
cupin plant food allergen family, which, unlike other structural families, appears to be broken
down rapidly following gastrointestinal digestion.
Objective Using Ara h 1 as a model allergen, the ability of digested protein to sensitize has
been investigated.
Methods Ara h 1 was purified from whole roasted peanuts. Intact Ara h 1 was digested in an in
vitromodel, simulating the human gastrointestinal digestion process. Digestion products were
analysed for peptide sizes and their ability to aggregate. Brown Norway (BN) rats, used as an
animal model, were immunized with purified intact Ara h 1 or the gastrointestinal digestion
products thereof. The sensitizing capacity was evaluated by analyses of specific antibody
(IgG1, IgG2a and IgE) responses and ability to trigger mediator release of rat basophilic
leukaemia (RBL)-2H3 cells.
Results The present study showed that Ara h 1 was broken down, resulting in peptide
fragments of sizeso2.0 kDa, of which approximately 50% was in aggregated complexes of
Mr up to 20 kDa. Ara h 1 digesta were shown to have sensitizing capacity in BN rats, being
capable of inducing specific IgG and IgE antibodies. The IgE response was functional, having
the capacity to induce specific degranulation of RBL cells.
Conclusion From this study, it can be concluded that lability of a food allergen to
gastrointestinal digestion does not necessarily abrogate its allergenic sensitizing potential.
Keywords animal model, Ara h 1, Brown Norway rats, digestion, food allergy, peanut,
peptides, sensitization
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Introduction
Food allergies are responsible for a variety of reactions
including fatal anaphylaxis [1, 2]. Peanut allergy is one of
the most common and serious immediate-type hypersen-
sitivity reactions to food in terms of persistence and
severity [3–5]. Unlike most other food allergies, reactions
to peanut are rarely outgrown [6]. While estimates of
prevalence of food allergy in general are imprecise and
vary between countries and cultures [7, 8], it seems that
the overall prevalence of peanut allergy is around 0.6% of
the US [4] and 0.5% of the British population [5]. Peanut
allergy appears to be a growing phenomenon, since there
has been an increase in the prevalence over the last 10–15
years [9, 10].
The causative agents of food allergies, known as aller-
gens, are almost entirely proteinaceous in nature, the
majority of those from plant-based foods belonging to
just four structural types, including the so-called cupin
superfamily [11]. The peanut allergen, Ara h 1, is repre-
sentative of the cupin superfamily of allergens, being a
vicilin-type seed storage protein [12, 13], consisting of
glycosylated subunits of molecular weight Mr 63 500 [14],
which assembles into homotrimers maintained by hydro-
phobic interactions between amino acids at monomer–
monomer contact points, the same structural regions
where the majority of IgE epitopes appear to cluster
[15, 16]. An abundant protein, comprising around 12–16%
of peanut proteins [17], Ara h 1 is recognized by serum IgE
Allergens
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from more than 80% of peanut-allergic patients, indicat-
ing that it is a major allergen [14, 18]. Epitope mapping
of Ara h 1 using overlapping peptides has identified
23 independent binding sites evenly distributed along
the entire linear sequence of the molecule [18].
What makes only a few protein families, including the
cupin superfamily [11], so prominently as allergen fa-
milies? One hypothesis is that for a protein to sensitize an
individual and elicit an allergic reaction, it must survive the
acidic and proteolytic environment of the gastrointestinal
tract and interact with the intestinal mucosa where sensi-
tization may occur [6, 19–21]. In a study comparing the in
vitro stability of food allergens and non-allergenic proteins
to simulated gastric fluid, it was concluded that there was
an association between resistance to digestion and aller-
genic potential [22]. This has led to pepsin resistance being
used as a predictive parameter in the allergen risk assess-
ment of novel proteins introduced into genetically mod-
ified organisms and novel foods [23]. However, in recent
years, the relationship between resistance to digestion and
the allergenic potential of a protein and the validity of
taking this parameter into account in the risk assessment of
allergenic potential have been questioned [24, 25]. While
the premise that resistance to digestion correlates with the
allergenicity of a protein may still hold true for some
allergens [26], this does not appear to hold true for Ara h 1,
where several studies have shown that Ara h 1 is degraded
relatively quickly by proteases, although several peptide
fragments persisted [15, 27–29].
Ara h 1 is labile to digestion and is a major allergen
[14, 24]. Low-molecular-weight products of digested Ara
h 1 retain T-stimulatory and IgE-binding properties [29].
But does digested Ara h 1 have the ability to sensitize?
To our knowledge, the sensitizing capacity of a digested
allergen has not been investigated before, so the current
study was designed to investigate the effects of simulated
gastrointestinal digestion on the sensitizing potential of the
model cupin allergen Ara h 1, using a Brown Norway (BN)
rat model of sensitization. The BN rat is a high Ig (particular
IgE) responder strain, which, to a certain degree, resembles
atopic humans in their genetic predisposition to react more
readily with an IgE production towards allergens [30, 31].
Although no ideal animal model mimicking the major
aspects of human food allergy has been developed as yet,
studies have shown that food allergy models using BN rats
have the potential to categorize food proteins as non-
allergens and weak and strong allergens [32, 33]. Never-
theless, additional studies are still needed before BN rats
can be consolidated as a useful animal model for examina-
tion of the mechanisms of food allergy and assessment of
the allergenic potential of food proteins.
This study demonstrated that even though Ara h 1 was
extensively degraded to peptide fragments of o2.0 kDa,
these peptides still retain sensitizing potential, inducing
specific antibody responses in the BN rats and mediator
release of basophils. Such low-molecular-weight peptides
do not normally possess the ability to stimulate humoral
immune responses. Stimulation may result from the pre-
sence of a mixture of non-covalently linked peptides
retaining both B and T cell epitopes or from the ability of
the peptides to aggregate into larger, immunologically
active complexes. These results demonstrate that gastro-
intestinal digestion of an allergen to small peptide frag-
ments does not necessarily lead to elimination of the
sensitizing potential.
Materials and methods
Purification and simulated digestion of Ara h 1
Ara h 1 was purified from defatted peanut meal (from
roasted peanuts) as described by Eiwegger et al. [29] and
was adjudged 99% pure by reverse-phase (RP) high-
performance liquid chromatography (HPLC). The final
concentration of purified intact Ara h 1 was 2.5mg/mL
in the sample used for in vitro digestion and 1.74mg/mL
in the sample used for animal sensitization studies and
immunochemical examinations. Gastric and gastro-duo-
denal digestions were performed essentially as described
by Moreno et al. [34], with the following modifications, in
order to provide enzyme-free digesta suitable for animal
sensitization studies. Surfactants (gastric phosphatidyl
choline vesicles and duodenal model bile salt mix) were
omitted to avoid adverse effects in sensitization studies.
Phosphatidyl choline has previously been shown not to
affect the digestion of Ara h 1 (Clare Mills, personal
communication). In brief, for gastric digestion, soluble
porcine pepsin was substituted with porcine pepsin im-
mobilized to agarose beads (P0609, Sigma, Saint Louis,
MO, USA). Ara h 1 (2.5mg/mL in 0.25 M NaCl) was adjusted
to pH 2.5 with 1 M HCl, and the immobilized pepsin was
added to yield an activity of approximately 182U per mg
of protein. The solution was placed in a shaking incubator
at 37 1C for 120min at 200 r.p.m. Immobilized pepsin was
removed by centrifugation [1000g, at room temperature
(RT) for 2min] and the resulting supernatant was further
clarified by passing through a 0.45 mm filter (Millipore,
Bedford, MA, USA). The pH of this ‘enzyme-free’ gastric
digesta was adjusted to 7 with 1 M NaOH. For duodenal
digestion calcium and Bis-Tris were added to the gastric
Ara h 1 digesta and the pH was adjusted to 6.5 with 1 M
HCl, and a mixture of bovine trypsin (T1763, Sigma) and
chymotrypsin (C9135, Sigma) immobilized to agarose
beads was added to yield an activity corresponding to
34.5U of soluble trypsin per milligram of protein and
0.44U of soluble chymotrypsin per milligram of protein.
This yielded a solution equivalent to 2.3mg/mL intact
Ara h 1, 9.2mM CaCl and 24.7mM Bis-Tris, which was
placed in a shaking incubator at 37 1C for 15min at
200 r.p.m. Immobilized enzymes were again removed by
c 2009 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 39 : 1611–1621
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centrifugation (1000g, at RT for 2min) and the resulting
supernatant was filtrated through a 0.45mm filter (Milli-
pore). The resulting ‘enzyme-free’ gastro-duodenal digesta
were aliquoted and stored at 20 1C until required for
further analysis or animal sensitization studies.
High-performance liquid chromatography analyses
Digested and intact Ara h 1 samples were applied (50mL) to
a protein (C4 Phenomenex Jupiter 300 A˚ pore size, 5mm
particle size, 2504.6mm i.d., Phenomenex Macclesfield
Cheshire, UK) column coupled to a Jasco PU-1585 triple
pump HPLC equipped with an AS-1559 cooled autoinjec-
tor, a CO-1560 column oven and a UV-1575 UV detector
(Jasco Ltd, Great Dunmow, UK). Proteins and peptides were
eluted using 0.1% (w : v) trifluoroacetic acid (TFA) in
double-distilled water as solvent A and 0.085% (w : v) TFA
in double-distilled water : acetonitrile (ACN) (10 : 90, v : v)
as solvent B. The column was equilibrated with 1% solvent
B. Initial elution (0–5min) was performed using 1% solvent
B in the isocratic mode, followed by elution with a linear
gradient of increasing concentration of solvent B from 1%
to 55% over 55min. The HPLC column temperature was
maintained at 25 1C and the autoinjector at 4 1C. The eluate
was monitored for protein using UVabsorbance at 280 nm.
Peptide mass profiling analyses by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis and
matrix-assisted laser desorption/ionization-time of flight
The Ara h 1 digestion process was followed by SDS-PAGE
analysis under reducing conditions as described by Mor-
eno et al. [34], using the marker protein Mark 12TM
Unstained Standard (Invitrogen, Carlsbad, CA, USA),
comprising 12 protein bands in the range 2.5–200 kDa.
The exact peptide mass distribution was determined by
separating the peptides by RP HPLC, followed by matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOFMS). For fractionation, a sample
of Ara h 1 digesta [50mL of 0.8mg/mL in 0.1% TFA (w : v)]
was applied to a mRPC C2/c18 SC 2.1/10 column coupled to
a SMART System (GE Healthcare, Hillerod, Denmark).
Peptides were eluted with a linear gradient of ACN
(5–40%) over 25min in 0.1% TFA (w : v), with a flow rate
of 200mL/min. Fractions of 100mL were collected, dried in
a vacuum centrifuge and rediluted in 3mL Milli Q water.
For mass spectrometric analysis, 1 mL of each of the
rediluted fractions were loaded onto a MALDI target,
followed by addition of 1 mL 2% TFA and 1 mL a-cyano-
4-hydrocinnamic acid [5 mg/mL in 70% ACN (v : v), 0.1%
TFA (v : v)]. Mass spectra for the individual fractions of
Ara h 1 digesta were acquired on a Bruker MALDI-TOF MS
(MALDI TOF/TOF, Ultraflex II, Bruker Daltonik GmbH,
Bremen, Germany) equipped with pulsed ion extraction
and a 200Hz Smart BeamTM laser (Bruker Daltonik
GmbH, Bremen, Germany). All mass spectra were initially
calibrated with a tryptic digest of b-lactoglobulin.
Profiling of aggregated peptides by gel permeation
chromatography
Digested Ara h 1 was analysed by gel permeation chro-
matography (GPC) under analytical conditions at RT on a
Superdexs 75 PC 3.2/30 column coupled to a SMART
System (GE Healthcare). A sample of Ara h 1 digesta
(50 mL of 1mg/mL) was applied to the column and eluted
at 50 mL/min with a phosphate buffer (150mM NaCl,
31.75mM K2HPO4, NaH2PO4), pH 7.0. The eluate was
monitored for peptides by absorbance at 220 and 280 nm.
The column was calibrated for molecular weight determi-
nation by injecting a standard mixture consisting of
ferritin (440 kDa; Sigma, F-4503), BSA (66 kDa; Sigma,
A-2153), carbonanhydrase (29 kDa; Sigma, C-3934), cyto-
chrom C (14 kDa; Sigma, C-2506), apotinin (6 kDa; Sigma,
A-1153) and vitamin B12 (1.3 kDa; Sigma, V-2876).
Animals
BN rats were from the breeding colony at the National
Food Institute (DTU, Denmark), weaned at 3 weeks of age
and then housed in macrolon cages (two per cage) with a
12-h light : dark cycle with light from fluorescent tubes
from 9:00 to 21:00 hours, at 221 1C and 555% relative
humidity. Rats were observed twice a day and clinical
signs were recorded. Body weight was recorded weekly.
The rats were kept on a diet free from leguminosa for at
least three generations to avoid tolerization with other
legume proteins homologous to Ara h 1. Because com-
mercially available rat diets contain soy proteins, it was
decided to produce a diet in house without leguminosa,
egg and milk (Table 1), the sources of some of the most
common food allergens studied in rodent models. The
nutrient content was in accordance with rodent diet AIN-
93 [35] and all ingredients were ground to a similar
Table 1. Composition of the in-house produced rodent diet used for
breeding of Brown Norway rats not tolerant to Ara h 1
Ingredients Diet (g/kg)
Maize flakes 700
Protastar 100
Fish meal 80
Maize oil 50
Cellulose 30
Mineral mixture 28
Vitamin mixture 12
The diet is free from leguminosa, egg and milk and based on crushed
maize flakes, potato protein and fish meal as protein sources.
A potato protein concentrate with a low content of solanine (AgroKorn,
Videsbaek, Denmark).
c 2009 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 39 : 1611–1621
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particle size to ensure a homogeneous mixture. Diet and
acidified tap water were given ad libitum.
The animal experiments were carried out at the Na-
tional Food Institute (DTU, Denmark) facilities under the
supervision of the National Agency for Protection of
Experimental Animals and the in-house committee for
animal care and use.
Experimental design
To examine the sensitization capacity of intact and digested
Ara h 1, groups of 8–16 BN rats were immunized intraper-
itoneally (i.p.) with 0 (control), 1mg (low), 50mg (medium) or
200mg (high) of purified intact Ara h 1 or with 200mg of
gastro-duodenal digested Ara h 1 in 0.5mL phosphate-
buffered saline (PBS, pH 7.2; 137mM NaCl, 3mM KCl, 8mM
Na2HPO4, 1mM KH2PO4) per rat on days 0, 14 and 28. One
week after the last immunization, the study was terminated
(day 35) and blood was collected at sacrifice. I.p. models are
not ideal for assessment of the allergenic potential of food
proteins. However, this model was chosen because only very
low amounts of purified protein are required compared with
oral models. Furthermore, we wanted to examine how in
vitro digestion affected the immunogenic and allergenic
potential of Ara h 1. Using an i.p. model, in vivo digestion
was avoided, to know what was presented to the immune
system of the rats.
Positive control sera were produced by i.p. immuni-
zation of BN rats with 100 mg/0.5mL per rat of purified
Ara h 1 absorbed on 12mg Al(OH)3 at day 1 and with
10 mg/0.5mL per rat at days 21, 35 and 49. Blood was
collected at sacrifice (day 56). A pool of these sera
was used for development and optimization of ELISAs
and included on each plate as a positive control.
In all experiments, sera were obtained from blood
samples and stored at 20 1C until analysis.
Enzyme-linked immunosorbent assays for detection of
specific immunoglobulin G1, G2a and E
Serum samples were analysed for intact and digested
Ara h 1-specific IgG1 and IgG2a (indirect ELISAs) and
intact Ara h 1-specific IgE (antibody-capture ELISA). A
positive and a negative control serum pool were included
on each ELISA plate to check assay reproducibility.
Indirect enzyme-linked immunosorbent assays for detec-
tion of specific immunoglobulin G1 and G2a against intact
Ara h 1 or Ara h 1 digesta. Plates (96-well, microtitre,
Maxisorp, Nunc, Roskilde, Denmark) were coated with
100 mL/well of 1 mg/mL native Ara h 1 or 10 mg/mL Ara h 1
digesta in carbonate buffer (pH 9.6; 15mM Na2CO3, 35mM
NaHCO3) and incubated overnight at 4 1C. Between each
step, the plates were washed five times in PBS with 0.05%
(w : v) Tween 20 (PBS-T). Plates were blocked for 1 h at
37 1C with 200 mL/well of 1% (w : v) BSA (for Ara h 1-
specific IgG1 and Ara h 1 digesta-specific IgG2a) or with
200 mL/well of 1% (v : v) rat serum (for Ara h 1-specific
IgG2a) in PBS-T. A blocking step was not performed for
plates used for detection of Ara h 1 digesta-specific IgG1
as optimization procedures showed no effect of blocking
on background absorbance values. Twofold serial dilu-
tions of serum (starting at 1 : 8, v : v) in PBS-T, 50 mL/well,
were added and incubated for 1 h at RT. For detection, 100
mL/well HRP-labelled mouse-a-rat IgG1 or HRP-labelled
mouse-a-rat IgG2a (Zymed, Berlin, Germany) diluted
1 : 2000 (v : v) in PBS-T was added to each well and
incubated for 1 h at RT. The reaction was visualized by
adding 100 mL/well of 3,30,5,5-tetramethylbenzidine-one
substrate (Kem-En-Tec, Copenhagen, Denmark) for 10min
and stopped with 100 mL/well of 0.2 M H2SO4. Absorbance
was measured at 450 nm with a reference wavelength
of 630 nm, using a microplate reader (BioTek Instruments,
Winooski, VT, USA). Serum from untreated rats was used
as negative control. The antibody titres were expressed as
log2 titres and defined as the interpolated dilution (three-
parameter analysis) of a serum sample leading to the mean
absorbance for the negative control serum 13 SD. The
detection limit was calculated to an absorbance value of
0.1 for IgG1 and 0.15 for IgG2a (KC4, BioTek Instruments).
Antibody-capture enzyme-linked immunosorbent assay for
detection of Ara h 1-specific immunoglobulin E. Plates
(96-well, Maxisorp, Nunc) were coated with 100mL/well of
0.5mg/mL mouse-a-rat IgE (Oxford Biotechnology,
Kidlington, UK) in carbonate buffer (pH 9.6) and incubated
overnight at 4 1C. Washing procedures were as described
above. After blocking for 1 h at 37 1Cwith 200mL/well of 1%
(v : v) rabbit serum in PBS-T, twofold serial dilutions of
serum (starting at 1 : 8, v : v) in PBS-T, 50mL/well was added
and incubated for 1h at RT. Plates were incubated with
100mL/well of 1mg/mL digoxigenin (DIG)-coupled Ara h 1
(10 :1) for 1h at RT. For detection 100mL/well of HRP-labelled
sheep-a-DIG (Roche, Mannheim, Germany) diluted 1 :1000
(v : v) in PBS-T was added and incubated for 1 h at RT
before development for 15min following the procedures
described above. Titre values were determined as described
above. The mean absorbance values for the negative control
serum 13SD varied between 0.4 and 0.7 between plates
(KC4, BioTek Instruments). As a consequence of this plate
variation in background absorbance values, detection limits
for calculation of titre values were set for each plate
individually.
Mediator release from rat basophilic leukaemia cells
Rat basophilic leukaemia (RBL)-2H3 cells (DSMZ, Braun-
schweig, Germany) were cultured in Eagle minimum
essential medium (MEM) with Earles salt (M2279, Sigma)/
RPMI 1640 (R0883, Sigma) medium (76 : 24, v : v)
c 2009 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 39 : 1611–1621
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supplemented with 10% (v : v) heat-inactivated horse
serum (2605088, Invitrogen), 1% (v : v) penicillin/strepto-
mycin solution (10 000U/10mg/mL, P4333, Sigma), 1%
(v : v) amphotericin (250 mg/mL, A2942, Sigma) and 1%
(v : v) L-glutamine (200mM, G7513, Sigma) at 37 1C in a
humidified atmosphere of 5% CO2.
RBL-2H3 cells were harvested in the stationary phase,
after overconfluence had been reached, and resuspended
in Eagle MEM with Earles salts supplemented with 1%
(v : v) penicillin/streptomycin, 1% (v : v) amphotericin
and 1% (v : v) L-glutamine to a concentration of 1.5106
cells/mL. Cells were plated at 1.5105 cells/well in flat-
bottomed cell culture microtitre plates (Nunc) and incu-
bated overnight (37 1C in 5% CO2) for attachment in a box
with a lid and wet tissue for moisture. The attached cells
were sensitized passively with 50 mL/well of undiluted rat
serum for 1 h at 37 1C in 5% CO2. After sensitization, the
plates were centrifuged (300g, 3min) and washed two
times in Tyrode’s buffer with 1% (v : v) HEPES (1 M,
15630056, Invitrogen) and 3% (v : v) fish gelatine
(G7765, Sigma). Subsequently, for IgE cross-linking, the
RBL-2H3 cells were incubated for 1 h (37 1C in 5% CO2)
with 100 mL/well of allergen dilutions in Tyrode’s buffer
with 1% (v : v) HEPES. Based on optimization studies with
serum pools and because of a limited serum supply, only
two concentrations of native and digested Ara h 1 (10 and
100 mg/mL) were examined for individual sera. After
incubation, cells were spun down by centrifugation
(300g, 3min) to avoid detached cells in the supernatant.
Thirty microlitre of the supernatant was transferred to a
second microtitre plate (Nunc), and the released enzymatic
activity was detected by hydrolysis of the substrate
p-nitro-phenyl-N-acetyl b-D-glucosamimide (50 mL) for
1 h. For termination of the reaction, 100 mL/well of 0.2 M
glycine (NaOH) solution (pH 10.7) was added. b-hexosa-
minidase release was quantitatively measured spectro-
photometrically at 405 nm [36]. The total release was
quantified by treating the cells with Tyrode’s buffer con-
taining 1% Triton X-100 (X100, Sigma). As negative
controls, Tyrode’s buffer without allergen was added to
each plate to measure spontaneous release (equivalent to
the background reading) and as positive controls, cells were
sensitized with positive control sera and subsequently
stimulated with a crude peanut extract (a gift from Uni-
lever, Sharnbrook, Bedford, UK). For control of IgE-
mediated degranulation, serum-sensitized cells were sti-
mulated with mouse-a-rat IgE (BD Pharmingen, San Diego,
CA, USA) or mouse-a-rat IgG2a (Zymed, San Francisco,
CA, USA). Results are expressed as the percentage of the
total release after subtraction of the spontaneous release.
Statistical analysis
The ELISA results for antibody titres for the various experi-
mental groups were compared using a non-parametric
statistical analysis because normality distribution could not
be obtained for all experimental groups even with various
transformation procedures. The Kruskal–Wallis test was
used, followed by theWilcoxon two-sample test. Differences
between the experimental groups were regarded as signifi-
cant when P40.05. Asterisks indicate a statistically
significant difference of a given group compared with the
control group. Asterisks over a horizontal line indicate a
statistically significant difference between the two given
groups: P40.05, P40.01 and P40.001. Statistical
analysis was conducted using the statistical analysis system
(SAS, Enterprise Guide 3, Cary, NC, USA).
Results
Ara h 1 is susceptible to gastro-duodenal digestion with
immobilized enzymes and is easily broken down
Ara h 1 digesta from simulated gastrointestinal digestion
with soluble enzymes have been described previously [29].
In order to prevent immune responses from developing
towards the digestive enzymes (pepsin, trypsin, chymo-
trypsin) and the protease inhibitor used to prepare these
digesta, simulated gastro-duodenal digestion was under-
taken with immobilized enzymes, which were removed
once digestion was completed. Analysis of ‘enzyme-free’
digesta by RP HPLC showed that no intact Ara h 1 survived
the digestion process (Fig. 1). This is indicated by the lack of
a polypeptide peak running at 46–48min, which corre-
sponds to the intact Ara h 1 (Fig. 1, inset). Thus, intact Ara h
1 was not detected in digesta down to a levelo0.00025%,
the estimated detection limit of the HPLC analysis.
More detailed information on the peptide mass profile
of Ara h 1 digesta was obtained by analysing individual
fractions, obtained with RP HPLC (graph not shown), by
mass spectrometry. Figure 2 shows a histogram of the
Fig. 1. Reverse-phase high-performance liquid chromatography of intact
and digested Ara h 1. Comparison of the time span of elution of digested
Ara h 1 made with immobilized enzymes and intact Ara h 1 (inset). For
digested Ara h 1, the retention time is shown from 0 to 50min, while the
intact Ara h 1 retention time is only shown between 40 and 50min, the
time interval in which the single peak corresponding to eluted Ara h 1
appears.
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peptide mass distribution of the Ara h 1 digesta. Detailed
analysis showed that Ara h 1 was broken down to very
small peptide fragments, which, in general, were lower
than 2 kDa. More than 85% of the detected peptide
fragments had masses between 0.5 and 1.5 kDa, while the
rest of the peptide fragments had masses below 0.5 kDa or
between 1.5 and 2.0 kDa.
Ara h 1 digesta aggregate to complexes of larger sizes
Analysis of digestion products of Ara h 1 by GPC under
physiological conditions showed that, even though Ara h
1 was broken down to very small peptide fragments, these
peptides occurred in complexes of larger sizes (Fig. 3).
From the area under the curve, showing an absorbance at
220 nm, it appears that more than half (55.8%) of the
peptides were in aggregated complexes of sizes between
2 and 20 kDa.
Ara h 1 digesta are able to induce both a specific
immunoglobulin G and a specific immunoglobulin E
response
To examine the effect of simulated gastro-duodenal diges-
tion on the sensitizing potential of the model allergen
Ara h 1, a dose–response experiment was performed. BN
rats, used as an animal model, were immunized i.p. either
with 1 (low), 50 (medium) or 200 mg (high) of intact Ara h
1 or with 200 mg of digested Ara h 1. Rat sera were
evaluated for specific IgG1 and IgG2a responses against
both intact and digested Ara h 1 and a specific IgE
response against intact Ara h 1.
The immunogenic response of individual rats within each
immunization group showed that the rats responded in a
dose-dependent manner towards the intact Ara h 1 (Fig. 4).
While immunizations with 50 or 200mg of intact Ara h 1
induced a statistically significant different IgG1 (P40.001)
and IgG2a (50mg: P40.01; 200mg: P40.001) response
against intact Ara h 1 compared with the control group
(immunized with PBS), immunizations with 1mg of intact
Ara h 1 were not able to mount a specific IgG response
different from the response found for the control group
(Figs 4a and b). Interestingly, digested Ara h 1 was found to
induce a significant IgG response against intact Ara h 1
compared with the control group (IgG1: P40.01; IgG2a:
P40.05). Immunizations with 200mg of digested Ara h 1
induced an almost identical IgG response against both
intact and digested Ara h 1 whereas immunizations with
50 or 200mg of intact Ara h 1 induced a significantly higher
IgG response against intact Ara h 1 compared with digested
Ara h 1 (50mg: P40.01; 200mg: P40.001). In general, both
high- and low-titre sera raised against digested Ara h 1
reacted equally well with digested and intact Ara h 1. In
contrast, analysis of sera from rats immunized with intact
Ara h 1 showed that some of the high-responding sera
bound to intact as well as digested Ara h 1 (e.g. animal no.
53, 54, 56, 57 and 60), while others only bound to intact but
not digested Ara h 1 (e.g. animal no. 49, 51 and 52).
Fig. 2. Peptide mass distribution. Mass spectra of the Ara h 1 digesta
made with immobilized enzymes shown in the histogram of matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry-
derived peptide masses, where each bar corresponds to peptide size
intervals of 0.5 kDa. The figure shows the peptide mass distribution when
both the number and the intensity of each peak are included.
Fig. 3. Gel permeation chromatography of Ara h 1 digesta under physiological conditions. Gel permeation profile of Ara h 1 digesta made with
immobilized enzymes, shown at 220 and 280 nm, respectively. Standard molecular mass markers at 220 and 280 nm are shown across the top of the
graph.
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Figure 5 shows the IgE response towards intact Ara h 1.
Also with IgE, the rats reacted in a dose-dependent manner,
where a statistically significant increase in the IgE response
against intact Ara h 1 compared with the control group
was found for groups immunized with 50mg (P40.05) and
200mg (P40.001) of intact Ara h 1. In addition, IgE raised
against intact Ara h 1 reactedmore readily with intact Ara h
1 than IgE raised against digested Ara h 1. Immunizations
with 50 or 200mg of intact Ara h 1 induced a significantly
higher IgE response against intact Ara h 1 compared with
immunizations with digested Ara h 1 (50mg: P40.01;
200mg: P40.001). In the group immunized with digested
Ara h 1, it was only possible to detect an IgE response
against intact Ara h 1 for two out of 16 animals (no. 18 and
19), which were also those that had the highest IgG titres.
Because IgE titres could only be determined against intact
protein, given that it was not possible to couple peptide
fragments to DIG, it may be that antibody responses that
preferentially recognized digested Ara h 1 compared with
intact Ara h 1 might be missed. Nevertheless, the antibody
titre responses indicate that digestion reduced the immu-
noreactivity of intact Ara h 1.
Ara h 1 digesta-specific immunoglobulin E is biologically
relevant
While a substance may induce an IgE response, it may not
be biologically relevant, i.e. incapable of inducing hista-
mine release and may hence trigger an allergic reaction.
Consequently, the biological activity of the specific IgE
responses raised in the immunized rats was tested using
the RBL assay [36].
To ensure that degranulation of the RBL cells was
dependent on allergen cross-linking of IgE molecules and
not IgG2a molecules [37], tests were performed where
sensitized RBL cells were stimulated with anti-IgE or anti-
IgG2a. Anti-IgE resulted in a mediator release of approxi-
mately 88%, while anti-IgG2a resulted in no mediator
release (data not shown).
A functional IgE response was obtained in rats immu-
nized with 200 mg of intact Ara h 1 as well as 200 mg of
digested Ara h 1, resulting in allergen-specific degranula-
tion of the RBL cells (Fig. 6). These data show that within
each group, there were animals with nearly maximum
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Fig. 4. Comparison of specific IgG responses induced against digested or
intact Ara h 1. Groups of rats (n= 4–8/sex) were dosed on days 0, 14 and
28 with either phosphate-buffered saline (PBS; control), 200mg of
digested Ara h 1 (dAra) or 1mg (low), 50mg (medium) or 200 mg (high) of
intact Ara h 1 (Ara). Serum was obtained at sacrifice (day 35) and
analysed by ELISA for measurement of a specific IgG1 (a) and IgG2a (b)
response against digested Ara h 1 (open symbols) or intact Ara h 1 (closed
symbols). Each symbol represents an animal. Horizontal bars indicate the
median values. Statistically significant difference between groups was
determined using the Kruskal–Wallis test, followed by the Wilcoxon two-
sample test. Asterisks indicate statistically significant differences of an
allergen-dosed group compared with the control group (PBS). Asterisks
over a horizontal line indicate a statistically significant difference
between the IgG response against intact and digested Ara h 1 for an
allergen-dosed group: P40.05, P40.01 and P40.001. dAra,
digested Ara h 1; Ara, intact Ara h 1; Anti-dAra, specific IgG against
digested Ara h 1; Anti-Ara, specific IgG against intact Ara h 1.
Fig. 5. Specific IgE response against intact Ara h 1. Groups of rats
(n= 4–8/sex) were dosed on days 0, 14 and 28 with either phosphate-
buffered saline (PBS; control), 200mg of digested Ara h 1 (dAra) or 1, 50
or 200 mg of intact Ara h 1 (Ara). Serum samples obtained at sacrifice
(day 35) were analysed by ELISA. Each symbol represents the specific IgE
response against intact Ara h 1 for an individual animal. Horizontal bars
indicate median values. Statistically significant difference between
groups was determined by the Kruskal–Wallis test, followed by the
Wilcoxon two-sample test. Asterisks indicate a statistically significant
difference of an allergen-dosed group compared with the control group
(PBS). Asterisks over a horizontal line indicate a statistically significant
difference between two allergen-dosed groups: P40.05, P40.01 and
P40.001. dAra, digested Ara h 1; Ara, intact Ara h 1.
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mediator release as well as animals with no detectable
release. IgE molecules from animals immunized with
digested Ara h 1 were cross-linked equally well with
digested and intact Ara h 1 at the 100 mg/mL level (Fig.
6a). In contrast, IgE molecules from animals immunized
with intact Ara h 1 were cross-linked much better with
intact Ara h 1 compared with digested Ara h 1 (Fig. 6b).
These results parallel the pattern of IgG sensitization
observed by ELISA for the same animals (Fig. 4). The
sensitivity of the RBL assay is much higher than the
antibody-capture ELISA, and hence was able to detect
IgE responses in more animals than the ELISA. Never-
theless, the only two rats (animal no. 18 and 19) for which
it was possible to detect an IgE response to intact Ara h 1
by ELISA were also the ones with the highest degranula-
tion response in the RBL assay.
Discussion
One hypothesis linking the structural attributes of certain
proteins with their allergenic potential is that certain
structures are more resistant to gastrointestinal digestion
and hence are more effective in sensitizing via the gastro-
intestinal tract. This is possible based on the hypothesis
that for a protein to sensitize an individual and elicit an
allergic response, it must survive the acidic and proteoly-
tic environment of the human gastrointestinal tract to be
absorbed through the intestinal mucosa and sensitize via
the mucosal immune system [6, 19, 21, 38]. However, most
importantly, the belief is based on a study by Astwood
et al. [22], who compared the in vitro stability of allergens
and non-allergenic proteins to simulated gastric fluid and
found an association between resistance to digestion and
allergenicity. While this premise may hold true for some
food proteins, it does not seem to hold true for the major
peanut allergen Ara h 1, a member of the cupin super-
family.
The current study was designed to investigate the basis
for linking gastro-duodenal digestibility and allergenicity,
in terms of sensitization. We confirmed that Ara h 1 is a
food protein labile to gastrointestinal digestion. When
subjected to digestive conditions that simulate those
found in the human gastrointestinal tract, intact Ara h 1
was broken down to peptide fragments of sizes generally
o2.0 kDa. More than 50% of these peptide fragments
were in aggregated complexes of sizes between 2 and
20 kDa. This was not a result of disulphide bonds sustain-
ing some 3D structure as only one cysteine residue is left
Fig. 6. Allergen-specific degranulation of rat basophilic leukaemia (RBL) cells. RBL cells were passively sensitized with undiluted serum from individual
rats immunized with either 200mg digested Ara h 1 (a) or 200 mg intact Ara h 1 (b), and subsequently stimulated with the indicated concentrations of
digested Ara h 1 (10 or 100 mg/mL) or intact Ara h 1 (10 or 100mg/mL) for degranulation. Data are presented as percentage b-hexosaminidase release of
the total release. Because of a limited serum supply for rat no. 57, no result was obtained for IgE cross-linking with 100 mg Ara h 1/mL.
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in the Ara h 1 molecule after N-terminal cleavage [39].
Therefore, this study shows that a food protein known to
be allergenic does not necessarily resist digestion. This is
in agreement with studies by Fu et al. [24] and Kenna and
Evens [25], who found that food allergens are not neces-
sarily more resistant to digestion than non-allergenic
proteins with a similar cellular function.
Variable results, some in agreement [27, 28] with our
findings and others not [40], were obtained in previous
reports on Ara h 1 digestibility. The diverse findings of the
digestibility of Ara h 1 may be a result of the different
enzymatic and/or chemical treatments used in the experi-
ments. This indicates that the choice of methods used to
evaluate the digestibility of an allergen is highly impor-
tant for the obtained results, which is also suggested by
Fu [41] and Untersmayr et al. [42].
The present sensitization study in BN rats showed that
both intact and digested Ara h 1 were immunogenic, being
able to induce IgG1 and IgG2a responses. Likewise, this
study showed that both intact and digested Ara h 1 were
allergenic, being able to induce specific and functional
IgE responses.
Ara h 1-specific IgG and IgE titres in rats immunized
with 200 mg digested Ara h 1 were significantly lower than
Ara h 1-specific IgG and IgE titres in rats immunized with
50 or 200 mg intact Ara h 1. This indicates that the
digestion process may have eliminated some epitopes.
However, our results showed that some IgG and IgE
antibodies raised against digested Ara h 1 could react with
intact Ara h 1, suggesting that some IgG and IgE epitopes
had survived the digestion process. Survival of IgE epi-
topes during the digestion process is most clear from the
RBL results, where both intact and digested Ara h 1 were
able to induce a specific degranulation response in RBL
cells stimulated with sera raised against digested Ara h 1.
That Ara h 1-specific IgE epitopes can survive the gastro-
duodenal digestion process has also been shown in an
epitope mapping study by Bgh et al. (personal commu-
nication). Similar results were obtained by Eiwegger et al.
[29], who demonstrated that Ara h 1 digesta were as
potent as the intact allergen molecule in T cell activation
and IgE-cross-linking experiments.
Based on the present study, it cannot be concluded
whether or not neo-epitopes have developed as a result of
the digestion process.
Together, these findings indicate that Ara h 1-derived
breakdown products resulting from gastro-duodenal
digestion still retain the potential to induce sensitization
and elicitation of an allergic response. In contrast to this
study, some previous studies have shown that digestion of
Ara h 1 abrogates its IgE-binding capacity. Both Astwood
et al. [22] and Hong et al. [43] reported that no residual
IgE-binding capacity remained after gastric digestion,
shown by means of immunoblotting. This may, however,
be a result of the methods used to monitor the IgE
reactivity. Vieths et al. [28] reported that investigation of
the allergenic potential by monitoring degradation of
bands by analytical electrophoresis and immunoblotting
was not sufficiently sensitive. The generation of small
IgE-reactive proteolytic fragments with a molecular
weight lower than 10 kDa could be below the range of
separation in electrophoretic systems. Instead, immuno-
logical assays should be used to assess the allergenic
potential of digestive products [28]. Similar conclusions
were arrived at by Diaz-Perales et al. [44].
That allergens do not necessarily have to survive the
acidic and proteolytic environment of the gastro-duode-
nal tract to act as an allergen is a relevant issue for the risk
assessment of allergenic potentials of novel proteins,
because the resistance to digestion is one of the para-
meters in such a test regime [23]. Van Beresteijn et al. [45]
reported that the minimal molecular weight to elicit
immunogenicity and allergenicity of whey protein hydro-
lysates appeared to be between 3 and 5 kDa. Poulsen and
Hau [46] showed that peptides with a molecular weight
below 3.4 kDa, obtained by enzymatic hydrolysis of whey
protein, were unable to sensitize mice whereas peptides
with a molecular weight above 6.5 kDa were able to
sensitize mice. Huby et al. [47] suggested that the minimal
size for a peptide to cross-link two IgE molecules on the
surface of a mast cell to initiate degranulation was at least
3 kDa. Thus, peptide fragments below the size of 3.5 kDa
should not have the ability to act as a sensitizing allergen.
This is not in accordance with our findings. Although
Ara h 1 may have a unique epitope density such that small
fragments might retain allergenicity after digestion, we
suggest that the allergenic potential found in this study is
primarily a result of aggregated complexes of the peptide
fragments and that small peptide fragments are held
together by non-covalent interactions, e.g. hydrophobic
interactions. That aggregation could be an important
player in sensitization potential is indicated by King et al.
[48] and Hermeling et al. [49]. The allergenicity of the
digestive products of Ara h 1 could also partly be a result
of synergistic effects. It has been observed that there is a
strong synergistic effect by co-immunizing mice with a
mixture of different peptides in small and equal amounts
compared with immunization with a single peptide in a
much higher quantity [50–53].
In summary, digested Ara h 1 was both immunogenic
and allergenic. This can only be explained if peptides
within the digesta mixture comprise both B and T cell
epitopes and/or the presence of peptide aggregates that
are able to induce an immune response and cross-link IgE.
These data also indicate that while gastrointestinal diges-
tion may be relevant for certain structural types of
allergens, including the lipid transfer proteins [26] and
2S albumin allergens, this does not necessarily hold true
for other structural types of allergens such as Ara h 1
belonging to the cupin superfamily. It also demonstrates
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that in vitro digestion using the pepsin assay approach
developed by Astwood et al. [22] as part of the risk
assessment of allergenic potentials of novel proteins [23]
needs to be linked with other studies, such as animal
sensitization.
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ABSTRACT: The major peanut allergen Ara h 1 is an easily digestible protein under physiological conditions. The present study
revealed that pepsin digestion products of Ara h 1 retained the sensitizing potential in a Brown Norway rat model, while this
sensitizing capacity was lost by separating the digest into fractions by gel permeation chromatography. Protein chemical analysis
showed that the peptide composition as well as the aggregation profiles of the fractions of Ara h 1 digest differed from that of the
whole pool. These results indicate that the sensitizing capacity of digested Ara h 1 is a consequence of the peptides being in an
aggregated state resembling the intact molecule or that most peptides of the digests need to be present in the same solution,
having a synergistic or adjuvant effect and thereby augmenting the immune response against other peptides.
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■ INTRODUCTION
Food allergy most often involves an allergen-specific IgE
antibody-mediated immunologic response. It is an adverse
reaction to an otherwise harmless food or food component that
involves an abnormal response of the immune system to
specific food proteins. One of the major unanswered questions
in food allergy research is what makes a protein a food allergen.
Yet, no definite answer to this exists. However, one of the
hypotheses has been that for a protein to be a food allergen, it
must survive the digestion process through the gastrointestinal
tract, to reach the immune system as an intact protein or as
large peptide fragments.1,2 The first systematic assessment of
food allergen digestibility was conducted in 1996 by Astwood
et al.3 They showed that in general food allergens were resistant
to pepsin digestion, whereas nonallergenic proteins were more
easily digested. Since this, several studies examining the
correlation between resistance to digestion and allergenicity
have been made, where the correlation between stability
and allergenicity was less clear.4−10 However, it may still be
reasonable to think that proteins being resistant or at least
partially resistant to digestion have an increased probability of
reaching the intestinal mucosa in a form that is sufficiently
immunologically active to sensitize the mucosal immune system
and be sufficient in size to retain the ability to cross-link two
IgE molecules and thereby elicit an allergic reaction. The
stability to digestion is for those reasons also recommended for
use in the safety assessment of newly introduced proteins in
genetically modified foods based on a decision tree or a weight
of evidence approach, which includes, among a variety of tests,
the assessment of resistance to digestion by pepsin.11−13 How-
ever, while pepsin stability as a part of an allergenicity assess-
ment would still seem reasonable for the purpose of safety
evaluation of most food proteins, we now know that for some
allergenic proteins, this approach would be misleading. The milk
allergen β-casein (Bos d 8)7,14,15 as well as the peanut allergen
Ara h 19,10 have several times been shown to be easily digestible
food allergens.
Peanut allergy is one of the most common and serious types
of IgE-mediated food allergies in terms of persistency and
severity16,17 and seems to be an increasing problem in the
western world.18,19 The peanut protein Ara h 1, which is a
major allergen,20,21 is a 7S globulin protein belonging to the
cupin superfamily of allergens.22 Ara h 1 is a homotrimeric
protein, consisting of 63.5 kDa large subunits,20 held together
by hydrophobic interactions between amino acids at
monomer−monomer contact points.23,24 Ara h 1 is a readily
digestible allergen, being digested to small peptide fragments by
gastroduodenal digestion.9,10 Even though Ara h 1 is a labile
protein, Eiwegger et al.9 and Bøgh et al.10 showed that the
digestion products of Ara h 1 retain allergenic potential, being
able to sensitize as well as elicit allergic reactions. These studies
indicated that aggregation of peptides may play a major role in
maintaining allergenic activity. Epitope mapping studies of this
protein have suggested both linear21 and conformational25 IgE-
binding epitopes, at least some of which are able to survive the
digestion process.10,26
Peptides need to have a certain size to be allergenic, but the
exact lower molecular weight (MW) size limit is not known.
Yet, many suggestions for such a lower MW size limit have
been presented,11,27−31 and the general view appears to be that
peptides need to be approximately 3.5 kDa to contain sen-
sitizing and eliciting allergenic capacity. This may be a realistic
limit for some allergen-derived peptides. We have previously
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shown that peptide fragments, as small as 2 kDa, have the
capacity to sensitize and elicit allergic reactions.10 In the present
study, we focus on examining under which conditions such
peptide fragments retain their allergenic potential.
The objective of this study was to increase our knowledge
and understanding of the allergenic capacity of small peptide
fragments. This was done by using the known major peanut
allergen Ara h 1 as a model allergen, based on the knowledge
that this allergen retains its allergenic potential when digested
to small peptide fragments while using pepsin as the enzyme for
digestion. Digestion products of Ara h 1 and fractions hereof
were thoroughly characterized, and examination of sensitizing
capacity was performed using a Brown Norway (BN) rat model
for food allergy.
■ MATERIALS AND METHODS
Purification of Peanut 7S Protein Ara h 1. Raw redskin peanuts
(Julian Graves LTD, Kingswinford, United Kingdom) were skin
peeled. Peanuts were frozen with liquid nitrogen and blended in a steel
blender until a fine texture was obtained. Subsequently, the crushed
peanuts were taken through two rounds of defatting [peanut:hexane,
1:5, w:v, 1 h, room temperature (RT)] and further homogenized in a
coffee grinder.
Proteins were extracted in double-distilled water (peanut:water, 1:5,
w:v) with 0.02% sodium azide (v:w), containing a protease inhibitor
tablet (Roche complete mini protease inhibitor tablet, Roche, Sussex,
United Kingdom) for 1 h at RT. After clarification by centrifugation
(3 000g, 20 min) ammonium sulfate was added to a saturation of 70%
and centrifuged (30 000g, 30 min). The supernatant was dialyzed
against buffer (Tris 20 mM, pH 7.5, 500 mM NaCl) at 4 °C, and
samples of 40 mL were applied to a column of 10 mL of Con A
Sepharose (GE Healthcare, Buckinghamshire, United Kingdom).
Unbound protein was removed by washing with the buffer, while
pure Ara h 1 was eluted by addition of 400 mM methyl α-D-
mannopyranoside. For further purity, eluted Ara h 1 was applied to a
column of Superdex 200 prep grade (HiLoad 16/60 and 26/60
Superdex 200 prep grade, GE Healthcare) and eluted with 25 mM
Tris, pH 7, and 150 mM NaCl. Purified Ara h 1 was filtrated through a
Millipore filter paper (0.22 μm, Millipore Corp., Bedford, MA) with
vacuum and afterward ultrafiltrated through an ultrafilter membrane
(pore size, 10 kDa) with gas (argon, 10 psi). The Ara h 1 was dialyzed
against 150 mM NaCl, and the concentration was determined by UV
absorbance reading at 280 nm. Furthermore, concentration of purified
Ara h 1 was determined by amino acid analysis to be 4.38 mg/mL. The
purified intact Ara h 1 was analyzed for the presence of endotoxin by
Lonza endotoxin testing service (Lonza, Verviers, Belgium).
N-Terminal Sequencing of Intact Ara h 1. To analyze the
isotype composition of intact Ara h 1, amino terminal sequencing was
performed. Protein sequencing of the intact Ara h 1 (5 μL, 16 pmol/μL)
was carried out by automated N-terminal Edman degradation in a Procise
494 sequencer (Applied Biosystems, Foster City, CA) in liquid phase
mode.
Simulated Gastric Digestion of Ara h 1. Gastric digestion was
performed essentially as described by Bøgh et al.10 In short, pepsin
immobilized to agarose (P0609, Sigma, St. Louis, MO) was washed
two times (100g, 1 min) in 10 mL of 1 mM HCl. Purified Ara h 1
(2.4 mg/mL in 150 mM NaCl) was adjusted to pH 2.5 with 1 M HCl
and added to the immobilized pepsin to yield an activity of pepsin of
approximately 170 U per mg Ara h 1. The solution was placed in a
shaking incubator (200 rpm, 37 °C) for 120 min. Reaction was
stopped by adjusting the pH to 7 with 1 M NaOH, centrifugation
(1 000g, RT, 2 min), and filtration of supernatant through a 0.45 μm
Millipore filter followed by a 0.22 μm filter.
Separation of Digested Ara h 1 into Fractions. For
fractionation of the digested Ara h 1, preparative gel permeation
chromatography (GPC) was performed. The digested Ara h 1 (6 mL,
2.3 mg/mL) was loaded onto a Superdex 75 prep grade, HiLoad
26/60 column (GE Healthcare, Uppsala, Sweden) connected to GradiFrac
system (Pharmacia Gradifrac FPLC system, GE Healthcare). Peptides
were eluted at RT with 150 mM NH4HCO3, pH 7.8, at 1 mL/min and
collected in fractions of 4 mL. The eluted peptides were detected by
absorbances at 280 and 226 nm. Four runs were made to fractionate all
digested Ara h 1. The column was calibrated for MW determination by
applying a standard mixture consisting of 1 mg/mL ferritin (440 kDa;
F4503, Sigma), 0.75 mg/mL ovotransferrin (79 kDa; C-0880, Sigma),
1 mg/mL carbonic anhydrase (29 kDa; C-3934, Sigma), 1 mg/mL
cytochrome C (14 kDa; C-2506, Sigma), 2 mg/mL apotinin (6 kDa;
A-1153, Sigma), and 0.1 mg/mL vitamin B12 (1.3 kDa; V-2876,
Sigma).
Fractions from the four consecutive runs were collected and pooled
according to the GPC profile (Figure 1) in three different pools
(in the following designated: digested Ara h 1, large complexes, and
small complexes), where digested Ara h 1 constitute the fraction of
large and small complexes. The pools were placed at −80 °C for a
minimum of 1 h, afterward freeze-dried for approximately 48 h, and
rediluted in Milli Q water [water drawn from a Milli Q System
equipped with an Organex cartridge from Millipore (Bedford, MA)] to
give a concentration of approximately 1 mg/mL.
Reverse Phase High-Performance Liquid Chromatography
(RP-HPLC) Analysis. For analysis of purity and residual intact Ara h 1
in the digests, analytical RP-HPLC was performed. Samples (40 μL, 1
mg/mL) were applied to a μRPC C2/C18 SC 2.1/10 column (120 Å
pore size, 3 μm particle size, 100 mm × 2.1 mm i.d., GE Healthcare)
connected to a SMART system (GE Healthcare). Chromatography
was performed at RT using 0.1% trifluoroacetic acid (TFA) in Milli Q
water (v:v) as solvent A and 0.1% TFA in Milli Q water:acetonitrile
(ACN) (10:90, v:v) as solvent B. Elution was performed at a flow rate
of 200 μL/min for 2.5 min with 5% solvent B, followed by elution with
a linear gradient of increasing concentration of solvent B from 5 to
50% for 22 min. Elution profiles were monitored using UV absorbance
at 220 and 280 nm. Fractions of 100 μL were collected, dried in a
vacuum centrifuge, and rediluted in 3 μL of Milli Q water for analysis
by matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrometry (MS).
Amino Acid Analysis. For examination of amino acid composition
and quantification, amino acid analysis was performed according to
Barkholt and Jensen32 after hydrolysis overnight in HCl.
Figure 1. Preparative GPC of Ara h 1 digests. For fractionation of the
Ara h 1 digest, preparative GPC was performed in 150 mM
HN4HCO3, where Ara h 1 digest was separated into fractions based
on the chromatographic profile. From the profile, shown with
absorbances at 226 and 280 nm, it was decided to make three
different pools, indicated by the vertical dashed lines. The pools are
referred to as: digested Ara h 1, large complexes and small complexes,
where digested Ara h 1 is the whole pool of digest, consisting of both
the fraction of large and the fraction of small complexes. The first
double peak had an apparent MW of 60−440 kDa, indicating that
some intact Ara h 1 could be left in this fraction. To avoid the possible
presence of any intact Ara h 1 in the digests, this double peak was
excluded.
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MALDI-TOF MS. For analysis of peptide mass distribution in
samples of Ara h 1 digests, MALDI-TOF MS was performed on a
Bruker MALDI-TOF MS (MALDI TOF/TOF, Ultraflex II, Bruker
Daltonik GmbH, Bremen, Germany) equipped with pulsed ion
extraction and 200 Hz Smart Beam laser. One microliter of the
rediluted fractions from RP-HPLC was loaded onto a MALDI target,
followed by addition of 1 μL of 2% TFA and 1 μL of α-cyano-4-
hydrocinnamic acid [5 μg/μL in 70% ACN (v:v), 0.1% TFA (v:v)]. All
mass spectra were initially calibrated with a tryptic digest of
β-lactoglobulin.
GPC Analysis. For analysis of aggregation profiles in samples of
Ara h 1 digests, analytical GPC was performed. Samples (40 μL, 1 mg/mL)
were applied to a Superdex 75 PC 3.2/30 column (GE Healthcare)
connected to a SMART system (GE Healthcare). Chro-
matography was performed at RT with a flow rate of 50 μL/min
using 150 mM HN4HCO3 (pH 7.8) as the eluent. The eluent profiles
were monitored using UV absorbances at 220 and 280 nm. The
column was calibrated for MW using 12 μL of the standard mixture
previously described.
Animals. BN rats were from the in-house breeding colony at the
National Food Institute (DTU, Denmark), weaned at 3 weeks of age
and then housed in macrolon cages (two per cage) with a 12 h
light:dark cycle, at 22 ± 1 °C and 55 ± 5% relative humidity. Rats were
observed twice daily, and clinical signs were recorded.
Rats were kept on diet free from leguminous fruit for three
generations to avoid tolerance against Ara h 1. Rat diet was produced
in-house and based on rice flour, potato protein, and fish meal as
protein sources, as previously described,10 with the exception of maize
flakes being substituted with rice flour. Diet and acidified water were
given ad libitum. Animal experiments were carried out at the National
Food Institute (DTU, Denmark) facilities under conditions approved
by the Danish Animal Experiments Inspectorate and the in-house
Animal Welfare Committee.
Animal Sensitization Experiment. To study the sensitization
capacity of intact Ara h 1, digested Ara h 1 and fractions of the
digested Ara h 1, BN rats, 5−8 weeks of age, were allocated into five
groups of 8−12 animals. Rats were immunized ip with PBS (control),
200 μg of intact Ara h 1, 200 μg of digested Ara h 1, or 200 μg of
either the large or the small complexes, with the use of Alhydrogel 2%
in PBS as adjuvant. Rats were immunized three times, at days 0, 14,
and 28, and sacrificed at day 35 by exsanguination using carbon
dioxide inhalation as anesthesia. For further details, see Bøgh et al.10
Enzyme-Linked Immunosorbent Assays (ELISAs) for the
Detection of Specific IgG1, IgG2a, and IgE. ELISAs were
performed as previously described.10 Specific IgG1 and IgG2a were
detected by direct binding of antibodies to plate-coated antigens, while
IgE was detected in an antibody-capture ELISA, where Ara h 1 was
coupled to digoxigenin.
Curve Calculations and Statistical Analysis. Curve calculations
(XY analyses) and statistical calculations were made using GraphPad
Prism version 5.00 (GraphPad Software, San Diego, CA). ELISA re-
sults expressed as antibody titers were examined for group differences,
using the nonparametric one-way ANOVA, Kruskal−Wallis test,
followed by Dunn's multiple comparison test for comparison of three
or more groups. Differences between animal groups were regarded as
significant when P ≤ 0.05. Asterisks indicate a statistically significant
difference between the given group and the control group. Asterisks
over a horizontal line indicate a statistically significant difference
between the two given groups: * = P ≤ 0.05, ** = P ≤ 0.01, and *** =
P ≤ 0.001
■ RESULTS
Characteristics of Purified Ara h 1. From N-terminal
sequencing of the purified Ara h 1, it was evident that both
known isoforms of Ara h 1 were present, in the ratio of
approximately 1:1 (data not shown). The sequences identified
were RHPPGER and RSPPGER, demonstrating that the
purified isoforms of Ara h 1 start at amino acid residue 79
(RHPPGER, Ara h 1, clone P17, SwissProt no. P43237) or 85
(RSPPGER, Ara h 1, clone P41B, SwissProt P43238), a
confirmation of a study by Wichers et al.,33 showing that Ara h
1 is expressed as a truncated protein, in which the first 78 and
84 amino acids, respectively, are cleaved off. The endotoxin
analysis of the purified intact Ara h 1 was <2 endotoxin units
(EU)/mg of Ara h 1. From RP-HPLC analysis (Figure 2A), Ara
h 1 was calculated to be >98% pure.
Characteristics of Digested Ara h 1 and Fractions
Hereof. From RP-HPLC analyses, it was evident that no
residual intact Ara h 1 was left in the three pools of Ara h 1
digests, since no detectable peak at the elution time for intact
Ara h 1 was seen in the chromatography profiles (Figure 2A vs
B−D). When comparing the RP-HPLC profiles for digested
Ara h 1, large complexes and small complexes (Figure 2B−D),
no significant differences are shown, indicating no apparent
variation in peptide composition. However, when comparing
Figure 2. Analytical RP-HPLC. Comparison of chromatography profiles performed with 0.1% TFA/ACN for intact Ara h 1 (A), digested Ara h 1
(B), large complexes (C), and small complexes (D), shown with absorbances at 280 and 220 nm.
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the total amino acid distribution of the peptides present in the
three different pools (Figure 3), it was revealed that differences
did exist. While the amino acid distribution of digested Ara h 1
represented the amino acid distribution for intact Ara h 1, the
large complexes and the small complexes were found to have an
amino acid distribution different from that of the intact Ara h 1.
That digested Ara h 1 had an amino acid distribution similar to
the distribution of intact Ara h 1 confirms that this pool
contains a peptide composition representative of the intact
Ara h 1, where hydrophobic amino acids are responsible for
approximately 40%, the polar for approximately 12%, and the
charged for approximately 48% of total amino acids. In contrast,
the large complexes contain approximately 35% hydrophobic
amino acids, approximately 9% polar, and approximately 56%
charged amino acids, while the small complexes contain
approximately 48% hydrophobic amino acids, approximately
15% polar, and approximately 37% charged amino acids. This
shows that peptides constituting the two fractions of digested
Ara h 1 are different from each other and thereby different from
the whole pool of digested Ara h 1 and, therefore, do not
contain peptides representing the intact Ara h 1.
For examination of the peptide mass distribution profiles of
the three different pools of Ara h 1 digests, MALDI-TOF MS
was performed and demonstrated that Ara h 1 was digested to
small peptide fragments of sizes ≤ Mr 4 000 (Figure 4), of
which more than 75% had apparent Mr between 500 and 2 000.
As in the whole pool of digested Ara h 1, the peptides in the
large complexes had sizes up to Mr 4 000, while in the small
complexes, the peptides were ≤ Mr 3,000. So while the digested
Ara h 1 and the fraction of large complexes contained peptides
that were up to 33 amino acids, the longest peptides in the
fraction of small complexes were up to 25 amino acids.
However, for all three pools of Ara h 1 digests, by far, most
peptides were between 4 and 16 amino acids.
Realizing from the preparative GPC profile (Figure 1), based
on which the fractions of Ara h 1 digests were made that the
peptides were in some kind of aggregated state, we analyzed in
more detail the aggregation profiles of the three different pools.
From the analytical GPC profiles shown in Figure 5, it is
evident that the peptides in all three pools were indeed
aggregated into complexes of larger sizes. However, from the
profiles, it is revealed that the state of aggregation is very
different for the three different pools. From the area under the
220 nm GPC absorbance curves, it was indicated that 25% of
the peptides in digested Ara h 1 were aggregated into com-
plexes of up to Mr 104 000, that 53% of the peptides in the
large complexes were aggregated into complexes of up toMr 56
000, and that 7% of the peptides in the small complexes were
aggregated into complexes of up to Mr 9 000. So, depending on
the peptide composition profiles of the digested Ara h 1 and
fractions hereof, the aggregation profiles differed significantly.
See Table 1 for a summary of protein-chemical characteristics
of the three different pools of Ara h 1 digests.
Sensitizing Capacity of Digested Ara h 1 and
Fractions Hereof. Sera from individual BN rats dosed with
either PBS (control), 200 μg of intact Ara h 1, 200 μg of
digested Ara h 1, 200 μg of large complexes, or 200 μg of small
complexes were evaluated for specific antibodies against both
intact Ara h 1, digested Ara h 1, and fractions hereof. Looking
at the antibody response, it was evident that while both intact
Ara h 1 and whole pool of digested Ara h 1 could induce
specific IgG response, neither the large complexes nor the small
complexes could induce specific IgG antibodies. Analyses of the
specific IgG1 (Figure 6) and IgG2a, which revealed similar
Figure 3. Amino acid frequency distribution. Comparison of the amino acid distribution for intact Ara h 1 (A), digested Ara h 1 (B), large complexes
(C), and small complexes (D). The bars represent the frequency percentage of the indicated amino acid(s), represented by their one letter code, for
either the intact Ara h 1 or all peptides represented in the different pools of Ara h 1 digests. Amino acids are grouped according to their
physicochemical features.
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results (data not shown), showed that antibodies raised against
intact Ara h 1 were able to recognize both intact Ara h 1,
digested Ara h 1, and both fractions of the digested Ara h 1,
all to a statistically significant level. Although it is seen from
Figure 6 that all animals immunized with intact Ara h 1 could
react with all four samples of allergens, it is seen that the
binding capacity was different (although not statistically
significantly). IgG1 antibodies from the rats immunized with
intact Ara h 1 had the highest binding capacity toward the
intact Ara h 1, followed by the whole pool of digested Ara h 1
and then the fraction of large complexes. The lowest binding
capacity was toward the fraction of small complexes. Contrary
to antibodies raised against intact Ara h 1, the antibodies raised
against the whole pool of digested Ara h 1 could only react with
intact Ara h 1 and the whole pool of digested Ara h 1, the latter
being the only one that was statistically significant. The specific
antibody responses showed no statistically significant differ-
ences between rats immunized with intact and digested Ara h 1.
From Figure 7, it is seen that both intact and digested Ara h 1
could induce specific IgE, although the intact Ara h 1-specific
IgE response was only significant for antibodies raised against
intact Ara h 1. However, no statistically significant difference
was seen between rats immunized with intact and digested
Ara h 1, respectively, by use of a multiple comparison test.
Because it was not possible to couple the small peptide
fragments in digested Ara h 1 to a coupling protein, which
could be detected by commercially available secondary
antibodies, we could not determine digested Ara h 1-specific
IgE responses. We anticipate, however, that the specific IgE
response of rats immunized with digested Ara h 1 would be
higher for digested Ara h 1 than the one shown for intact Ara h 1.
These speculations are based on our knowledge that specific IgE
follows the specific IgG1 and IgG2a.10,34
■ DISCUSSION
The present study confirms that Ara h 1 retains both the
sensitizing and the reacting potential, when digested to small
peptide fragments. This signifies that digestion of Ara h 1 is not
an effective approach for significant reduction of neither
sensitizing nor IgE binding capacity and manifest that a
correlation between resistance to digestion and allergenicity
is not a general parameter. While Ara h 1 does not need to
survive the digestion process as an intact protein or as large
fragments to react with the immune system for induction of
a specific immune response, this could still be the case for
other food allergens. Previous studies examining the
influence of digestion on the allergenic potential of other
Figure 4. Peptide mass frequency distribution. Mass spectra of di-
gested Ara h 1 (A), large complexes (B), and small complexes (C),
shown in a histogram, where each bar corresponds to a peptide size
interval of 0.5 kDa.
Figure 5. Analytical GPC. Comparison of chromatography profiles
performed in 150 mM NH4HCO3 for digested Ara h 1 (A), fraction of
large complexes (B), and fraction of small complexes (C), shown
with absorbances at 280 and 220 nm. Standard MW markers
for absorbances at 280 and 220 nm are shown across the top of
the graph.
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food proteins have revealed digestion to be an effective
approach for a significant impairment of sensitization35,36
and IgE-binding capacity.35,37,38
We have previously shown that mixtures of peptides smaller
than 2−5 kDa, which was generally thought to be the lower size
limit for a peptide with inherent sensitizing capacity,31 may still
act as a “complete” allergen,39 being able to sensitize, elicit
allergic reaction, and react with IgE. The aim of this study was
to further examine how small peptides retain their sensitizing
capacity. This was done by studying the specific antibody
responses in BN rats immunized with digested Ara h 1 and
fractions hereof, separated on the basis of the aggregation
profile of the peptides.
From the GPC analysis of the digested Ara h 1, it was evident
that peptides did aggregate into complexes of larger sizes. This
may be a result of noncovalent interactions, like hydrophobic
interactions, since the single cysteine residue present in the Ara
h 1 molecule cannot account for the amount and sizes of the
complexes. That the sensitizing capacity of digested Ara h 1 is a
result of the peptide fragments forming aggregates was
hypothesized in earlier studies.9,10 That aggregation may
enhance the immune response toward antigen subunits was
already recognized in 1978, where Morein et al.40 showed that
aggregation of subunits by hydrophobic interactions induced a
significant higher immune response as compared to free
subunits, suggesting an importance of multimeric structures.
The same has been shown with the allergen melittin, a bee
venom protein of 2.8 kDa (26 amino acids), with one B cell
epitope41 and one T cell epitope.42 Melittin was able to induce
specific IgG and IgE responses in humans and animals. The
immunogenicity and allergenicity of the melittin were found to
correlate with oligomerization of the molecules.43−45 Also, the
state of aggregation may influence the way in which proteins
are presented to the immune system in the gastrointestinal
tract. This was indicated in a study by Roth-Walter et al.,46
which showed that aggregation of proteins from milk inhibited
their uptake by intestinal epithelial cells and redirected uptake
to Peyer's patches, promoting a significantly higher Th2-
associated antibody response. This supports the theory that
aggregation is a plausible explanation for the allergenic potential
of digested Ara h 1.
It is well recognized that small peptides in general are poor
immunogens and that peptides in general need to be of a
certain size to behave as sensitizing allergens. Muller31 stated
that it is commonly assumed that peptides in the range of 2−5
kDa behave like haptens and are not immunogenic. It is known
that for a protein to induce an allergic response, it requires the
presence of both T and B cell epitopes. However, immunization
with free peptides as small as 6−14 amino acid residues long
has been reported to induce acceptable antibody re-
sponses.31,47,48 This is in concordance with the earlier study
of sensitizing capacity of digested Ara h 1, where peptides of
less than 2 kDa were able to induce a statistically significant
antibody response without the use of additional adjuvant.10
This may indicate that the sensitizing capacity of digested Ara h
1 could also be an intrinsic feature of the free peptides
themselves. It has been shown several times that induction of
antibodies does not require covalent linkage between the
Table 1. Overview of Protein-Chemical Characteristics of the Different Pools of Ara h 1 Digests
amino acid distribution (%) aggregation profile
pool of digested Ara h 1 hydrophobic polar charged peptide sizes (Mr) amount (%) sizes (Mr)
digested Ara h 1 40 12 48 ≤4 25 104 000
fraction of large complexes 35 9 56 ≤4 53 56 000
Fraction of small complexes 48 15 37 ≤3 7 9 000
Figure 6. Specific IgG1 response. Comparison of specific IgG1 titer
values, for groups of rats immunized with either PBS (control), intact
Ara h 1, digested Ara h 1, large complexes, or small complexes. In each
group of rats, IgG1 antibodies were examined for their binding to both
intact Ara h 1, digested Ara h 1, the fraction of large complexes, and
the fraction of small complexes. Each symbol represents an individual
rat. Horizontal bars indicate the median value for each group of rats.
The statistically significant difference between the groups was
determined using Kruskal−Wallis test followed by Dunn's multiple
comparison test. Asterisks indicate statistically significant difference of
the given allergen-dosed group as compared with the control group for
the given specificity (represented by identical symbols).
Figure 7. Specific IgE response against intact Ara h 1. Comparison of
Ara h 1-specific IgE titer values, for groups of rats, immunized with
either PBS (control), intact Ara h 1, digested Ara h 1, large complexes,
or small complexes. Each symbol represents the specific IgE titer
response toward intact Ara h 1 for an individual rat. Horizontal bars
indicate median values. Statistically significant differences between
groups of rats were determined using Kruskal−Wallis test followed by
Dunn's multiple comparison test. Asterisks indicate statistically
significant difference of the given allergen-dosed group as compared
with the control group, and asterisks over a horizontal line indicate a
statistically significant difference between the two given allergen-dosed
groups.
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peptide behaving as T cell epitope and the peptide behaving as
B cell epitope.49−52 It has also been shown that amino acid
sequences that did not function as an antibody epitope when
part of a larger peptide were able to function as an antibody
epitope when presented as free small peptides in mixtures with
other peptides.47,49 This is consistent with the present study
showing that antibodies raised in rats immunized with the
whole pool of digested Ara h 1 had higher binding capacity
toward the digested Ara h 1 than toward the intact, indicating
that new epitopes that were not accessible in the intact Ara h 1
became accessible when digested to small peptides. These
results indicate that poor immunogenicity of peptides can be
overcome by coimmunization with mixtures of the peptides.
To further elucidate why digested Ara h 1 retained the
sensitizing potential, BN rats were immunized with fractions of
the digest. Strikingly, this study showed that by separating the
peptides of digested Ara h 1 into two fractions, the sensitizing
capacity was lost. While only a small part of the peptides in the
fraction of small complexes did aggregate, more than half of the
peptides in the fraction of large complexes were in aggregates of
sizes up to Mr 56 000. This is a larger part than in the whole
pool of digested Ara h 1 where only 25% of the peptides
aggregated. This reveals that allergenicity of the digested Ara h
1 is not simply a result of the peptides aggregating. The given
fact that aggregated complexes in the digested Ara h 1 was up
to Mr 104 000, nearly twice the size of the largest aggregates in
the large complexes, indicates that the aggregation profile
changed by means of fractionation in GPC. Instead of the
sensitizing capacity being simply a result of aggregation of the
peptides, the present study indicates that sensitization depends
on the way the peptides do aggregate. A possible explanation
may be that the aggregated peptides in the digested Ara h 1 are
in an architecture representing the natural configuration of
intact Ara h 1, while the peptides in the large complexes are in a
state of de novo aggregation. Epitopes have been classified as
either linear or conformational,53,54 and it is believed that most
B cell epitopes are conformational.39,55,56 However, for food
allergens, it has been suggested that linear epitopes could be of
importance, since the protein is presented to the mucosal
immune system of the gastrointestinal tract as denatured and
digested protein fragments, favoring a B cell response toward
linear sequences of amino acids.57,58 Indeed, linear IgE-binding
epitopes have been identified for various food allergens.58
Nevertheless, linear IgE-binding epitopes have been found to
contribute only a little to the total IgE binding,53,54,56,59 and no
biochemical characteristics were found to be shared between
the linear IgE-binding epitopes.58
If sensitizing potential of digested Ara h 1 is an intrinsic
feature of the free peptides themselves, however, coimmuniza-
tion with B and T cell epitopes does not explain why the
digested Ara h 1 retained sensitizing capacity, while this
sensitizing capacity was abolished when the peptides were
separated into fractions. An explanation could be that the
stability of digested Ara h 1 by some means was changed when
the peptides were separated. From amino acid analysis, it is
evident that when the peptides of digested Ara h 1 were
separated by GPC, the amino acid distribution was significantly
changed, leaving most charged peptides in the fraction of large
complexes and most hydrophobic peptides in the fraction of
small complexes. Consequently, the same peptides may
possibly not be present in the two different fractions and
certainly not to the same extent. That the type and amount of
peptides are of importance has been shown in several studies of
peptide vaccine development. Mixtures of peptides have been
shown to induce more B cell epitopes than did the very same
peptides when fused or administered alone,47,49,51,60 indicating
that peptides may function as adjuvant or in a synergistic way.
Accordingly, the present study suggests that most peptides in
the digest need to be present to serve as adjuvant augmenting
the immune response against other peptides and therefore need
to be administered together. In addition, it has been
demonstrated that peptides representing different T cell
epitopes varied significantly in their ability to provide help to
B cells. This suggests that the inherent property of the peptides
constituting T cell epitope peptides differ in efficacy and that
this feature may be independent of the protein from where they
origin.51,52
The present study revealed that different requirements are
needed for a protein to retain sensitizing and antibody binding
capacity. While the fractions of digested Ara h 1 had no
sensitizing potential, both fractions retained reactivity with
antibodies raised in rats immunized with intact Ara h 1. This
shows that there are larger requirements for peptides to
sensitize than for the peptides to retain reacting activity. These
results seem reasonable, since reacting activity only needs an
amino acid sequence resembling an antibody epitope, while
sensitizing capacity requires the ability to be recognized by the
immune system de novo, priming of specific B cells as well as
activation of T cells, providing the additional help needed for
proper differentiation and proliferation of antibody secreting
plasma cells. If most B cell epitopes of Ara h 1 are
conformational, this leaves us to explain how antibodies
directed against intact Ara h 1 are able to react with peptides
from the small complexes. Peptides in the small complexes do
not aggregate to an extent where they could represent
conformational epitopes but must instead be epitopes derived
from the linear sequence of the allergen. Aalberse39 states that
the main factor is the huge difference in binding affinity
between antibodies interacting with intact protein versus
interacting with peptides from the very same protein. This
means that the peptides are much less efficient as compared to
the intact protein for antibody binding. The peptide may for
instance represent only a fraction of the epitope39,54 or may
only be a mimic of the epitope for which the antibody was
originally directed against,53 with only a certain degree of
resemblance. The strength of interaction with the peptide could
be decreased even more because of the higher flexibility of free
peptides as compared to the complete protein.39 This is in
agreement with our own unpublished data, demonstrating a
higher avidity between the binding of antibodies and intact
protein as compared to the binding of the antibodies and
digests. It is suggested that about 10% of antibodies directed
toward conformational epitopes are able to react with linear
peptide fragments of the protein,53,54,56 which correlates well
with the present study.
In summary, the current study showed that while digested
Ara h 1 has sensitizing capacity, this capacity was lost after
separation of the peptides in the digest into fractions. The
sensitizing capacity of the digest was not dependent on single
peptides but rather the sum of peptides. However, to unravel if
the sensitizing capacity is a result of mixtures of free peptides or
is a result of the peptides being in a defined aggregated state,
further studies are needed. On the basis of the present study,
we may conclude that the way in which the digests are
presented to the immune systems is of significant importance
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for the outcome and confirms the complexity of the
mechanisms involved in sensitization.
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Abstract 
 
 
Background: Allergen epitope characterization provides valuable information useful for the understanding 
of proteins as food allergens. It is believed that IgE epitopes in general are conformational, nevertheless, 
for food allergens known to sensitize through the gastrointestinal tract linear epitopes have been suggested 
to be of great importance. 
Objective: The aim of this study was to identify IgE specific epitopes of intact and digested Ara h 1, and to 
compare epitope patterns between humans and rats. 
Methods: Sera from five peanut allergic patients and five Brown Norway rats were used to identify intact 
and digested Ara h 1-specific IgE epitopes by competitive immunoscreening of a phage-displayed random 
hepta-mer peptide library using polyclonal IgE from the individual sera. The resulting peptide sequences 
were mapped on the surface of a three-dimensional structure of the Ara h 1 molecule to mimic epitopes 
using a computer-based algorithm. 
Results: Patients as well as rats were shown to have individual IgE epitope patterns. All epitope mimics 
were conformational and found to cluster into three different areas of the Ara h 1 molecule. Five epitope 
motifs were identified by patient IgE, which by far accounted for most of the eluted peptide sequences. 
Epitope patterns were rather similar for both intact and digested Ara h 1 as well as for humans and rats. 
Conclusions: Individual patient specific epitope patterns have been identified for the major allergen Ara h 1. 
IgE binding epitopes have been suggested as biomarkers for persistency and severity of food allergy, 
wherefore recognition of particular epitope patterns or motifs could be a valuable tool for prevention, 
diagnosis, and treatment of food allergy. 
 
 
 
1  Introduction 
 
 
Peanut allergy is one of the most persistent and severe forms of food allergy (Emmett et al., 1999; Sicherer 
et al., 2001, 1999) and is mediated by allergen-specific IgE molecules, which bind to high affinity receptors 
on mast cells or basophils. Cross-linking of receptor-bound IgE by specific allergen, leads to degranulation 
and mediator release of the effector cells (Holowka and Baird, 1996; Lin and Sampson, 2009). For a food 
protein to be a ‘complete’ allergen (Aalberse, 2000, 1997) it must therefore be multivalent, i.e. expressing a 
minimum of two IgE-binding epitopes. 
Since most IgE-binding epitopes are thought to be conformational (Aalberse, 2000; Barlow et al., 1986; 
Roggen, 2006; Van Regenmortel, 1996), the epitope profile of a globular protein is greatly influenced by the 
micro-environment. Thus, changes in e.g. pH, ionic strength, or binding to other molecules may affect the 
number of epitopes that are accessible for the antibodies by tightening or loosening the protein structure. 
In the latter case, new epitopes (neo-epitopes) may be observed. Such neo-epitopes are believed to be very 
prominent after proteolytic cleavage of the protein, as occur during digestion (Rich et al., 2001). 
Different methods for identifying epitopes exist. Linear epitopes can be identified by analysis of IgE binding 
to peptides derived from the primary sequence (Burks et al., 1997; Lai et al. 2004; Roggen, 2006; Stanley et 
al., 1997). However, identification of conformational epitopes requires more elaborated methods, such as 
X-ray crystallography of antibody-antigen complexes (Niemi et al., 2007; Spangfort et al., 2003) or site- 
directed mutagenesis (Karisola et al., 2004; Lai et al., 2004; Spangfort et al., 2003). A promising alternative 
to these methods is competitive immunoscreening of a phage-displayed library of random oligopeptides to 
select  epitope  mimicking  peptides  followed  by  computer-based  mapping  of  the  identified  peptide 
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sequences (Mittag et al., 2006; Roggen, 2006). Epitope mimics are small peptides, which mimics binding 
sites of the protein and are able to compete with the native protein for antibody binding (Meloen et al., 
2000). 
The peanut protein Ara h 1 is a major allergen, which is recognized by serum IgE from more than 80% of 
peanut allergic patients (Burks et al., 1997, 1991). In its native form Ara h 1 is a 63.5 kDa protein that forms 
stable homotrimers maintained by hydrophobic interactions between amino acids at the monomer- 
monomer contact points (Maleki et al., 2000; Shin et al., 1998). Both linear and conformational IgE binding 
epitopes of Ara h 1 have been mapped. Ditto et al. (2010) presented a case report supporting the presence 
of conformational Ara h 1-specific IgE epitopes. In addition, Ara h 1 are suggested to consist of 23 
independent linear binding sites ranging from 6-10 amino acids in length (Burks et al., 1997) and a single 
linear binding site consisting of 25 amino acids (Shreffler et al., 2004), that have no obvious sequence 
motifs (a sequence pattern of amino acids) shared by them. Individual patients with IgE antibodies to Ara h 
1 were shown to have IgE that recognized multiple epitopes on the Ara h 1 molecule, and of these epitopes 
four of them appeared to be immunodominant in that they were recognized by sera from more than 80% 
of the patients tested and bound more IgE than any other Ara h 1 epitopes. The 24 linear epitopes were 
evenly distributed along the entire primary sequence of the molecule (Burks et al., 1997; Shreffler et al., 
2004). However, a molecular model of the tertiary structure of the Ara h 1 protein showed that the IgE 
epitopes were clustered into two main regions, the same regions where Ara h 1 monomer-monomer 
contact points are located (Maleki et al., 2000; Shin et al., 1998). Such reports, that the majority of the 24 
linear IgE binding epitopes were suggested to be located in these hydrophobic contact sites led to the 
assertion that they may be protected from digestion, and that the quaternary structure of the Ara h 1 
protein may play a significant role in its allergenicity (Maleki et al., 2000; Shin et al., 1998). Additionally, it is 
suggested that the structure may be so compact that potential cleavage sites are inaccessible until the 
protein is denatured and that the formation of a trimeric complex and further higher order aggregation 
may also afford the molecule some protection from protease digestion and denaturation (Shin et al., 1998). 
Studies on the  in vitro digestibility of Ara h 1 have produced rather divergent results. Becker (1997) 
reported that Ara h 1 was completely resistant to in vitro digestion. In contrast, Maleki et al. (2000) and 
Vieths et al. (1999) reported that it was digested but to relatively large MW peptide fragments only. Finally, 
the protein was reported to be easily digestible producing peptide fragments with maximum sizes as small 
as 2 kDa (Bøgh et al., 2009; Eiwegger et al., 2006; Kopper et al., 2004). The contradicting reports appearing 
in the literature is probably a result of different digestion conditions. However, although Ara h 1 was 
broken down to small peptide fragments, IgE binding epitopes survived the digestion process (Bøgh et al., 
2009; Eiwegger et al., 2006). Digested Ara h 1 was shown to retain both sensitizing and eliciting capacity, 
which was suggested to be a result of the small peptide fragments aggregating to complexes of larger sizes 
(Bøgh et al., 2009). This notion is supported by a recent study, further indicating that the way in which the 
peptide fragments of digested Ara h 1 aggregate, is of major importance for the sensitizing capacity and 
suggesting that the peptide fragments is in an aggregated state resembling the intact Ara h 1 (Bøgh et al., 
2012). 
Susceptibility to digestion is an important issue since a characteristic feature of allergenic proteins in food is 
believed  to  be  resistance  to  digestion  (Astwood  et  al.,  1996;  FAO//WHO,  2001).  Presently,  it  is 
recommended to include digestibility in risk assessment of novel proteins introduced into genetically 
modified food (FAO/WHO, 2001; EFSA, 2010). 
This study was performed to investigate the impact of in vitro digestion on the IgE epitope profile of Ara h 1 
as revealed by humans and rats. This was accomplished by competitive immunoscreening of a phage- 
displayed random peptide library using polyclonal IgE from individual patient and rat sera. The resulting 
88 
 
peptide mimics were mapped on the surface of a model of the 3-dimensional (3D) structure of the Ara h 1- 
monomer using a computer-based algorithm. 
 
 
 
2 Material and Methods 
 
 
2.1  Allergens 
Ara h 1 was purified as described by Eiwegger et al. (2006), and digested as described by Bøgh et al. (2009). 
In short, purified Ara h 1 was digested in an in vitro gastro-duodenal model, designed to simulate the 
human digestion process, as described by Moreno et al. (2005a; 2005b). Digestion was performed with 
immobilized enzymes to make enzyme-free digests suitable for animal sensitization. The digestion process 
was divided into two phases, a gastric phase where intact Ara h 1 was digested with immobilized pepsin for 
120 min at pH 2.5 and a duodenal phase where the gastric digests were further digested with immobilized 
trypsin and chymotrypsin for 15 min at pH 6.5. 
 
 
2.2  Allergen characteristics 
Purity of Ara h 1 was confirmed by reverse phase high-performance liquid chromatography to be > 99%. 
Ara h 1 was digested to small peptide fragments, with sizes ≤ 2 kDa, of which more than 85% of the 
peptides had masses between 0.5 and 1.5 kDa, demonstrated by mass spectrometry. From gel permeation 
chromatography it was indicated that more than 50% of the peptide fragments occurred in aggregated 
complexes of up to Mr 20.000, as described in Bøgh et al. (2009). 
 
 
2.3  Peanut allergic patient sera 
Sera from five individual patients (patient no.: 2205, 2208, 2209, 2304, and 2305) with clear-cut peanut 
allergy diagnosed by an experienced allergologist were used. These patients had convincing history of 
peanut anaphylaxis (severe, potentially fatal, systemic allergic reaction that occurred suddenly after contact 
with    peanut)    or    clear    peanut    exposure-related symptoms    (urticaria,    itching    of    the    skin, 
gastrointestinal symptoms) within the last 12 months (Table 1). Due to severity and clear-cut exposure- 
related recent reactions a DBPCFC was not justified from an ethical point of view. 
All sera were tested positive for peanut extract-specific IgE by ImmunoCAP and Ara h 1-specific IgE by ELISA 
(Eiwegger et al., 2006). The protocol was approved by the local ethical committee of the Medical University 
of Vienna and written informed consent was obtained (protocol no° EK 428/2008). 
 
 
2.4  Brown Norway rat sera 
Sera from five individual Brown Norway (BN) rats immunized three times i.p. with either 200 µg purified 
intact Ara h 1 (rat no.: 49, 52, 53, and 54) or 200 µg gastro-duodenal digestion products hereof (rat no.: 19) 
without the use of adjuvant were used. The BN rats were kept on a diet free from leguminosa for at least 
three generations. 
All sera were tested positive for intact and digested Ara h 1-specific IgE by ELISA and Rat Basophilic 
Leukaemia (RBL)-assay. From the RBL-assay it was also evident that IgE was biologically functional being able 
to induce degranulation of RBL cells with both intact and digested Ara h 1 (Bøgh et al., 2009). Animal 
experiments were carried out at the National Food Institute (DTU, Denmark) facilities and performed under 
conditions approved by the Danish Animal Experiments Inspectorate and the in-house Animal Welfare 
Committee. 
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2.5  Selection of phage-displayed IgE epitope mimicking peptides 
IgE epitope mimicking peptides were identified by competitive immunoscreening of phage-displayed 
libraries of random oligopeptides essentially described by Mittag et al. (2006), which allows for detection of 
both  linear  and  conformational  epitopes.  In  short,  four  x  500  µL  aliquots  of  tosyl-activated  M280 
Dynabeads suspension (Dynal Biotech, Olso, Norway) were each coated with 25 µg rabbit-α-human IgE 
(DAKO, Glostrup, Denmark) or mouse-α-rat IgE (Oxford Biotechnology, Kidlington, UK) for 48 h at 37 °C, and 
blocked with 0.5 % (w/v) skimmed milk powder (SMP) in Phosphate Buffer Saline (PBS). Patient serum 
(1000 µL) or rat serum (500 µL) was diluted in PBS with 0.5 % SMP (w/v) and 0.05 % (w/v) Tween 20 
(dilution buffer), and incubated overnight at 4 °C with 400 µL or 200 µL coated bead suspension, 
respectively. After extensive washing, 2 x 50 µL (for human) or 2 x 25 µL (for rat) of the coated beads were 
used immediately for the first round of selection, while the remaining 300 µL or 150 µL, respectively, were 
restored for later selection rounds. 
2.5.1  First selection round 
Fifty µL or 25 µL beads with immobilized IgE were blocked in 1 mL of 2% (w/v) SMP in PBS for 1 h at room 
temperature (RT) and washed extensively. The beads were then incubated overnight with 10 µL (~2 x 1011) 
phages  from  a  library  of  phages  displaying linear  random  hepta-mer  peptides  (Ph.D.-7  Phage  Display 
Peptide Library Kit, New England BioLabs, Beverly, MA, USA), followed by extensive washing and negative 
selection to remove unbound phages. For positive selection, phages were eluted by competitive 
immunoscreening, by adding 25 µg allergen (intact or digested Ara h 1). Eluted phages were amplified by 
direct infection of ER2738 E.coli cells (provided with the phage library). Phage amplification was allowed 
overnight at 37 °C. Amplified phages were purified by PEG/NaCl-precipitation and tittered. 
2.5.2  Second selection round 
Fifty µL or 25 µL beads with immobilized IgE were incubated with ~109-1010  amplified phages selected in 
the first round. All further steps were performed as described for the first selection round. 
2.5.3  Third selection round 
Third  selection  round  took  place  as  described  for  the  second,  besides  that  eluted  phages  were  not 
amplified right away. Instead phages were tittered and single colonies were picked, isolated and amplified 
as described by the library manufacturer. 
 
 
2.6  Phage-capture   ELISA   for   determination   of   IgE-reactivity   to   phage-displayed 
peptides 
For selection of positive phage clones microtitre plates (Maxisorp, Nunc, Roskilde, Denmark) were coated 
overnight at 4˚C with 100 µL/well of 8.3 µg/mL rabbit-α-human  IgE (DAKO, Glostrup, Denmark) or 100 
µL/well of 1.0 µg/mL rabbit-α-rat IgE (Zymed, Berlin, Germany) in PBS. All following steps were performed 
at RT for 1 h. Plates were blocked with 200 µL/well of 2% (w/v) SMP in PBS. Between each step plates were 
washed 3 times in PBS with 0.05% (w/v) Tween 20 (PBS-T). One half of the plate was incubated with 100 
µL/well of serum diluted 1:60 (human) or 1:20 (rat) in dilution buffer while the other halve of the plate was 
incubated with 100 µL/well of dilution buffer (background). For plates with rat serum, plates were blocked 
once more, this time with 200 µL/well of naïve rat serum diluted 1:20 in dilution buffer. Sequently, all 
plates were incubated with 100 µL/well supernatants from single colonies of amplified phages or wild type 
phage without an insert coding for a peptide (negative control), followed by incubation with 100 µL/well of 
mouse-α-M13 phage (Amersham Biosciences UK Limited, Buckinghamshire, UK) diluted 1:1000 in dilution 
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buffer. For detection, the plates were incubated with 100 µL/well of alkaline phosphate (AP)-conjugated 
goat-α-mouse Ig (DAKO, Glostrup, Denmark) diluted 1:1000 in dilution buffer. Phage-IgE interactions were 
visualized   with   100   µL/well   of   1   mg/mL   p-NitroPhenyl   Phosphate   (Sigma,   Berlin,   Germany)   in 
diethanolamine  buffer  as  AP-substrate.  Incubation was  conducted  at  37  ˚C for  30  min.  Reaction  was 
stopped by adding 100 µL/well 1.0 M NaOH. Absorption was measured at 405 nm with a microtitre reader 
(Molecular Devices, Sunnyvale, CA, USA). 
The results were corrected for background, where OD values of greater than OD + 3 x S.D. of the negative 
control were regarded as a positive result. 
 
 
2.7  Phage DNA precipitation and sequencing 
Precipitation of DNA from the selected phages was carried out according to manufacturer instruction. DNA 
sequencing of the displayed hepta-mer peptides was performed using M13 phage specific primers. 
 
 
2.8  Mapping of peptides on the Ara h 1 monomer surface using 3D-structure 
Amino acids corresponding to the selected peptides were localized on the 3D structure of the Ara h 1 
monomer (SwissProt no. P43237) amino acid 164-583. (The homology based model of Ara h 1 amino acid 
164-583, was constructed from the X-ray crystal structure of canavalin from jack bean (Ko et al., 2000), 
which have a sequence identity with Ara h 1 of 48%, and optimized to give lowest Gibbs free energy (G). 
The peptides obtained by immunoscreening of the phage-displayed peptide library were localized on the 
Ara  h  1  surface  using  a  computer-based  algorithm  (Epitope  mapping  tool  (EMT),  Novozymes  A/S, 
Bagsvaerd, Denmark) as described by Batori et al. (2006). The potential epitope mimics on the Ara h 1 
molecule  were  subjected  to  structural  analyses  using  Swiss-PdbViewer  (http://www.expasy.org/)  to 
remove those that were unlikely to occur due to severe structural constraints. By mapping the selected 
peptides on the 3D structure of industrial enzymes no localization of epitope mimics were possible. 
 
 
 
3  Results 
 
 
The IgE binding regions of intact and digested Ara h 1 were assessed by competitive immunoscreening of a 
phage-displayed random hepta-mer peptide library using polyclonal IgE from five individual peanut allergic 
patients and five individual BN rats immunized with either intact or digested Ara h 1. The resulting peptide 
mimics were mapped on the surface of a model of the 3D structure of the Ara h 1-monomer using a 
computer-based EMT. The obtained data were analyzed in order to identify quantitative and qualitative 
differences between the epitope profiles of intact and digested Ara h 1, as well as between the profiles for 
humans and rats. 
 
 
3.1  Identification of IgE binding epitope mimics 
3.1.1  Peanut allergic patients 
A total of 123 IgE binding peptide mimics were selected for the five individual peanut allergic patients. The 
number of mimics was rather similar (N = 20-32) for all patients, and (N = 8-17) for both intact and digested 
Ara h 1. Some of the peptide sequences were eluted multiple times for an individual patient, some eluted 
with both intact and digested Ara h 1, and some shared by two or more peanut allergic patients (Table A.1). 
Each patient was found to have an individual pattern of eluted sequences, which was independent of the 
elution condition (i.e. if eluted using either intact or digested Ara h 1). However, five motifs (a sequence 
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pattern of amino acids) were found to account for more than 65% of all eluted sequences; K*PAF*L, 
PRG[I/L/V]F, SPI*LY, DRGLF and PYTL[D/S]K (Table 2). As can be seen from the Table 2, the recognition of 
these five motifs was not equally distributed between the five peanut allergic patients. While the motif 
K*PAF*L and motif PYTL[D/S]K were only eluted for a single patients the motif DRGLF were eluted for four 
patients. While the patients 2208, 2209 and 2305 recognized three of the five motifs, patient 2205 only 
recognized one motif. Also the proportion of eluted sequences corresponding to a motif varied between 
the five patient, where all eluted sequences for patient 2205 corresponded to a single motif, less than half 
of all eluted sequences corresponded to a motif for patient 2305. This demonstrates heterogeneity of the 
Ara h 1-specific IgE antibody response between patients, which yet seems to overlap to a significant degree 
for some of the patients. However, the absence of a motif recognition for a patient does not exclude that 
such motif could not be recognized by the patient but only implies that the IgE antibody-affinity for this 
motif was not high enough to be selected for sequencing. 
Importantly form the Table 2 it is shown that all five motifs were eluted with both the intact and the 
digested Ara h 1, revealing the survival of these epitope motifs after simulated gastro-duodenal digestion. 
3.1.2  BN rats 
A total of 138 IgE binding peptide mimics were selected for the five individual rats. The number of mimics 
was rather similar (N = 23-38) for all rats, as well as was the number (N = 11-22) for intact and digested Ara 
h 1, respectively. (Rat no 52 only had sequences eluted with intact Ara h 1 because of serum shortness) 
(Table. A.2). Some of the peptide sequences were eluted multiple times for an individual rat, some eluted 
with both intact and digested Ara h 1, and some shared by two or more rats. However, each rat was found 
to have an individual pattern of epitope mimics, which was irrespective of the immunization and eluting 
condition (intact vs. digested Ara h 1). 
 
 
3.2  Amino acid distribution of the epitope mimics 
To identify if any qualitative differences in amino acid composition of the found epitope mimics existed 
between intact and digested Ara h 1 and between humans and rats, an analysis of the amino acid 
distribution was performed. No apparent difference in overall physico-chemical characteristics of the amino 
acids involved in the epitope mimics between intact and digested Ara h 1 and between humans and rats 
was observed (data not shown). Hydrophobic amino acid residues occurred most frequently, responsible 
for over 50% of all amino acids in the identified epitope mimics, with polar residues being the next most 
frequent type of amino acids, responsible for around 30%, and charged residues representing the least 
frequent amino acid group containing around 16%. This was applicable for both eluting conditions as well 
as both immunization conditions (intact and digested Ara h 1), and for both human and rat specific epitope 
mimics. This amino acid distribution according to physico-chemical characteristics, is not a picture of the 
general amino acid distribution of the Ara h 1 molecule (SwissProt no. P43237; amino acid 79-614, which is 
the full length of the purified Ara h 1 molecule after cleavage of the N-terminal (Bøgh et al., 2012)), where 
the hydrophobic amino acids account for 40.6%, the polar for 24.6%, and the charged amino acids for 
34.6% of all amino acids. This indicates that the epitope mimics are clustered into the more hydrophobic 
and less charged areas of the Ara h 1 molecule. 
Differences in amino acid distribution, according to single amino acids, between sequences eluted with 
intact and digested Ara h 1 and between humans and rats (Fig. 1A-F), are small, especially when compared 
to the general amino acid distribution for the Ara h 1 molecule (Fig 1G). The most common amino acids in 
the eluted sequences were Leucine (L), Proline (P), and Serine (S) for both humans and rats. In contrast the 
most common amino acids in the entire Ara h 1 molecule are Glutamic acid (E) and Arginine (R). In fact 
Glutamic acid, which are the most common amino acid in the Ara h 1 molecule, occurred only seldom in the 
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eluted sequences. Comparing amino acid distribution according to immunization condition in the rats 
(intact vs. digested Ara h 1) (Fig. 1E-F) small differences are evident. These are most pronounced for the 
amino acid Alanine (A) and Serine (S). 
 
 
3.3  Ara h 1 IgE binding fingerprinting profile 
The Ara h 1 epitope fingerprinting profile, defined as the frequency distribution of amino acid residues 
identified as being involved in IgE binding along the primary protein sequence is shown in Fig. 2. From the 
IgE binding epitope fingerprinting profiles it is evident that some amino acid residues along the primary 
sequence of the Ara h 1 molecule appear more often than others in the suggested mapped epitope mimics. 
This indicates that some regions of the primary structure is more likely than others to be involved in IgE 
binding and that amino acid residues being part of the IgE epitopes cluster into specific areas. Some amino 
acid residues account for nearly 5% of all specific amino acids found in IgE binding sequences and other 
amino acid residues did not occur in any mapped epitope mimics at all. 
When comparing the IgE binding profile for Ara h 1 according to eluting condition (intact vs. digested Ara h 
1), it is seen that the profiles are very similar, for both patients and rats, respectively (Fig. 2A-D). A similar 
pattern is seen for both peaks and gaps, which are lying in the same areas of the Ara h 1 primary structure. 
It was also seen that most amino acids occurring in the epitope mimics are clustered, according to primary 
structure, between amino acid residue 220 and 270. 
When comparing the Ara h 1 IgE binding fingerprinting profile according to immunization condition (intact 
vs. digested Ara h 1) for rats (Fig. 2E-F), it is seen that the profiles are different from each other. This is 
primarily  shown  by  the  larger  gaps  in the  fingerprinting  profile  obtained  for  the  rat  immunized  with 
digested Ara h 1. Any conclusions should however be taken with caution, since the results are based on a 
single rat immunized with digested Ara h 1. 
Comparing the Ara h 1 IgE binding fingerprinting profiles for humans and rats (Fig. 2A-D) it is seen that the 
profiles  are  very  similar,  with  peaks  in  the  same  areas  of  the  primary  structure  of  Ara  h  1,  though 
differences in frequency for single amino acid residues occur. 
 
 
3.4  Mapping of epitope mimics on the surface of Ara h 1 
3.4.1  Peanut allergic patients 
Computer-based mapping of the eluted sequences on the 3D structure of the monomer Ara h 1 (SwissProt 
no.P43237, amino acid 164-583) revealed that all sequences corresponded to conformational epitopes, 
although short stretches of juxtaposed amino acids were found in some mimics. 
Irrespective of whether the sequences were eluted with intact or digested Ara h 1, the mapped epitope 
mimics clustered into three areas when based upon those amino acid residues which occurred in at least 
3% of all mapped IgE epitope mimics. This cut-off corresponds to specific amino acids occurring four or 
more times in all epitope mimics. Most epitope mimics were thus clustered in the yellow area (Fig. 3.). So in 
consistency to identification of the localization along the primary sequence of Ara h 1 (Fig. 2.), it is also here 
identified that the epitope mimics are not distributed equally throughout the entire molecule but seems to 
cluster into some areas. 
Mapping of the eluted heptameric sequences on the surface of Ara h 1 showed that the epitope mimics 
were well exposed on the molecular surface of the 3D model of an Ara h 1 molecule and that no significant 
differences was evident between the elution with intact or digested Ara h 1 (data not shown). 
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3.4.2  BN rats 
As was the case for the peanut allergic patients, only peptide sequences corresponding to conformational 
epitope mimics emerged from the selection. For a few of these sequences more than one good match 
could be found on the surface of the Ara h 1 model. 
Even though, each rat was found to have an individual pattern of epitope mimics, most IgE selected 
peptides were shown by the EMT to be localized into the same three surface areas of the Ara h 1 molecule, 
as were the peptides selected with the patient sera. See Figure 3. However it was observed that no motifs 
was shared by the eluted peptide sequences, which was in contrast to the results found for the peanut 
allergic patients. 
With regard to the accessibility of the epitope mimics on the surface of an Ara h 1 molecule, also for the 
rats no significant differences were seen between the elution with intact and digested Ara h 1, respectively 
(data not shown). 
 
 
 
4   Discussion 
 
 
This study supports the notion that most IgE binding epitopes are conformational and not linear in nature 
(Aalberse, 2000; Barlow et al., 1986; Roggen, 2006; Van Regenmortel, 1996). Although we used a method 
able to detect both linear and conformational epitopes, we only identified sequences (regardless of human 
or rat) mimicking epitopes on Ara h 1 which were composed of amino acid residues put together by the 
tertiary structure of the molecule or by two or more short stretches of juxtaposed amino acid residues. This 
is in contrast to most of the previous studies of Ara h 1-specific IgE binding epitopes showing that these are 
linear in origin. Burks et al. (1997) identified a total of 23 IgE binding epitopes consisting of 6-10 amino 
acids and Shreffler et al. (2004) identified yet another consisting of 25 amino acid, using the methods of 
overlapping peptides, which allows for detection of only linear epitopes, to identify the IgE binding sites. 
Additional studies confirmed the importance of such linear Ara h 1-specific IgE binding epitopes (Beyer et 
al., 2003; Flinterman et al., 2008; Shin et al., 1998). This is in agreement with the suggestion that linear IgE 
epitopes could be of special importance for food allergens known to sensitize through the gastrointestinal 
tract (Bannon and Ogawa, 2006; Lin and Sampson, 2009; Pomes, 2010). 
The present study indicates that there could be five important conformational IgE binding epitopes on Ara 
h 1, since more that 65% of all eluted sequences, based on patient sera, could be categorized as belonging 
to one of only five motifs. The five motifs showed patterns of a minimum of five amino acids, which is also 
the number of amino acids suggested to be involved in binding between antibody and antigen. Even though 
epitopes are suggested to consist of at least 8 amino acids, energy calculations suggest that a smaller 
subset of 5-6 amino acids are the key contributors to the binding between antibody and epitope (Bannon 
and Ogawa, 2006; Laver et al., 1990; Van Regenmortel, 1996). When choosing the use of short heptameric 
peptides for competitive immunoscreening and selecting only the eluted sequences showing the highest 
affinity in ELISA, we are in favor of selecting only those peptides containing the essential amino acids 
contributing to the binding between IgE molecules and epitopes, and deselect those which could simply be 
a result of non-specific binding. Also we are in favor of selecting only those peptides representing epitopes 
with  the  highest  affinity  to  the  specific  IgE  antibodies,  while  deselecting  those  with  lower  affinity. 
Therefore, the absence of an epitope mimic for one of the patients does not necessarily imply that this 
epitope could not be recognized by the patient. However, that 65% of all eluted sequences could be 
adjusted to belong to only five motifs and that these five motifs were identified not only with one patient 
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and with one eluting condition, indicate that these motifs could be very important for the allergenicity of 
Ara h 1. Indeed all five motifs were identified by both intact and digested Ara h 1, and three of them were 
identified by three or four patients. 
Motifs were only identified by humans and not rats. Rats showed a much more heterogeneous pattern and 
only few eluted sequences were shared by two or more rats, and a greater proportion of the complete 
allergen surface seemed to be involved in mimicking IgE binding sites. This indicated that in contrast to 
humans no or only little affinity-maturation had occurred in rats. This, however, seems reasonable since 
the allergic history of rats consisted of only 5 weeks in contrast to patients which had a long and consistent 
history of peanut allergy. Arnon and Van Regenmortel (1992) and Van Regenmortel (2009) states that 
epitopes are not an intrinsic characteristic of an allergen that exists independently of its antibody partner. 
It is estimated that by immunization of an individual with a protein-antigen, more than 100 different 
antibodies will be formed, which differ in their epitope-specificity and may be directed against partly 
overlapping  epitopes,  so  that  the  entire  accessible  surface  of  an  allergen  harbors  many  overlapping 
epitopes (Kawamura et al., 1984; Schroer et al., 1983). Upon reexposure to the same allergen affinity- 
maturation occurs, where progressively higher affinity B cell clones are generated, as a result of somatic 
hypermutation and antigen-specific selection of high affinity B cells (Griffiths et al., 1984; Kocks and 
Rajewsky, 1988; Neuberger et al., 2000; Siskind and Benacerraf, 1969). Another explanation for the many 
eluted sequences seen for the rats, could be a result of ‘true’ cross-reaction. As the relationship between 
an antibody and an epitope is not of an exclusive nature, ‘true’ cross-reactivity may occurs, where an 
antibody reacts with other epitopes (here, eluted sequences) that is different in structure, but related to 
the epitope, which the particular antibody was originally raised against (Arnon and Van Regenmortel, 
1992). This could in particular be relevant in situations where affinity maturation have not been fully 
established. Only a limited degree of resemblance is suggested to be sufficient to allow cross-reactivity 
(Arnon and Van Regenmortel, 1992; Van Regenmortel, 2009). 
Besides the occurrence of motifs the epitope mapping profile of humans and rats were very similar. Both 
the IgE binding fingerprinting profile, amino acid distribution and the localization and clustering of epitopes 
on the Ara h 1 molecule were similar, indicating that humans and BN rats direct their antibody-response 
against the same areas of the allergen. This is one important issue in identifying a suitable animal model 
(Knippels and Penninks, 2005), and has also been shown in an earlier study comparing human and BN rat 
allergic responses (Miller et al., 1999). 
The definition of epitope seems to be a little unclear, so instead of talking about specific epitopes, it would 
make more sense to talk about epitope areas. The same amino acid residues in a protein can be part of 
different overlapping epitopes recognized by different antibodies, which is also evident from this study. 
Therefore, as Van Regenmortel (2009) states, it is not possible to draw clear boundaries between individual 
epitopes and there is no clear definition of an epitope on e.g. the atomic composition of binding interface 
to the antibody or the binding affinity that can be used as an benchmark to decide what is an epitope or if 
two epitope are the same or not. In light of this it seems even more important for the validation of the BN 
rat model that epitopes were clustered into the same areas of Ara h 1. Earlier studies have also indicated 
that Ara h 1-specific IgE epitopes could be clustered into areas of the monomeric Ara h 1 molecule (Maleki 
et al., 2000; Shin et al., 1998). Clustering of IgE epitopes have also been shown for Bos d 4 (Hochwallner et 
al., 2010), Phl p 1 (Flicker et al., 2006), Bet v 1 (Fedorov et al., 1997), and Phl p 5 (Flicker et al., 2000), and 
have been suggested to be a general phenomenon for allergens determining the allergenic activity 
(Hochwallner et al., 2010; Flicker et al., 2006). 
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In the present study we found that the IgE epitope profiles of intact and digested Ara h 1 were very alike, as 
the fingerprinting profile, amino acid distribution, localization and clustering of epitopes on the monomeric 
Ara h 1 molecule came out similar when elution was made with intact or digested Ara h 1, respectively. It 
seems especially important that all five identified motifs were identified when elution was made with both 
intact and digested Ara h 1. This indicates that even though Ara h 1 is digested to very small peptide 
fragments IgE binding epitopes survived the digestion process. This is in agreement with our earlier studies, 
showing that both intact and digested Ara h 1 were able to sensitize BN rats and elicit a biological relevant 
response (Bøgh et al., 2009, Bøgh et al., 2012). Ara h 1 is a labile protein digested to peptides of ≤ 2 kDa, 
which correspond to around 17 amino acids. However, more than 50% of these peptides were aggregated 
to complexes of sizes up to 20 kDa. Aggregation of Ara h 1-digests is suggested to be the reason for the 
retained allergenicity of the digested Ara h 1 (Bøgh et al., 2009). That the peptides are in aggregated form 
under  physiological  conditions  make  the  survival  of  conformational  epitopes  possible.  Further,  it  is 
suggested that the digested Ara h 1 are kept in a conformation resembling the native structure of Ara h 1 
(Bøgh et al., 2012), probably by non-covalently interactions, such as hydrophobic interactions. It has been 
shown that the hydrophobic amino acids of the Ara h 1 molecule are important for the IgE binding (Maleki 
et al., 2000; Shin et al., 1998). This is consistent with our findings showing that the amino acid residues 
composing the epitopes are relatively hydrophobic compared to the general Ara h 1 monomeric molecule. 
That conformational epitopes of a labile food allergen are able to survive digestion has not been shown 
before. Since most B cell epitopes are thought to be conformational and the fact that we find a significant 
cross-reactivity between intact and digested Ara h 1, supports the hypothesis that the peptides in digested 
Ara h 1 are in an aggregated form which represents the original folding of the intact Ara h 1. 
 
The eluted epitope mimics are localized on a 3D model of Ara h 1 (amino acid 164-583), which is made by 
homology modeling of canavalin (Ko et al., 2000), and is therefore shortened in both N- and C-terminal 
ends. This makes it possible that some epitopes are missed. Also sequences obtained with peptide libraries 
are not necessarily real epitopes but only a mimic of epitopes. However, the level of mimicry is significant 
since an assessment of binding activity is the foundation for the selection of epitope mimics in the study. 
Since the epitope-specificity of an antibody is never of completely unique nature, considerable cross- 
reactivity may occur and inherent multispecificity of antibodies may exist (Arnon and Van Regenmortel, 
1992; Van Regenmortel, 2009). The identified epitope matches on the Ara h 1 surface is not a precise 
identification but more an attempt to indicate the most likely location of the epitopes. Identification of IgE- 
binding epitopes is an important issue in allergic diseases, where it can be used for a better understanding 
of the immune response. Epitope profiles can be useful for studying potential cross-reactivity between 
homologous proteins (Pomes, 2010), for design of recombinants for immunotherapy (Karisola et al., 2004), 
for design of peptide vaccines (Hochwallner et al., 2010), in a predictive manner when assessing allergenic 
potential of novel foods and genetically modified foods, and as a predictive biomarker for persistency, 
severity or diagnostic treatment of an allergic disease (Lin and Sampson, 2009; Huang and Honda, 2006). 
Indeed, different IgE epitope patterns have been found to be associated with the allergic phenotype, where 
e.g. epitope specificity correlated with persistency and diversity correlated with severity (Lin and Sampson, 
2009). The present described epitope mapping technique could be a useful tool in allergic diseases for 
studying motif identification and pattern recognition by IgE. 
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Figure legends 
 
Fig. 1. Amino acid distribution in IgE binding sequences. The bars represent the total number of a particular 
type of amino acid residue found in all of the eluted IgE binding peptides. Amino acid distribution is 
represented  as  overall  frequency  of  a  single  amino  acid  residue  for  a  given  condition:  Amino  acid 
distribution based on patient sera for peptide sequences eluted with intact (A) or digested (B) Ara h 1, or 
amino acid distribution based on sera from BN rats for sequences eluted with intact (C) or digested (D) Ara 
h 1, or amino acid distribution based on BN rats immunized with either intact (E) or digested (F) Ara h 1, 
and the general amino acid distribution for the expressed Ara h 1 molecule (G). The amino acids are 
grouped according to their physico-chemical feature. 
 
 
Fig. 2. Ara h 1 IgE binding epitope fingerprinting profiles. Epitope frequency is represented as sums of each 
amino  acid  residue  along  the  primary  protein  sequence  (amino  acid  164-583)  found  in  all  suggested 
mapped epitope mimics in a given condition: For peanut allergic patients, where sequences were eluted 
with intact (A) or digested (B) Ara h 1, for rats where sequences were eluted with intact (C) or digested (D) 
Ara h 1, and for rats immunized with intact (E) or digested (F) Ara h 1. 
 
 
Fig. 3. Ribbon diagram of the 3D structure of the Ara h 1 monomer. Localization of the IgE binding areas 
characterized by the polyclonal IgE response of the five peanut allergic patients. When cut off level for 
frequency of single amino acid residues in the suggested epitope mimics was set to four, it was seen that 
the epitope mimics were clustered into three epitope areas on the surface of the Ara h 1 molecule, 
indicated by the yellow, red, and blue regions. By far the majority of the epitope mimics were clustered into 
the area indicated by yellow colour. The figures are views of the Ara h 1 molecule by means of 180° 
rotation about a vertical axis. 
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Tables 
 
Table 1. 
Patients’ characteristics. 
ID Anti-whole 
peanut IgE 
(IUA/L) 
Anti-Ara h1 
IgE (IAU/L) 
Total IgE 
(kU/L) 
Clinical symptoms 
after peanut 
consumption 
Age Gender 
2205 45 29 535 A, OE, BO, GI 25 M 
2208 18 10 26.9 A, OE, GI 23 M 
2209 250 91 >2000 A, RBP, BO 27 F 
2304 327 262 1013 A, BO, GI 25 M 
2305 155 129 >2000 A, RBP, OE, U, GI 18 F 
A: anaphylaxis, BO: bronchial obstruction, GI: gastro-intestinal symptoms, OE: oral oedema, RBP: reduced blood 
pressure, U: urticaria, M: male, F: female 
 
Table 2. 
The five motifs found in the epitope mimics for the five peanut allergic patients. 
Motifs 
Localization of the Ara h 
1 monomer molecule 
Proportion of sequences eluted with either intact (I) or 
digested (D) Ara h 1, belonging to the given motif for each 
individual patients 
  
2205 2208 2209 2304 2305 
K*PAF*L(a) 
K431XP512A514F577XL399 
K248XP221A242F264XL421 
17/17 (I) 
15/15 (D) 
0/8 (I) 
0/12 (D) 
0/9 (I) 
0/11 (D) 
0/10 (I) 
0/13 (D) 
0/14 (I) 
0/14/ (D) 
PRG[I/L/V]F P168P172R175G502L499F505 
0/17 (I) 
0/15 (D) 
1/8 (I) 
2/12(D) 
2/9 (I) 
0/11 (D) 
0/10 (I) 
0/13 (D) 
1/14 (I) 
0/14 (D) 
SPI*LY S262P261I260XL269Y267 
0/17 (I) 
0/15 (D) 
2/8 (I) 
6/12 (D) 
2/9 (I) 
5/11 (D) 
0/10 (I) 
0/13 (D) 
5/14 (I) 
3/14 (D) 
DRGLF D394R393G255L524F526 
0/17 (I) 
0/15 (D) 
0/8 (I) 
2/12 (D) 
1/9 (I) 
1/11 (D) 
2/10 (I) 
2/13 (D) 
0/14 (I) 
1/14 (D) 
PYTL[D/S]K P221Y267T238L524XK379 
0/17 (I) 
0/15 (D) 
0/8 (I) 
0/12 (D) 
0/9 (I) 
0/11 (D) 
5/10 (I) 
6/13 (D) 
0/14 (I) 
0/14 (D) 
Total  
17/17 (I) 
15/15 (D) 
3/8 (I) 
10/12 (D) 
5/9 (I) 
6/11 (D) 
7/10 (I) 
8/13 (D) 
6/14 (I) 
 4/14 (D) 
 
(a) Amino acids are indicated with their one-letter code. * and X represents any given amino acid and indicate that no single amino acid was found to match on the basis 
of the eluted peptide sequence (*) and no specific amino acid residue was therefore to be assigned.  
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Fig. 1. 
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Table A.1: IgE-binding epitope mimics, based on sera from five peanut allergic patients  
Eluted with intact Ara h 1 Eluted with digested Ara h 1 
Amino acid sequence 
of the peptide eluted 
Best fitting heptameric epitope 
sequence 
Amino acid sequence of 
the peptide eluted 
Best fitting heptameric epitope 
sequence 
Patient no. 2205 
KAPAFDL (4) K431XP512A514F577XL399 
K248XP221A242F264D227L421 
KAPAFDL (3) K431XP512A514F577XL399 
K248XP221A242F264D227L421 
KAPAFNL K431XP512A514F577N401L399 
K248XP221A242F264XL421 
KAPAFNL K431XP512A514F577N401L399 
K248XP221A242F264XL421 
KLIAFDL (4) K431XP512A514F577XL399 
K248XP221A242F264D227L421 
KEPAFML K431XP512A514F577XL399 
K248XP221A242F264XL421 
KLPAFML (2) K431XP512A514F577XL399 
K248XP221A242F264XL421 
KLPAFML (2) K431XP512A514F577XL399 
K248XP221A242F264XL421 
KQPAFNL (5) K431XP512A514F577N401L399 
K248XP221A242F264XL421 
KLPAFQL K431XP512A514F577XL399 
K248XP221A242F264XL421 
KSPAFNL K431XP512A514F577N401L399 
K248XP221A242F264XL421 
KQPAFNL (2) K431XP512A514F577N401L399 
K248XP221A242F264XL421 
    
KSPAFDL (3) K431XP512A514F577XL399 
K248XP221A242F264D227L421 
  
KTAAFNL (2) K431XP512A514F577N401L399 
K248XP221A242F264XL421 
Patient no. 2208 
ASPKSLL A335S300P297K222S266L220L218 AKPASWA A224K222P221A298S304XA335 
FHTARPW F295H223S266A242R247P389X DSPRGVF D194S168P172R175G502V449F505 
FSPIVLY XS262P261I260V239L269Y267 MSDRGIF (2) XXD394R393G255L524F526 
SPIMDYF S262P261I260M284D225Y267F296 SPIINYY S262P261I260I265XY267X 
SPPRGIF S164P168P172R175G502L499F505 SPIISHY (2) S262P261I260I265S266H223Y267 
TSRADTL S519S518A514E458T496L449 SPILAHY (2) S262P261I260L258A257H256Y267 
TTSVRNT T217T238S249V241R247N246S266 SPITLYY S262P261I260T240L269Y267X 
VTLAPLR V400T496L457A514P438L435R581 VPPRGLF S164P168P172R175G502L499F505 
 V239T238L269A213P215L277R278 YDVSSLP Y180D302XS304S305L307P297 
Patient no. 2209 
ATETSYR A242T240E382T238S249N246R247 DLTWAPK D253L252T240XA242P221K222 
HAPRGVF XP168P172R175G502V449F505   D394L425T425XA509P508K443 
LPPRGLF XP168P172R175G502L499F505 FSPIIAF XS262P261I260I265A257F296 
MSDRGIF XXD394R393G255L524F526 GLAGYPP G525L425A257G255L392P389P416 
SIPYPAP S173I447P508Y170P168F193P289 LSPIIVY XS262P261I260I265V239Y267 
SNATWVP S518N456A497T496XV460P512 MSDRGIF XXD394R393G255L524F526 
SPIINYY S262P261I260I265XY267X NLVLFSY N216L218V381L168F296S266Y267 
STIMSSR S266T240F268S381S249R247 QWAFAIP (2) Q303A176F264A224I260P261 
WSPIVHP XS262P261I260V239H223X  Q339XA224F295A242I265P297 
  SPILAHY S262P261I260L258A257H256Y267 
  SPIVLYF S262P261I260V239L269Y267F296 
  SPIVNNY S262P261I260V239XXY267 
 
106  
Table A.1: IgE-binding epitope mimics, based on sera from five peanut allergic patients. Continued… 
 
 
 
 
  
Eluted with intact Ara h 1 Eluted with digested Ara h 1 
Amino acid sequence 
of the peptide eluted 
Best fitting heptameric epitope 
sequence 
Amino acid sequence of 
the peptide eluted 
Best fitting heptameric epitope 
sequence 
Patient no. 2304 
AKQTDTM A280K281Q210T178D302S304S305 ADMRGLF XD394XR393G255L524F526 
DISRGLF D394XXR393G255L524F526 AKGTDNW A539K570G540S575D543N544X 
EWSRGIF E408XXR393G255L524F526 AKQTDTM (2) A280K281Q210T178D302S304S305 
IPYTLDK (3) I268P221Y267T238L524S381K379 GSAFSAF G309S304A517F264S266A224F292 
LHRPLHP L269H272R345P215L218XP221  G433S299A298F295S579A580F264 
 L523H522R405P397L399XP438 GVYSLSK XXY267T238L524S381K379 
TPYTLDK (2) T240P221Y267T238L524XK379 IPYTLDK I268P221Y267T238L524S381K379 
VTGPAKT V219T217G343P215A213R186T178 LPYTLSK (3) L220P221Y268T238L524S381K379 
  SFPARFY S300F295P221A242R247F250Y267 
  TPYTLDK T240P221Y267T238L524XK379 
  WPDRGIF XXD394R393G255L524F526 
Patient no. 2305 
FSPIVLY (2) XS262P261I260V239L269Y267 ACCRSIP A257G255C427R405S400I430P397  
KSIYHQW K248S249I268Y267H223N287X AVESNDK A580V578E574S575N481D541K570 
LPSRGLF XP168P172R175G502L499F505 FPPKPKL F440P512P508K443E531K410L425 
LTDLTQK L269T238D253L277T217Q344R345 KNVYHQT (2) K248N246V241Y267H223N287T288 
QSLTRLP Q191S273L499T496R494L457P438 LINQALK L568I569N571Q572A539L538K542 
SPILAHY S262P261I260L258A257H223Y267 MSDRGIF XXD394R393G255L524F526 
SPITEFY (2) S262P261I260T240E382F250Y267    SPIISHY  S262P261I260I265S266H223Y267 
TFKLHPI T238F250K248V241H223P221I229 SPITLYY S262P261I260T240L269Y267X 
TPPRVHL T387P389P416R393V366H367L369 SPITTYY S262P261I260T240T238Y267X 
VLPGSKS V231L258P261G263S266K248S381  TPFSNSP T240P221F264S262N287S283P289 
WESRGVF W476E475S488R472G470V462F169 VMPGSKP (3) V286M284P261G263S266K248P389 
YPPKPLH Y306P297P221K222XL269Y267   
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Table A.2: IgE-binding epitope mimics, based on sera from five Brown Norway rats. 
Eluted with intact Ara h 1 Eluted with digested Ara h 1 
Amino acid sequence 
of the peptide eluted 
Best fitting heptameric epitope 
sequence 
Amino acid sequence of 
the peptide eluted 
Best fitting heptameric epitope 
sequence 
Animal nr. 19; Rat immunised with digested Ara h 1 
AQSQFNS (5) A298Q303S304Q308F310N313S311 APHRHPH A539P438H439R535H534P522H511 
AYTLPSR  A461Y495T496L457P172S173R174 APKAAPL A509P508K443A510A461P512L538 
HFSKVPR H223F264S264K248V241P261R259 AQLAPET A280Q234L277A213P215E341T217 
SNAARAY S442N441A510A461R494A497Y495 AQSQFNS (2) A298Q303S304Q308F310N313S311 
YHPFLQV Y267H223P297F296L220Q338V219 GGQFGPP G562G560Q564F558A557P559L556 
YSTQVRP (2) Y267S266T240N243V241R247A242 IHLPPAL I536H439L538P438P512A514L435 
  
  
  
  
  
  
  
  
  
  
NQTRTTH N216Q344T217R271T238T240X 
N334Q339 T217R271T238T240X 
QPMINML Q199P508M445I528N529M524L525 
QPPTANA Q199P508P512S442A509N441A510 
TPMAWSQ T288P289M284P261F264S266X 
VHNTRLL V449H522N451T454R498L499X 
V231H256N251T238R271L269X 
Animal nr. 49; Rat immunised with intact Ara h 1 
AYPLRAH A298Y306P297L307R327A321N320 GPPPLPK G540P438P512P508I508A505K443 
GLTPSKN G255L252T240P221S266K248N388 HHMHTTR H511H439M436N516S519T454R498 
GPPPLPK G540P438P512P508I505A509K443 IAMKPLA I528A530M445K443P508F390A514 
HHLHQTN H511H439L538K542Q572S575N401 LPSLPRI L258P221S266I265P261R259I229 
LPLPVVR L435P438L538P512V460V462R493 LQSKTLH L568Q572S575K542N544I536H534 
NLANKMA N451L524A280N228K281M284P261 NTSNPYT N451T454S519N516P582A580S579 
SLYKPHP S381L269Y267K222P221H223P261 QATFSHS Q339A213T217I268S266H223S262 
SSYSQLN S304S305Y306S300Q308L315N313 STFLPHP S249T238F250L258P261H223P221 
YGTHKSP Y280G285T217H272R271T238T240 TASGLYS (4) T314A317S311G309L307Y306S305 
YSIPKSS Y267S266I260P389K248S249S291 VPPQLSR V219P221P297Q308L331S304R301 
VTAPFRV V460T496A497P172P168R165X VTAPFRV V460T496A497P172P167R165X 
    VYPMAMS V492Y495P172M507A510M445S442 
    YHGSVSL Y306H223G263S266V241S249L252 
Animal nr. 52; Rat immunised with intact Ara h 1 
AMPPLPP A510M507P172R498I515P438P512     
HPWAPMQ H223P297F295A266P172M284Q291     
KPPNLPN K414P416P389N391L258P261N228     
KWLPTPL K542F537L538P512S442P508I506     
SASWQES S299A298S305F296Q303E333X     
SLTSWAT S381L269T240S266F264A242S249T238     
STFLPHP (7) S249T238F250L258P261H223P221     
TQMSKHL T288Q291M284S262A224H223I265     
VIAKTRL V219I265A242K248T240R259L258     
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Table A.2: IgE-binding epitope mimics, based on sera from five Brown Norway rats. Continued… 
Eluted with intact Ara h 1 Eluted with digested Ara h 1 
Amino acid sequence 
of the peptide eluted 
Best fitting heptameric epitope 
sequence 
Amino acid sequence of 
the peptide eluted 
Best fitting heptameric epitope 
sequence 
Animal nr. 53; Rat immunised with intact Ara h 1 
ALGASHG A514L435G433A517S519H522G453 AKTSSNV A242K248S249T240S381N251L252 
AQSQFNS (4) A298Q303S304Q308F310N313S311 APLPKLM A213P215L218P221K222L230S266 
FHDTPQS F295H223D225T288P289Q291M284 AQSQFNS (3) A298Q303S304Q308F310N313S311 
HISLGRI H522I530S518L499G502R175V504 DQWHRAP D194Q199P512H511R463A461P508 
LGTYGHY L315G309S304Y306F295H223Y267 FGFPTTS F264G263F295P221T240T238S381 
NPASSHM Q583P582A580S518S519H522I430 FPTPRVA F296P297S299P221R247V241A252 
NYLSLLH N167Y170I506S173L499L457N456 HQPQQLF H272Q275P215Q234Q236L252F250 
QIPSGTP Q417I390P389T387K248T240P221 ISVNIQA I187S177V189Q191I208Q210A280 
QLSAPPP Q308L331S304A298P297P221A242 IVQHTVP I187V189Q191H206S283V286P289 
SASLMLQ S518A217S577L435M436L457N456 KPWLPQH K222P221Y267L218P215Q275H272 
TMSKDST T426M423M284K281D227S262X NAHHTYP N456A514H439H511T496Y495P172 
YPPMTQV Y170P168P172M507P508Q199F200 NHTTLKA N451H522T454S518L435K431A580 
YTQGWNL Y180T178Q210G502V449N451L524 NPLPSQL N388P389L258P261S262N228L421 
    QPVPPRL Q339P261V241P297P221K222L230 
    SDRFPPK S575D543R535F440P512P508K443 
    SDYHRVM S304D302Y180R179R188V209S177 
    SLDTCLR S400L399D498T426C427L425R393 
    SPSPQRS S305P297S266P221Q308R301S311 
    TGGVWSK T454G453G502V504F505S173R174 
    YNPAVIA Y170N167P172A497V504I208A280 
Animal nr. 54; Rat immunised with intact Ara h 1 
AETVESC A213E341T217V219E338S300S305 FTDTSWM F407T426D398S400S575F577M436 
DAFTRGT D225A224F296S304R301G336S300 HGWPVPK H223G263F264P261V241P389K248 
GMTMATP (2) G525M424T426M423M284S262P261 H223G263F264P261V241P416K414 
GPPPLPK G540P438P512P508I505A509K443 ITLQRTF I268T217L218Q339R186T178F176 
GVGVPQR (2) G502V449G525V446P508Q199R196 I268T217L277Q236R271T238F250 
IPSLPMR I173P221S266L307P297S304R301 LHGRYFP L459H256G255R393F407T400P397 
LPVPIGY L220P221V241P261I265G263Y306 LTSPLRL L252T240S266P221L218R271L277 
MHTQDLM M507H511S442N532D412L418M423 QGSQYTQ Q339G336S300Q303Y306S305Q308 
MLNATSK M436L435N516A517T454S519K452 TGSSNLY T454G453S519S518N516L457Y495 
QDWNFKK Q195D194F193N205F200K198K464 T238G380S381S249N251L269Y267 
SGEIHFK S519G433E432I430H522L523K452 TLLTTSP T217L218L269T238T240S266P221 
STFLPHP S249T238F250L258P261H223P221 TMTTPQQ T217L218T238T240P221Q339Q183 
VIAKTRL (2) V219I265A242K248T240R259L258 TTAPGKP T240S266A224P261G263K222P221 
VPFKPIR (2) V241P261F264K222P221I268R271 TTHYLHA T240S266H223Y306L307R312A317 
VTAPFRV (3) V460T496A497P172P167R165X WPELYPV F296P297E338L218Y267P221V241 
YPTRELS Y267P221T240R247E382L252S381 F440P438E458L457Y495P172V504 
    YSYPGLT Y267S266Y307P306A298L330T314 
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Abstract 
Background: It is generally believed that protein hydrolysis in the gastrointestinal tract decreases the 
allergenicity of food allergens. It remains however unsolved, if specific properties of digestion products 
determine whether a sensitisation or tolerogenic immune response will develop. We sought to examine the 
sensitising capacity of the cow’s milk allergen β-lactoglobulin (BLG) and digestion products hereof in a 
Brown Norway (BN) rat model of food allergy. 
Methods: Intact BLG was digested in an in vitro model simulating the gastro-duodenal digestion process 
and subsequently fractionated by gel permeation chromatography. BN rats were dosed with either PBS, 
200 µg of intact BLG, 30 µg of intact BLG, 200 µg of partially digested BLG, 200 µg of digested BLG, or with 
200 µg of a fraction of large complexes or a fraction of small complexes. Sera from BN rats were analysed 
for specific antibodies and avidity was measured. 
Results: BLG partly resisted the digestion process. However, the BLG molecules that did not survive the 
digestion process were rapidly broken down to peptides of sizes less than Mr 4,500. Specific antibody 
responses revealed that both 200 and 30 µg of intact BLG had immunogenic as well as sensitising capacity, 
while digested BLG could not induce any specific antibodies. Most importantly, while intact BLG showed a 
significant sensitising capacity when administered alone, this sensitising capacity was significantly reduced 
when co-administered with digested BLG. 
Conclusions: Co-immunisation with intact and digested BLG reduces the sensitising capacity of intact BLG, 
probably by tolerogenic mechanisms introduced by digestion products. 
 
 
Introduction 
 
Cow’s milk allergy (CMA) is a general health problem, mostly affecting young children. The prevalence of 
IgE-mediated CMA is estimated to be around 2.5% for infants [1], whereupon 80-85% of these children 
outgrow their allergy [2], resulting in less than 1% of adults suffering from CMA [3]. Cow’s milk contains 
several proteins able to induce allergic responses. The major cow’s milk allergen BLG, also designated Bos d 
5, is the most abundant protein in the milk whey fraction. It belongs to the lipocalin allergen family and 
contains two disulphide bonds and one free cysteine group [3, 4]. BLG consists of 162 amino acid residues, 
corresponding to a Mr of 18,300. Two isoforms of BLG exist and in physiological surroundings, these appear 
in dimer forms, which stabilises the structure of this globular protein [3, 4]. Numerous studies have been 
performed with the aim to identify BLG-specific epitopes. They indicate that many conformational as well 
as many linear epitopes exist, covering most of the molecule [5-7]. 
It is generally believed that dietary proteins must survive the gastrointestinal digestion process, as intact 
proteins or as large peptide fragments, to be absorbed and recognised by the intestinal mucosal immune 
system [8, 9]. This believe may partly be based on a study by Astwood et al. [9] showing that food allergens 
were more resistant to simulated gastric fluid compared to proteins of no proven allergenicity. Later 
studies have though shown that resistance to digestion is not an absolute characteristic of food allergens 
[10-12]. BLG is found to be a very stable protein, resisting both simulated gastric as well as gastro-duodenal 
digestion processes. The resistance of BLG to digestion coupled with its absence from human breast milk 
has been proposed to contribute to the major allergenicity of BLG [3, 4]. 
It is generally accepted that degradation of BLG reduces its allergenicity, but a few studies have shown 
digestion products of BLG to inhere similar IgE reactivity as the intact protein [13] or even greater IgE 
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reactivity than the intact BLG [14]. Such results indicate that the native BLG structure is not a necessity for 
the allergenicity of BLG and that linear IgE epitopes could be of importance for the reactivity of BLG, and 
further could suggest that humans may be sensitised to the denatured and digested BLG in addition to the 
intact protein. 
Hypoallergenic milk formulas based on hydrolysis products of whey or caseins are available for infants with 
CMA, and are divided into extensively hydrolysed formulas (eHF) and partially hydrolysed formulas (pHF), 
according to the degree of protein hydrolysis and the molecular weight of the present peptides. The 
purpose of eHF is to degrade proteins to such a degree that all potential allergenicity is lost, however, the 
likely concomitant loss of immunogenicity prevent the immune system from developing tolerance to the 
milk proteins. In contrast, pHF is designed to minimise the sensitising capacity, though at the same time 
containing peptides, with a size big enough to be recognised by the intestinal immune system for induction 
of oral tolerance [15]. While eHFs in general have been estimated to cause allergic reactions in 
approximately 5% of CMA infants, pHF is estimated to cause allergic reactions in between 33% and 50% of 
CMA infants [16]. While eHFs are considered efficient in treatment of infants already sensitised to cow’s 
milk protein, pHFs are on the other hand suggested to be useful for the prevention of cow’s milk 
sensitisation [15, 16]. These considerations are in agreement with animal studies, indicating that pHF is able 
to induce oral tolerance, whereas eHF is not [17-19]. For example, van Esch et al. [19] showed in a mouse 
model that whey based pHF given by gavage could induce tolerance to whey in contrast to eHF also based 
on whey, and Fritsche et al. [18] showed in a rat model that oral administration of whey based pHF was 
able to induce specific oral tolerance to BLG, whereas an eHF equally based on whey was not. Likewise, in 
the same rat model, moderately hydrolysed soy proteins could induce oral tolerance to intact soy proteins, 
whereas strongly hydrolysed soy proteins were not able to achieve this [17]. Nevertheless, Crittenden and 
Bennett [15] emphasise that no clinical studies completely confirms the animal studies and Bahna [16] 
state that both pHF and eHF can be useful for prevention of CMA.  
Fortunately in most people the intestinal immune system recognises the milk proteins as harmless and 
develops oral tolerance. This immunological active mechanism of unresponsiveness is believed to be 
achieved through deletion or anergy of the allergen-specific T cells or by the generation of regulatory T cells 
[20]. The mechanisms of oral tolerance induction versus sensitisation to dietary proteins remain generally 
unknown, but CMA is believed to form as a result of either failure or breakdown of tolerogenic processes 
[3].  
In the current study we sought to examine the sensitising capacity of intact BLG as well as different well-
characterised digestion products hereof in a BN rat model. 
 
 
Material and Methods 
 
Simulated gastro-duodenal digestion of BLG 
A pilot batch of purified BLG was kindly delivered by Arla Food Ingredients (Videbæk, Denmark). The 
endotoxin content was tested by Lonza endotoxin testing service (Lonza, Verviers, Belgium) to be < 0.01 EU 
per mg of BLG.  
Digestion was performed essentially as described by Bøgh et al. [11], with immobilised enzymes, in order to 
produce enzyme-free digests suitable for animal sensitisation studies. Addition of surfactant 
(phosphatidylcholine and bile salts) were omitted in order to avoid adverse effects on the sensitisation.  
Briefly, for simulated gastric digestion, pepsin immobilised to agarose (P0609, Sigma, Saint Louis, MO, USA) 
was washed twice in 1 mM HCl (1000 x g, 2 min). Purified BLG (20 mg/mL in Milli Q water (Water drawn 
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from a Milli Q System equipped with an Organex cartridge from Millipore (Bedford, MA, USA)) was adjusted 
to pH 2.5 with 6 M HCl and was added to the immobilised pepsin to yield a pepsin activity of approximately 
180 U per mg of BLG. The solution was placed in a shaking incubator (200 rpm, 37 °C) for 120 min. Reaction 
was stopped by adjusting pH to 7 with 6 M NaOH, and immobilised pepsin was removed by centrifugation 
(1000 x g, room temperature (RT), 2 min) followed by filtrating supernatant through a 22 µm filter (Sterile 
Syringe Filter, CA 0.2 µm, Frisenette Aps, Knebel, Denmark). 
For simulated duodenal digestion, CaCl2 and Bis-Tris propane was added to the solution of gastric digest of 
BLG, to yield a final concentration of 9.2 mM CaCl2 and 24.7 mM of Bis-Tris propane. pH was adjusted to 6.5 
with 6 M HCl. Trypsin immobilised to agarose (T1763, Sigma) and chymotrypsin immobilised to agarose 
(C9134, Sigma) were washed twice in Milli Q water and once in 9.2 mM CaCl2, 24.7 mM Bis-Tris propane 
and added to ¼ of the gastric digest of BLG to yield an activity corresponding to 34.5 U of soluble trypsin 
per mg of BLG digest and 0.44 U of soluble chymotrypsin per mg of gastric BLG digest (clarified in activity 
assays using BAPA as trypsin substrate and SUNA as chymotrypsin substrate). The solution was placed in a 
shaking incubator (200 rpm, 37 °C) for 15 min. Reaction was stopped by centrifugation (1000 x g, RT, 2 min) 
followed by filtrating supernatant through a 0.22 µm filter (Syringe Filter). To make all gastric digest 
undergo simulated duodenal digestion, the duodenal digestion phase was repeated three times and BLG 
digest from the four runs were pooled. (Reusability of enzymes was confirmed by comparing the digestion 
product profiles for the four runs by reverse phase high-performance liquid chromatography (RP-HPLC), 
data not shown). 
 
Fractionation of BLG digests 
Fractionation by preparative gel permeation chromatography (GPC) of gastro-duodenal digests of BLG was 
performed essentially as described in Bøgh et al. [21]. Separated fractions were collected and pooled 
according to the preparative GPC profile shown in Fig. 1, resulting in four different pools of BLG-digests, in 
the following designated: partially digested BLG, digested BLG, large complexes and small complexes, 
where partially digested BLG corresponds to the whole pool of BLG digests, containing intact BLG that 
resisted the digestion process, and where digested BLG corresponds to the combined large and small 
complexes and thereby the whole pool of digested BLG without any intact BLG.  
 
RP-HPLC analysis 
For analysis of purity and presence of residual intact BLG and for evaluation of chromatography profiles, 
RP-HPLC was performed as previously described [21]. 
 
Matrix assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry (MS) 
For analysis of peptide mass distributions in pools of BLG digests MADLI-TOF MS was performed as 
previously described [21]. 
 
Amino acid analysis 
For determination of concentrations and for examination of amino acid compositions amino acid analysis 
was performed by ion-exchange chromatography after hydrolysis in HCl overnight, as described by Barkholt 
and Jensen [22]. 
 
GPC analysis 
For analysis of the peptide aggregation profiles in the different pools of BLG digests analytical GPC was 
performed as previously described [21]. 
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Animals 
BN rats were from our in-house breeding colony at the National Food Institute (Technical University of 
Denmark, Denmark), weaned at three weeks of age and then housed in macrolon cages (two per cage) with 
light:dark cycle, at 22 ± 1 °C and 55 ± 5% relative humidity. Rats were observed twice daily and clinical signs 
recorded. 
Rats were kept on a diet free of milk for at least three generations to avoid tolerance against BLG, which 
like in human breast milk is not a constituent of rat’s milk. The rat diet was produced in-house and based 
on rice flour, potato protein and fish meal as protein sources, as previously described [11], with the 
exception of maize flakes being substituted with rice flour. Diet and acidified water was given ad libitum. 
 
Experimental design 
For studying the sensitising capacity of intact BLG, partially digested BLG, digested BLG and the two 
fractions hereof, BN rats, 4-9 weeks of age, were allocated into seven groups. Each group consisted of 12 
rats, besides the group immunised with 200 µg of intact BLG, which consisted of 20 rats. Rats were 
immunised i.p. with either PBS (control), 200 µg of intact BLG, 30 µg of intact BLG, 200 µg of partially 
digested BLG (which contained 30 µg of intact BLG), 200 µg of digested BLG (without any intact BLG), 200 
µg of large complexes or 200 µg of small complexes. Rats were immunised without any use of adjuvant, 
three times, at day 0, 14 and 28 and sacrificed at day 35 by exsanguination using carbon dioxide inhalation 
as anesthesia. Blood was collected and converted to sera, which was stored at -20 °C until use for analyses. 
I.p. sensitisation procedure was chosen for avoidance of in vivo digestion of antigens as well as for the small 
amount of antigens needed for immunisation.  
Positive control sera were produced by i.p. immunisation of BN rats three times, at day 0, 14 and 28 with 
200 µg of intact BLG in 2% Alhydrogel in PBS as adjuvant. Rats were sacrificed at day 35 and blood 
collected.  
Animal experiments were carried out at the National Food Institute (Technical University of Denmark) 
facilities under conditions approved by the Danish Animal Experiments Inspectorate and the in-house 
Animal Welfare Committee. 
 
Enzyme-linked immunosorbent assay (ELISA) for detection of specific IgG1 and IgG2a 
For detection of IgG1 and IgG2a antibodies specific for intact BLG, partially digested BLG, digested BLG as 
well as the two fractions of digested BLG, ELISA was performed. Plates (96 well, microtitre, Maxisorp, Nunc, 
Roskilde, Denmark) were coated with 100 µL/well of 10 µg/mL antigen solution in carbonate buffer (15 mM 
Na2CO3, 35 mM NaHCO3, pH 9.6) and incubated overnight at 4 °C. Between each step, plates were washed 
five times in PBS with 0.01% (w:v) Tween 20 (PBS-T). Two-fold serial dilutions of serum (starting at 1:8, v:v) 
in PBS-T, 50 µL/well, were added and incubated for 1 h at RT. For detection, 50 µL/well of either HRP-
labelled mouse-α-rat IgG1 (3060-05, Southern Biotech, Birmingham, AL, USA) diluted 1:20,000 (v:v) in PBS-T 
or HRP-labelled mouse-α-rat IgG2a (03-9620, Invitrogen, Camarillo, CA, USA) diluted 1:2,000 (v:v) in PBS-T 
was added to each well and incubated for 1 h at RT. Reaction was visualised by adding 100 µL/well of 
3,3’,5,5-tetramethylbenzidine (TMB)-one substrate (Kem-En-Tec, Taastrup, Denmark) for approximately 12 
min and stopped with 100 µL/well of 0.2 M H2SO4. Absorbance was measured at 450 nm with a reference 
wavelength of 630 nm, using a microtitre reader (Gen5, BioTek Instruments, Winooski, VT, USA). Antibody 
titres were expressed as the Log2 titre values and defined as the interpolated dilution of the given serum 
sample leading to the mean absorbance for the negative control serum + 3 SD, correlating to absorbance 
values of less than OD 0.1 for both IgG1 and IgG2a. 
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Antibody-capture ELISA for detection of specific IgE 
For detection of BLG-specific IgE antibody-capture ELISA was performed, where plates (96 well, Maxisorp, 
Nunc) were coated with 100 µL/well of 0.5 µg/mL mouse-α-rat IgE (HDMAB-123 HybriDomus, Cytotech, 
Hellebæk, Denmark) in carbonate buffer and incubated overnight at 4 °C. Between each step, plates were 
washed five times in PBS-T. Plates were blocked for 1 h at 37 °C in 200 µL/well of 3% (w:v) rabbit sera. Two-
fold serial dilution of serum (starting at 1:8, v:v) in PBS-T, 50 µL/well, were added and incubated for 1 h at 
RT. Subsequently, plates were incubated with 50 µL/well of 0.2 µg/mL of digoxigenin-coupled BLG (10:1) in 
3% rabbit sera in PBS-T for 1 h at RT. Plates were then incubated with 100 µL/well of HRP-labelled sheep-α-
digoxigenin (Anti-Digoxigenin-POD 1 633 716 001, Roche Diagnostics GmbH, Mannheim, Germany) diluted 
1:1,000 (v:v) in PBS-T for 1 h at RT. Reaction was visualised by adding 100 µL/well of TMB-one substrate 
(Kem-En-Tec) for approximately 12 min and stopped with 100 µL/well of 0.2 M H2SO4. Absorbance was 
measured at 450 nm with a reference wavelength of 630 nm, using a microtitre reader (Gen5, BioTek 
Instruments). IgE antibody titres were expressed as the Log2 titre values and defined as the interpolated 
dilution of the given serum sample leading to the mean absorbance for the negative control serum + 3 SD. 
 
ELISA for detection of specific IgA 
For detection of BLG-specific IgA plates (96 well, Maxisorp, Nunc) were coated with 100 µL/well of 10 
µg/mL intact BLG in carbonate buffer and incubated overnight at 4 °C. Between each step, plates were 
washed five times in PBS-T. Two-fold serial dilution of serum (starting at 1:8, v:v) in PBS-T, 50 µL/well, were 
added and incubated for 1 h at RT. For detection, 50 µL/well of HRP-labelled goat-α-rat IgA (STAR 111P, 
AbD Serotec, Oxford, United Kingdom) diluted 1:5,000 (v:v) in PBS-T was added to each well and incubated 
for 1 h at RT. Reaction was visualised by adding 100 µL/well of TMB-one substrate (Kem-En-Tec) for 
approximately 12 min and stopped with 100 µL/well of 0.2 M H2SO4. Absorbance was measured at 450 nm 
with a reference wavelength of 630 nm, using a microtitre reader (Gen5, BioTek Instruments). Antibody 
titres were expressed as the Log2 titre values and defined as the interpolated dilution of the given serum 
sample leading to the mean absorbance for the negative control serum + 3 SD. 
 
Avidity measurements 
For measurement of the strength of binding between antigens and IgG1 antibodies a thiocyanate inhibition 
ELISA based on the method described by El-Khouly et al. [23] was conducted. Plates (96 well, Maxisorp, 
Nunc) were coated with 100 µL/well of 10 µg/mL antigen solution in carbonate buffer and incubated 
overnight at 4 °C. Between each step, plates were washed five times in PBS-T. Serum samples were diluted 
in PBS-T to give an OD between 0.5 and 1 and 50 µL/well were added in six rows of quadruplicates for each 
serum sample. After incubation for 1 h at RT, 50 µL/well of potassium thiocyanate (KSCN, Sigma, St. Louis, 
MO, USA) diluted in 1% bovine serum albumin in PBS-T (w:v) was added to the plates in increasing 
concentrations (0, 0.1, 0.2, 0.5, 1 and 2 M) and incubated for 30 min at RT. For detection, 50 µL/well of 
HRP-labelled mouse-α-rat IgG1 (3060-05, Southern Biotech) diluted 1:20,000 (v:v) in PBS-T was added to 
each well and incubated for 1 h at RT. Reaction was visualised by adding 100 µL/well of TMB-one substrate 
(Kem-En-Tec) for approximately 12 min and stopped with 100 µL/well of 0.2 M H2SO4. Absorbance was 
measured at 450 nm with a reference wavelength of 630 nm, using a microtitre reader (Gen5, BioTek 
Instruments).  
Under the given assay conditions, it was determined that KSCN did not influence the binding of antigen to 
the plates. 
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Avidity results of individual serum samples are expressed as the concentration of KSCN required for 
inhibition of 50% (IC50) of antigen-antibody binding, defined as a 50% reduction of OD, so that the lower the 
concentration of KSCN needed for 50% inhibition the lower the avidity of antigen-antibody interactions. 
Calculations were performed as described by El-Khouly et al. [23]. 
 
Curve calculations and Statistical analyses 
Curve calculations (XY analyses) and statistical calculations were made using GraphPad Prism version 5.00 
(GraphPad Software, San Diego, CA, USA). Antibody titres were examined for group differences, using the 
non-parametric One-way ANOVA, Kruskal-Wallis test, followed by Dunn’s multiple comparison test for 
comparison of three or more groups. Curves (KSCN concentration against % reduction in absorbance) used 
for calculation of IC50 were tested for variances by the One-way ANOVA, Bartlett’s test for equal variances, 
followed by Turkey’s multiple comparison test. No significant differences between curves appeared, 
wherefore avidity measures expressed as IC50 were examined for group differences, using a parametric 
One-way ANOVA, followed by the Tukey’s multiple comparison test for comparison of three or more 
groups. Differences between groups of animals were regarded as significant when P≤0.05. Asterisks 
indicate a statistically significant difference between the given group and the control group. Asterisks over 
a horizontal line indicate a statistically significant difference between the two given groups. *=P≤0.05, 
**=P≤0.01, ***P≤0.001 
 
 
Results 
 
Characteristics of intact BLG and BLG digests 
BLG was digested in an in vitro model simulating the gastric as well as duodenal digestion process and 
subsequently subjected to prep grade GPC for separation of the digestion products by means of 
fractionation. From the prep grade GPC profile it was decided to make four different pools of BLG digests; 
partially digested BLG (corresponding to the whole pool of BLG digests), digested BLG (corresponding to all 
digestion products without any intact BLG), large complexes (corresponding to the fraction of peptides in 
digested BLG aggregating to the largest complexes) and small complexes (corresponding to the fraction of 
peptides in digested BLG only aggregating to small complexes or not aggregating at all) (Fig. 1).  
From analytical RP-HPLC analyses it was evident that BLG is a relatively resistant protein, being virtually 
completely resistant to proteolysis with pepsin (Fig. 2B), while being degraded to a greater extent by 
trypsin and chymotrypsin (Fig. 2C). Intact BLG was eluted at a retention volume of 4.6 mL (Fig 2A), revealing 
that some residual intact BLG was left after termination of the gastro-duodenal digestion process (Fig. 2C). 
By calculation of the area under the 220 nm RP-HPLC absorbance curve it was determined that 
approximately 15% intact BLG survived 2 h of simulated gastric digestion plus 15 min of simulated duodenal 
digestion. 
From RP-HPLC analyses it was evident that removal of residual intact BLG from the digestion products was 
successful, since no detectable peaks were evident at an elution volume of 4.6 mL corresponding to the 
elution volume for intact BLG in the chromatography profiles for neither digested BLG nor any of the 
fractions (Fig. 2A vs. D-F). While the chromatography profiles of the digestion products of partially digested 
BLG and digested BLG were virtually identical (Fig. 2C-D) it was apparent that chromatography profiles 
changed when digestion products were separated into fractions (Fig. 2D-F), suggesting that peptide 
composition varies between the two fractions of large and small complexes and hereby differs from the 
peptide composition of the whole pool of digested BLG. 
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A comparison of the total amino acid composition of intact BLG and the different pools of BLG digests, 
revealed the amino acid distribution to be essentially identical for intact BLG, partially digested BLG and 
digested BLG (Fig. 3A-C), indicating that no peptide fragments generated in the digestion process were lost 
in the separation of residual intact BLG from digestion products and that digested BLG contains a peptide 
composition representative of the intact BLG, with hydrophobic amino acids responsible for approximately 
45%, the polar for approximately 16% and the charged for approximately 39% of total amino acid residues. 
In contrast, the amino acid distribution of the two fractions of digested BLG differs from each other and 
thereby from that of intact BLG, with most hydrophobic amino acids gathered in the small complexes and 
most charged amino acid gathered in the large complexes (Fig. 3), indicating that the charged peptides are 
the ones aggregating to the largest complexes. The amino acid analyses confirms the result of RP-HPLC 
suggesting that peptide fragments of digested BLG were not distributed equally by the fractionation 
process and that the peptide profiles of the large complexes and small complexes were not representative 
of the intact BLG.  
For examination of the peptide mass distribution of the three pools of digested BLG without intact protein, 
MALDI-TOF MS was performed, which demonstrated that the intact BLG which did not escape the digestion 
process, was digested to small peptide fragments with an apparent Mr of up to 4,500, of which 
approximately 75% had a Mr between 500 and 2,000 (Fig. 4). As in the whole pool of digested BLG, the 
peptides in the large complexes were less than Mr 4,500, while in the small complexes the peptides were 
less than Mr 3,000. This indicates that while the peptides in the digested BLG and large complexes were 
composed of up to approximately 38 amino acid residues, the peptides in the small complexes were 
composed of up to approximately 25 amino acid residues. 
To analyse if the peptides did aggregate and if so to which degree, analytical GPC was performed. Intact 
BLG was eluted as a single peak corresponding to a Mr of around 36,000, revealing that BLG existed as a 
dimer (Fig 5A). A peak corresponding to the dimerised BLG is also evident in the analytical GPC profile of 
partially digested BLG, and from calculation of the area under the 220 nm curve it was revealed that this 
peak corresponded to approximately 15% of the total area, (equivalent to the 15% residual intact BLG 
revealed from the RP-HPLC absorbance curve), together indicating that the dimerised intact BLG did not 
aggregate with the peptide fragments generated from the digestion process (Fig. 5B). From analyses of the 
GPC profiles and the area under the 220 nm absorbance curves corresponding to the peptide fragments 
emerging form the gastro-duodenal digestion, shown in Fig. 5B-E, it was revealed that a substantial part of 
the peptides indeed did aggregate to larger complexes. The analytical GPC profiles of the peptide fragments 
in partially digested BLG and digested BLG appeared essentially identical and for both the partially digested 
BLG and the digested BLG, it was indicated that approximately 43% of the peptide fragments were in 
aggregated complexes between apparent Mr 28,000 and 4,500 (Fig. 5B-C). This indicates that the 
fractionation procedure when separating intact BLG from the digestion products did not influence 
aggregation state of the peptides. However, by separating the digested BLG into two fractions, the 
aggregation state was disturbed, making the complex-formation of the peptides change (Fig. 5C-E). While 
approximately 80% of the peptide fragments in the large complexes were aggregated to complexes 
between Mr 32,500 and 4,500, only approximately 32% of the peptide fragments in the small complexes 
were aggregated to complexes between Mr 13,250 and 3,000.  
 
Specific antibody-responses 
Sera from BN rats immunised with either PBS (control), 200 µg of intact BLG, 30 µg of intact BLG, 200 µg of 
partially digested BLG (containing 30 µg of intact BLG), 200 µg of digested BLG (without any intact BLG), 200 
µg of large complexes or 200 µg of small complexes, were evaluated for specific antibody responses against 
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intact BLG as well as the different pools of BLG digests. Analyses of specific IgG1 and IgG2a responses, 
revealed that while both the high (200 µg) and the low (30 µg) amount of intact BLG as well as the partially 
digested BLG could induce specific IgG antibodies, though only intact BLG alone to a statistically significant 
degree, neither the digested BLG nor the two fractions hereof could induce any specific IgG response. 
Specific IgG1 and IgG2a results were very similar, for which reason only the IgG1 results are shown in Fig. 6. 
The high and the low immunisation dose of intact BLG induced specific IgG1 reaching equal antibody titre 
levels in the BN rats that reacted similarly with intact BLG and the partially digested BLG. However, only 
IgG1 from sera raised in BN rats immunised with the high dose of intact BLG was able to react with digested 
BLG and the large complexes, indicating differences in IgG1 antibody specificities. From Fig. 6 it was evident 
that while digestion of BLG abolished the antibody inducing capacity of the resulting peptide fragments, 
both the whole pool of digested BLG and the large complexes retained some binding capacity. From the 
specific IgG1 response analyses it is revealed that by immunising the BN rats with 30 µg of intact BLG alone 
a statistically significant antibody response was reached, while immunising the rats with partially digested 
BLG, containing 30 µg of intact BLG together with 170 µg of BLG digestion products, a much lower antibody 
response was generated. This indicates that the digestion products reduced the antibody response induced 
by the intact BLG.  
From Fig. 7 it is evident that both the high dose (200 µg) and the low dose (30 µg) of intact BLG as well as 
partially digested BLG had sensitising capacity being able to induce specific IgE antibodies, though only the 
intact BLG alone to a statistically significant level. Digested BLG and the two fractions hereof, had on the 
other hand, no sensitising capacity. These results reflects the results of the specific IgG1 responses, 
indicating that intact BLG have a stronger sensitising capacity when dosed alone, compared to being dosed 
in combination with peptide fragments from the very same protein.  
Analysis of the specific IgA response (Fig. 8) shows that only the high (200 µg) and the low dose (30 µg) of 
intact BLG could induce specific IgA antibodies, both to a statistically significant level. These results indicate 
that the specific IgA response parallels the specific IgG1 and IgE response. 
For examination of the avidity between specific antibodies raised in the different groups of rats and the 
intact BLG as well as the different pools of BLG-digests, a KSCN inhibition ELISA assay was performed for 
those individual sera for which it was possible to obtain an OD of a minimum of 0.5. No statistically 
significant differences were observed for the avidity between specific IgG1 and any of the tested antigens. 
For example there was no statistically significant difference in the avidity of the binding between specific 
IgG1 antibodies raised in rats immunised with intact BLG and the antigen solutions of intact BLG, partially 
digested BLG, digested BLG or large fragments, respectively, though there seems to be a tendency of the 
antibodies reacting with a lower avidity towards the digestion products compared to the intact BLG. Also no 
statistically significant differences in avidity were seen between specific IgG1 raised in the different groups 
of rats. 
 
 
Discussion 
 
The present study confirmed the majority of earlier studies showing that BLG is a protein stable to 
simulated human digestion, showing that BLG is virtually completely resistant to pepsinolysis, while being 
more susceptible to digestion by trypsin and chymotrypsin under physiologically relevant conditions [12, 
24]. However, once broken down to larger fragments, BLG was rapidly digested to smaller peptide 
fragments of sizes less than Mr 4,500, of which more than 75% had an apparent Mr between 500 and 2,000. 
This suggests that when intact BLG is digested to a few larger fragments, these may not retain sufficient 
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structure to allow them to resist further degradation by proteases, rendering these fragments even more 
susceptible to additional digestion. Peptide fragments generated during the digestion process was shown 
to aggregate to complexes of larger sizes of up to Mr 24,500. With fractionation of the peptide fragments 
by means of GPC it was demonstrated that especially the peptides composed of charged amino acid 
residues tended to form aggregates. This is in accordance with another study, showing likewise that 
peptide fragments resulting from the digestion process of the peanut allergen Ara h 1, formed the largest 
complexes when composed mainly of charged and least of hydrophobic amino acid residues [21], indicating 
that non-covalently interactions other than hydrophobic are the main players in the formation of 
aggregates. 
Food allergy develops as a result of impaired formation or break down of oral tolerance. The immune 
system of the BN rats used in this study has never been introduced to BLG and the rats are consequently 
not tolerant to this protein. The present study showed that only immunisation solutions containing intact 
BLG could induce specific IgG and IgE responses in the BN rats, and only intact BLG alone to a statistically 
significant degree. Digestion products generated by simulated gastro-duodenal digestion could on the 
other hand neither induce an immunogenic nor an allergenic response. This demonstrates that the 
digestion process was successful in abolishing the sensitisation capacity of BLG and demonstrates the 
importance of a functional digestive system for lowering the risk of developing food allergies. This is in 
agreement with studies of Untersmayr et al. [25] and Scholl et al. [26] showing that impairment of digestion 
enhances the sensitising capacity of caviar and hazelnut proteins in a mouse model and support the 
inclusion of an assessment of the stability of proteins to in vitro digestion by proteases as a parameter in 
the weight-of-evidence approach for evaluation of the potential allergenicity of novel proteins in 
genetically modified food as recommended by the EFSA panel in 2010 [27].  Results from the present study 
showed that digestion of a food allergen completely abolish its sensitising capability. This is in contrast to 
our previous study, showing that Ara h 1 retained both the sensitising, IgE reacting and eliciting capacity, 
and thereby acted as a ‘complete’ allergen, when digested to small peptide fragment of less than Mr 2,000 
[11]. Additionally, in another study we showed that digested Ara h 1 with a peptide distribution profile very 
similar to that of digested BLG in the present study, likewise retained its sensitising capacity [21], proving 
that sizes of the break down products not alone determine whether or not the immune system mount a 
sensitising response. This also demonstrates the complexity of the immune mechanisms involved in 
directing the immune response towards a tolerogenic versus sensitising one. While the sensitising capacity 
of BLG was lost when digested to smaller peptide fragments, both the whole pool of digested BLG as well as 
the fraction of large complexes retained the binding capacity. Antibodies from BN rats immunised with the 
high dose of BLG could still react with the digestion products, though with a lower response than towards 
the intact protein, indicating that some but not all epitopes survived the digestion process, in agreement 
with results of Clement et al. [7]. This suggests that patients sensitised to intact BLG may still recognise the 
gastro-duodenal digestion products of BLG and that the digestion products may retain the capacity to elicit 
allergic responses. This may especially be true because of the aggregating tendency of the peptide 
fragments. Aggregation has earlier been suggested to be the reason for the sustained allergenic capacity of 
digestion products of allergens, which in theory were too small to contain two epitopes and thereby not big 
enough to cross-link two IgE molecules bound to the surface of mast cells or basophils [11, 21, 28]. The 
finding that IgE epitopes on BLG survive digestion is in accordance with previous studies, stating that the 
major IgE epitopes reported in the literature by Jävinen et al. [6] and Cocco et al. [5] corresponded to areas 
of BLG where peptides did resist simulated gastro-duodenal digestion [24]. This is in agreement with the 
current study and could support the presence of major linear B cell epitopes on BLG. Results from the 
avidity measurements, showing that no significant differences existed for the avidity of IgG1 antibody 
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binding to intact versus digested BLG, further strengthens the likelihood of linear epitopes. On the other 
hand if most epitopes of the BLG molecule were conformational, one would expect a significant reduction 
in the binding strength between antibodies and antigens, after the digestion process, because of the 
reduced possibility of small peptides to sustain sufficient structural integrity to bind antibodies raised 
against conformational epitopes with a similar avidity. It has been shown that a close relationship exist 
between the specificity of BLG specific IgE and IgG epitopes, showing that the major linear IgG epitopes 
generally colocalised with the major linear IgE epitopes [6]. If our results on IgG avidity are representative 
for IgE avidity, the present results are in accordance with earlier studies showing the very importance of 
just linear IgE epitopes on BLG [6, 29]. It may not be possible to generalise data on linear epitopes from BLG 
to other food allergens and in contrast to the above assertion we have previously shown that even small 
peptide fragments emerging from the digestion of Ara h 1 retained sufficient structural integrity to function 
as conformational IgE binding epitopes when present in aggregates probably resembling the intact Ara h 1 
molecule [21, 30]. 
It is well recognised that pHF based on milk proteins retain residual allergenic capacity which is generally 
significantly higher than that of eHF [16]. On the other hand pHF may be able to induce specific tolerance 
while eHF fails to do this [17, 18]. This indicates that certain specific features are required for a peptide 
mixture to induce oral tolerance and that different peptide mixtures may influence the intestinal mucosal 
immune system in different ways, even when based on the same parent protein mixture. The preventive 
effects of various hydrolysates have been shown not solely to depend on the degree of hydrolysis [31]. 
Does the digested BLG function as the pHF being able to induce tolerance mechanisms or does it work like 
eHF by failing to achieve such tolerance? To examine if the digested BLG induce tolerance mechanisms or if 
it was simply ignored by the immune system, specific serum IgA was measured, since specific serum IgA 
have been suggested to be an indicator for development of tolerance, correlating inversely with specific 
serum IgE in allergen sensitised patients [32, 33]. However, specific IgA levels in BN rats seem to correlate 
with the specific IgG1 and IgE responses. These results are therefore not informative about whether the 
digested BLG inheres tolerogenic potential or whether the digestion products were not recognised by the 
immune system of the rats.  
The present study showed that antibody levels in rats immunised with partially digested BLG (containing 30 
µg of intact BLG together with 170 µg of BLG digestion products) were strongly reduced compared to the 
antibody level in rats immunised with the low dose of intact BLG. The amount of intact BLG was the same in 
the two immunisation solutions, the difference being the additional presence of digestion products in the 
partially digested BLG. This indicates that the reduced response was induced by the BLG derived peptide 
fragments. As we see it, the lower response could be a result of two different situations. The first involves 
the masking of epitopes implicated in the sensitisation phase, by means of the peptide fragments 
camouflaging the epitopes by an aggregate formation with the intact molecule. The second situation 
involves tolerogenic properties of the peptide fragments, which by co-immunisation with the intact protein 
leads to impaired sensitising capacity of the intact BLG dimeric molecule. The first situation however seems 
unlikely, based on the knowledge from the analytical GPC showing that the dimeric BLG molecules did not 
form complexes with the peptide fragments present in the partially digested BLG, or at least not to a level 
which could be detected. This point to the second situation, that co-administration of the intact and 
digested BLG induced tolerance mechanisms, leading to antibody responses of significantly lower levels 
when administrating intact BLG together with peptide fragments from the same protein, compared to 
administrating the intact BLG alone.  
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Tolerance may be induced by fundamentally different mechanisms, shown in animal studies of low- versus 
high-dose induced tolerance [20] and in studies of carrier-specific tolerance induction [34]. From a study of 
a ovalbumin derived peptide and analogous hereof it was shown that even small differences in peptide 
composition can make huge differences in deciding if the peptide strengthens or weakens the allergen-
specific sensitisation response [35].  
Whether the peptide fragments are able to induce tolerance mechanisms alone, or whether they need to 
be presented to the immune system together with the native BLG, remains to be demonstrated. If so, it 
also remains to be demonstrated if the tolerance mechanisms involved are the same. Peptides may be 
processed and presented differently from the intact protein, and there is the possibility of presenting a 
greater variety of different T cell as well as B cell epitopes from the intact than the digested protein. Maybe 
the use of intact protein plus peptides ensures that there will be achieved tolerance against not only those 
sequences presented by the peptides but also other sequences of the protein and thereby the entire 
protein. 
Further studies are needed in order to reveal if digested BLG alone have tolerogenic capacity, studying the 
mechanisms underlying tolerance induction, and to elucidate the general tolerogenic capacity of co-
administration of intact allergen with peptide fragments hereof. This would in addition contribute to a 
better understanding of the underlying mechanisms of sensitisation versus tolerance induction which could 
be useful in the future for new strategies in the prevention and treatment of allergic diseases. In agreement 
with the message by Fritsche et al. [17], animal models would in such situations certainly be helpful in 
prediction of allergenic versus tolerogenic potential of different hydrolysates and in the understanding of 
the mechanisms involved.  
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Figure Legend 
 
Figure 1 Prep grade GPC of BLG digests. To separate intact BLG from the digestion products generated after 
120 min of simulated gastric digestion plus 15 min of simulated duodenal digestion and for fractionation of 
the digestion products, preparative GPC was performed. Based on the 280 nm absorbance GPC profile, it 
was decided to make four different pools of BLG-digests, indicated with the curly brackets; partially 
digested BLG, digested BLG, large complexes and small complexes. Partially digested BLG contained all 
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products resulting from the digestion process, including approximately 15% intact BLG, that resisted the 
digestion. Digested BLG consisted of all digestion products, after dissociation from the intact BLG, while the 
large complexes and small complexes were different fractions hereof separation based on the sizes of 
aggregates, together corresponding to the digested BLG. 
 
Figure 2 Analytical RP-HPLC profiles for intact BLG and BLG digests. Comparison of chromatography 
profiles, shown with absorbance at 220 and 280 nm, for intact BLG (A), gastric digests of BLG (B), partially 
digested BLG after gastro-duodenal digestion (C), digested BLG (D), large complexes (E) and small 
complexes (F). 
 
Figure 3 Amino acid frequency distribution of intact BLG and BLG digests. Comparison of amino acid 
distribution profiles for intact BLG (A), partially digested BLG (B), digested BLG (C), large complexes (D) and 
small complexes (E). The bars represent the frequency percentage for each amino acid(s), represented by 
their one letter code, grouped according to their physico-chemical features. 
 
Figure 4 Peptide mass distribution for digested BLG and fractions hereof. Mass distribution profiles for 
digested BLG (A), large complexes (B) and small complexes (C), shown in histograms, where each bar 
corresponds to a peptide mass interval of Mr 500. 
 
Figure 5 Analytical GPC for intact BLG and BLG digests. Comparison of chromatography profiles, shown with 
absorbance at 220 and 280 nm, for intact BLG (A), partially digested BLG (B), digested BLG (C), large 
complexes (D) and small complexes (E). 
 
Figure 6 Specific IgG1 responses. Comparison of specific IgG1 titre (Log2) values, for groups of rats 
immunised with either PBS (control), 200 µg of intact BLG, 30 µg of intact BLG, 200 µg of partially digested 
BLG (containing 30 µg of intact BLG), 200 µg of digested BLG, 200 µg of large complexes or 200 µg of small 
complexes. Sera from all rats in each immunisation group were examined for specific IgG1 antibodies 
against intact BLG, partially digested BLG, digested BLG, large complexes and small complexes, shown with 
different symbols. Each symbol represents an individual rat. Horizontal bars indicate the median IgG1 titre 
value for each group of rats towards the given antigen product. Statistically significant differences between 
groups of rats were determined by use of Kruskal-Wallis test followed by Dunn’s multiple comparison test. 
Asterisks indicate statistically significant differences of the given group compared to the control group. 
 
Figure 7 Specific IgE response against intact BLG. Comparison of BLG-specific IgE titre (Log2) values for 
groups of rats, immunised with either PBS (control), 200 µg of intact BLG, 30 µg of intact BLG, 200 µg of 
partially digested BLG (containing 30 µg of intact BLG), 200 µg of digested BLG, 200 µg of large complexes 
or 200 µg of small complexes. Each symbol represents the IgE titre value for an individual rat. Horizontal 
bars indicate median IgE titre value for each group of rats. Statistically significant differences between 
groups of rats were determined by use of Kruskal-Wallis test followed by Dunn’s multiple comparison test. 
Asterisks indicate statistically significant differences of the given group compared to the control group. 
 
Figure 8 Specific IgA response against intact BLG. Comparison of BLG-specific IgA titre (Log2) values for 
groups of rats, immunised with either PBS (control), 200 µg of intact BLG, 30 µg of intact BLG, 200 µg of 
partially digested BLG (containing 30 µg of intact BLG), 200 µg of digested BLG, 200 µg of large complexes 
or 200 µg of small complexes. Each symbol represents the IgA titre value for an individual rat. Horizontal 
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bars indicate median IgA titre value for each group of rats. Statistically significant differences between 
groups of rats were determined by use of Kruskal-Wallis test followed by Dunn’s multiple comparison test. 
Asterisks indicate statistically significant differences of the given group compared to the control group. 
 
Figure 9 Avidity measurements of specific IgG1 antibodies. Comparison of specific IgG1 antibody binding 
avidities towards the given antigen product, expressed as the KSCN concentration needed for inhibition of 
50% response, for groups of rats immunised with either 200 µg of intact BLG, 30 µg of intact BLG or 200 µg 
of partially digested BLG. Sera from all rats mounting a specific IgG1 response of at least OD 0.5 were 
included in the examination of IgG1 avidity. Each symbol represents the IgG1 avidity for an individual rat. 
Horizontal bars indicate mean IgG1 avidity for each group of rats. Statistically significant differences 
between groups of rats were determined by use a parametric One-way ANOVA, followed by the Tukey’s 
multiple comparison test for comparison of three or more groups.  
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SUMMARISING DISCUSSION 
 
Novel proteins in genetically modified foods have since the eighties been introduced into our food supply, 
and probably will continue to [1]. The potential allergenicity of these ‘new’ proteins is of major concern 
when bringing genetically modified foods into the market. Strategies for safety assessment of the potential 
allergenicity have been recommended, based on either a decision tree [2] or a weight-of-evidence 
approach [3;4]. A complete proof of safety seems, however, impossible, because of the lack of knowledge 
about what makes a dietary protein a food allergen. An evaluation of the stability to digestion with pepsin 
remains a central part of the allergenicity safety assessment of a novel protein, despite the fact that the 
relationship between resistance to digestion and allergenicity has been questioned in recent years [5-7].  
Undoubtedly, survival in the GI tract plays an important role for the sensitising capacity of some food 
allergens. This has been demonstrated in the current thesis, where the cow’s milk allergen BLG was shown 
to lose its sensitising capacity when broken down to peptides in an in vitro model simulating the human 
gastro-duodenal digestion process. While the peptide fragments of sizes less than 4.5 kDa, generated 
during the simulated gastro-duodenal digestion process of intact BLG, failed to induce specific IgE 
antibodies in BN rats, small peptides fragments of sizes less than 2 kDa generated during simulated gastro-
duodenal digestion of the peanut allergen Ara h 1 did on the other hand retain the capacity to induce 
specific IgE antibodies in the same BN rat model. This demonstrates that while degradation may be a 
successful method for abolishing the sensitising capacity of some food allergens, it is not a general 
phenomenon applicable for all food allergens. In parallel to intact dietary proteins, where some proteins 
may have an intrinsic capacity to sensitise an individual while others may not, peptide mixtures derived 
from the digestion of food allergens may also possess differences in their ability to sensitise; an ability not 
only depending on the sizes of the peptides.  
 
The peptide fragments of sizes less than 2 kDa, generated during the in vitro gastro-duodenal digestion of 
Ara h 1, could not only sensitise but also bind IgE and elicit a degranulation response, thus possessing all 
properties that define a ‘complete’ food allergen. These findings seem surprising, since the peptide 
fragments are smaller than originally thought to be the lower limit for peptides with inherent allergenicity 
[2;8-10]. Results presented in this thesis demonstrate that there does not exists an absolute correlation 
between resistance to digestion and allergenic potential, and that establishing a MW size below which 
peptide fragments from food allergens are not allergenic could be very challenging if not impossible. 
Lability to digestion may certainly be regarded as a factor that reduces the risk associated with allergenicity 
[1] but this project emphasises that protein stability to peptic proteolysis should be assessed along with 
other test parameters and that potential allergenicity of novel proteins should be evaluated on a case-by-
case basis.  
 
Peptide fragments generated during both the gastric and gastro-duodenal digestion of the purified Ara h 1 
were shown to aggregate to complexes of larger sizes. Whether an aggregation of the small peptides to 
complexes of larger sizes was the reason for the observed sensitising capacity was investigated by 
subjecting the digestion products to fractionation according to the sizes of the peptides and the aggregates 
formed. By means of this fractionation step, the digestion products of Ara h 1 lost their sensitising capacity. 
Both the peptide fragments in the whole pool of digested Ara h 1 as well as in the fractions of digested Ara 
h 1, were shown to aggregate, though to different degrees. This demonstrates that if the sensitising 
capacity of digested Ara h 1 is a result of the peptide fragments aggregating to complexes of larger sizes, 
this is not simply a result of them aggregating but more a result of how they aggregate. This however, did 
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neither confirm nor reject if the sensitising capacity was indeed a result of the peptide fragments 
aggregating to larger complexes. Instead it created the basis for the hypothesis that either the sensitising 
capacity was a result of the peptide fragments being in aggregated complexes resembling the intact Ara h 1 
or that the complete mixture of free peptide fragments had an intrinsic capacity to sensitise by themselves. 
That even very small peptides may hold the capacity to induce specific antibodies is evident from research 
with small free synthetic peptides [11-13]. In addition, the importance of formation of aggregates by small 
peptides has also been acknowledged [3;14-19]. It was for example suggested that assembling of small 
peptides in some kind of scaffold could enhance the immunogenicity of the small peptides, because the 
structural stability could be of great importance [17]. That the allergenic capacity of peptide fragments 
formed by the digestion process of food allergens may be a result of formation of larger complexes, have 
earlier been suggested for Ara h 1 [14], for the Brazil nut allergen Ber e 1 [19] as well as for digestion 
products of a cow’s milk allergens [15;18]. In light of the theoretically importance for antibody cross-linking 
events on APC, B cells, mast cells as well as basophils; an aggregation of the small peptide fragments could 
hypothetically explain the very potent sensitising and eliciting capacity of the digested Ara h 1 presented in 
the current thesis. Aggregation of peptide fragments creates the possibility of IgE binding epitopes being in 
close vicinity. Thus cross-linking of either surface-bound IgE antibodies on APC, surface-expressed IgE 
antibodies on B cells or FcԑRI-bound IgE on the surface of mast cells or basophils could occur (Figure 1).  
 
 
 
Figure 1. A hypothetical explanation for the importance of aggregate formation of small peptide fragments 
generated during the digestion process. Aggregation of small peptides (too small to be allergenic by themselves), may 
explain the potential to both induce sensitisation and eliciting allergic responses. Aggregation of small peptides allows 
epitopes to be in close vicinity permitting cross-linking events of; A. Surface-bound antibodies on APC, B. Surface-
expressed antibodies on B cells, and C. Surface-bound antibodies on mast cells or basophils. 
 
The epitope mapping study of intact and digested Ara h 1 indicated that IgE binding epitopes of Ara h 1 
survived the digestion process. This was most pronounced in the findings that five epitope motifs, 
corresponding to more than 65% of all epitopes identified for the five peanut allergic patients, were 
identified for both intact and digested Ara h 1. Furthermore, realising that all identified epitope motifs 
could be categorised as conformational supports the assumption that digested Ara h 1 is in an aggregated 
conformation resembling the intact molecule. For the first time it has been demonstrated, that even 
though a protein is digested to very small peptide fragments, the survival of conformational epitopes may 
be possible.  
For a dietary protein to sensitise through the intestinal mucosal immune system epitopes need to survive 
the digestion process or new ones need to be generated. IgE specific for epitopes surviving the digestion 
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process has been hypothesised to be associated with a severe and persistent food allergic phenotype [20-
22]. The epitope mapping results presented in the current thesis may support this hypothesis, as the 
peanut allergic patients had a history of both severe and persistent peanut allergy. Further this study 
supports the idea that IgE binding epitopes resisting the digestion process may be used as predictive 
biomarkers for the allergic phenotype [20]. In contrast to earlier studies suggesting a particular important 
role for linear IgE binding epitopes in food allergy [23], the present study suggests in addition that 
recognition of conformational IgE binding epitopes could be of major importance.  
While conformational epitopes may be of great importance for the peanut allergen Ara h 1, the cow’s milk 
allergen BLG-specific IgE binding epitopes surviving the digestion process seem to be linear.  
 
To avoid the introduction of novel dietary proteins with sensitising capacity, a clear guidance on how to 
interpret the result from a digestibility assay seems advisable, especially in light of the results presented 
here. This is in agreement with Fu [5] stating that a consensus on how to relate the measured digestibility 
to the allergenic potential of novel proteins needs to be reached, in order to allow susceptibility to 
digestion as a predictive tool. First, the choice of an applicable in vitro digestibility assay, preferable 
simulating physiologically relevant gastric as well as duodenal human digestion process, seems highly 
relevant. Second, the choice of appropriate methods, which should be performed in addition to SDS-PAGE, 
allowing for evaluation of the susceptibility to digestion of the novel protein, seems advisable. These 
methods should compensate for the inadequacies of the SDS-PAGE and allow for detection of even small 
amounts of residual intact protein, for detection of even very small peptide fragments as well as for 
detection of aggregates. Third, an assessment of the stability of the peptide fragments generated during 
the digestion process should be evaluated on equal terms as the intact protein. Fourth, an assessment of 
the susceptibility to digestion should be combined with different immunologically assays, allowing for 
detection of residual IgE binding capacity, eliciting properties as well as sensitising properties based on 
studies in animal models. Some of these suggestions are issues mentioned by the EFSA panel in 2010 [3]. 
 
While the digestion products of Ara h 1 retained sensitising capacity, digestion product of BLG failed to 
induce any specific antibodies. Instead the results suggested that the digestion products from BLG 
possessed tolerogenic capacity. This was indicated by the significantly lower sensitising potential of intact 
BLG co-administered with digested BLG compared to the sensitising potential of same amount of intact BLG 
alone. Whether the potential tolerogenic capacity was a feature of the peptide fragments per se or if the 
tolerogenic capacity was a result of the co-administration with intact BLG could not be elucidated with the 
study design used.  
These studies with digestion products from two different food allergens revealed that mixtures of peptide 
fragments, with very similar peptide size distributions may not necessarily stimulate the immune system in 
similar ways, but instead may direct the immune system in different directions. Collectively these studies 
show that several properties of dietary proteins will contribute to the allergenic sensitising potential, 
characteristics that involve not only the sizes of the peptides generated during the digestion but also the 
structure of these peptides, probably in addition to several other features. This is in agreement with Wijk 
and Knippels [24] reporting that several characteristics may together determine whether a protein will 
meet the requirements for inducing an immune response or not.  
Theoretically the observed immunologically differences between digested Ara h 1 and digested BLG could 
explain the variations seen between the allergic phenotypes associated with peanut and cow’s milk allergy. 
The potent allergenic capacity of digested Ara h 1 may explain why peanut allergy is such a persistent and 
severe type of food allergy compared to cow’s milk allergy [25-29]. 
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In conclusion this thesis demonstrates that resistance to digestion does not necessarily correlate with 
allergenicity and that peptide fragments generated during the digestion process, too small to be allergenic 
by themselves, may aggregate to complexes of sufficient size and with sufficient structure to retain 
sensitising potential. The combined results presented in this PhD thesis showed the complexity of the 
mechanisms underlying sensitisation and demonstrated that defining a single or even several 
characteristics of a dietary protein identifying it as a food allergen is very difficult if not impossible.  
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